Molecule ChEMBL ID;Molecule Name;Molecule Max Phase;Molecular Weight;#RO5 Violations;AlogP;Compound Key;Smiles;Standard Type;Standard Relation;Standard Value;Standard Units;pChEMBL Value;Data Validity Comment;Comment;Uo Units;Ligand Efficiency BEI;Ligand Efficiency LE;Ligand Efficiency LLE;Ligand Efficiency SEI;Potential Duplicate;Assay ChEMBL ID;Assay Description;Assay Type;BAO Format ID;BAO Label;Assay Organism;Assay Tissue ChEMBL ID;Assay Tissue Name;Assay Cell Type;Assay Subcellular Fraction;Assay Parameters;Assay Variant Accession;Assay Variant Mutation;Target ChEMBL ID;Target Name;Target Organism;Target Type;Document ChEMBL ID;Source ID;Source Description;Document Journal;Document Year;Cell ChEMBL ID;Properties;Action Type;Standard Text Value;Value
CHEMBL343296;;None;239.28;0;0.69;33;OC1C[n+]2cc3ccccn3c2-c2cccc[n+]21;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL3904423;;None;862.29;2;8.18;BDBM232388;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(N(C)C)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';30.0;nM;7.52;;405186;UO_0000065;8.72;0.18;-0.66;6.02;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;30.0
CHEMBL2031009;;None;746.72;2;6.91;BDBM50384340;CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';8.78;nM;8.06;;405267;UO_0000065;10.79;0.22;1.15;6.07;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;8.78
CHEMBL2031003;;None;704.90;2;6.35;4e;CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1;IC50;'=';430.0;nM;6.37;;;UO_0000065;9.03;0.17;0.02;4.59;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.43
CHEMBL2031017;;None;866.22;2;7.95;17;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(I)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';35.0;nM;7.46;;;UO_0000065;8.61;0.19;-0.49;6.13;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;35.0
CHEMBL2031018;;None;866.22;2;7.95;18;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';37.0;nM;7.43;;;UO_0000065;8.58;0.19;-0.52;6.11;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;37.0
CHEMBL2031025;;None;842.46;2;7.77;28;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCCOC)c(C)c1Cl;IC50;'=';22.0;nM;7.66;;;UO_0000065;9.09;0.18;-0.11;5.46;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;22.0
CHEMBL2031028;;None;852.50;2;6.96;31;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c(C)c1Cl;IC50;'=';140.0;nM;6.85;;;UO_0000065;8.04;0.16;-0.11;5.35;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;140.0
CHEMBL2031031;;None;742.30;2;7.14;37;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2COc3ccccc3C2)c(C)c1Cl;IC50;'=';120.0;nM;6.92;;;UO_0000065;9.32;0.18;-0.22;5.29;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;120.0
CHEMBL3703629;;None;984.63;3;9.23;BDBM156413;CN(C)[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';24.0;nM;7.62;;363159;UO_0000065;7.74;0.16;-1.61;5.94;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;24.0
CHEMBL4878326;;None;902.99;3;8.99;24g;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1;IC50;'=';1.0;nM;9.00;;;UO_0000065;9.97;0.19;0.01;5.32;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;1.0
CHEMBL336901;;None;336.35;0;4.06;17;[O-][n+]1c2c([n+]([O-])c3c4ccccc4ccc31)-c1cccc3cccc-2c13;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL137215;;None;367.45;0;3.25;22;CN(C)CCNCCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2031018;;None;866.22;2;7.95;BDBM50384349;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';40.0;nM;7.40;;405182;UO_0000065;8.54;0.19;-0.55;6.08;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;40.0
CHEMBL3980078;;None;853.67;2;8.76;BDBM232396;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';3.93;nM;8.41;;405194;UO_0000065;9.85;0.21;-0.35;6.91;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;3.93
CHEMBL3912906;;None;705.88;2;6.60;BDBM232445;CCCCN(CCCC)C(=O)c1cn(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';110.0;nM;6.96;;405257;UO_0000065;9.86;0.19;0.36;5.72;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;110.0
CHEMBL4108604;;None;1014.65;None;None;BDBM204936;CN(C)C[C@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';0.3;nM;9.52;;363146;UO_0000065;9.39;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.3
CHEMBL4470807;;None;417.29;1;5.75;S1-6;N#CC1=C(C#N)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O;IC50;'=';2310.0;nM;5.64;;;UO_0000065;13.51;0.30;-0.11;8.72;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;2.31
CHEMBL2030856;;None;742.90;2;6.38;3m;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(CCO)cc1;IC50;'=';20.0;nM;7.70;;;UO_0000065;10.36;0.19;1.32;5.43;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.02
CHEMBL2030863;;None;769.36;2;8.27;3t;CCCCCS(=O)(=O)NC(=O)c1ccc(-c2c(CO)nn(-c3ccc(Oc4cccc(Cl)c4)cc3)c2CCCC)c(C(=O)N2CCc3ccccc3C2)c1;IC50;'=';65.0;nM;7.19;;;UO_0000065;9.34;0.18;-1.08;5.49;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.065
CHEMBL1094250;1,1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-((R)-2-PHENYLPROPYL)-N5'-((R)-2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE (ATROPISOMERIC MIX);None;700.79;3;7.58;BI-97C1;Cc1cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c1O;IC50;'=';320.0;nM;6.50;;;UO_0000065;9.27;0.17;-1.09;3.62;1;CHEMBL5234919;Inhibition of BH3 peptide binding to Bcl-2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5233252;1;Scientific Literature;Eur J Med Chem;2020;None;;INHIBITOR;;0.32
CHEMBL5201326;;None;520.43;2;6.65;37;CC(C)COC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';164.0;nM;6.79;;;UO_0000065;13.04;0.27;0.14;9.56;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.16399999999999998
CHEMBL2063889;;None;785.44;2;8.56;13;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';85.3;nM;7.07;;;UO_0000065;9.00;0.18;-1.49;6.37;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;85.3
CHEMBL2159740;;None;936.60;3;10.62;28;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C;IC50;'=';1.4;nM;8.85;;;UO_0000065;9.45;0.19;-1.77;5.78;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;1.4
CHEMBL2325760;;None;895.50;3;9.83;27;Cc1oc(-c2ccc(Cl)cc2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1C(=O)O;IC50;'=';3.8;nM;8.42;;;UO_0000065;9.40;0.19;-1.41;5.21;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;3.8
CHEMBL2030852;;None;825.39;2;9.29;3i;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccc(Cl)cc2)cc1;IC50;'=';22.0;nM;7.66;;;UO_0000065;9.28;0.18;-1.63;5.85;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.022
CHEMBL2031005;;None;710.30;2;7.67;4g;CCCCN(CCCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';160.0;nM;6.80;;;UO_0000065;9.57;0.19;-0.87;6.04;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.16
CHEMBL2031013;;None;832.44;2;7.14;13;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(S(=O)(=O)CC)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';180.0;nM;6.75;;;UO_0000065;8.10;0.16;-0.40;4.33;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;180.0
CHEMBL2031021;;None;759.37;2;6.58;21;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';78.0;nM;7.11;;;UO_0000065;9.36;0.18;0.53;5.69;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;78.0
CHEMBL2031022;;None;890.33;2;9.06;22;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';16.0;nM;7.80;;;UO_0000065;8.76;0.18;-1.26;6.24;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;16.0
CHEMBL2031023;;None;754.35;2;7.91;26;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2C)c(C)c1Cl;IC50;'=';710.0;nM;6.15;;;UO_0000065;8.15;0.16;-1.76;5.05;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;710.0
CHEMBL3964058;;None;882.53;2;6.33;BDBM232413;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(CCO)CC2)c(C)c1Cl;IC50;'=';90.0;nM;7.05;;405217;UO_0000065;7.98;0.16;0.72;4.75;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;90.0
CHEMBL3937806;;None;818.35;2;7.54;BDBM232420;CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1ccc(C(=O)OC)cc1;IC50;'=';90.0;nM;7.05;;405225;UO_0000065;8.61;0.17;-0.49;4.76;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;90.0
CHEMBL3918064;;None;1002.38;None;None;BDBM232437;Cc1c(Cl)c(C(=O)NCc2ccc(-c3ccc(CC(=O)O)cc3)cc2)nn1-c1ccc(C(=O)NS(=O)(=O)c2ccc3c(c2)CCN3Cc2ccc(Cl)c(Cl)c2)cc1C(=O)N1CCc2ccccc2C1;IC50;'=';50.0;nM;7.30;;405242;UO_0000065;7.28;None;None;None;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;50.0
CHEMBL3890955;;None;984.20;2;11.49;BDBM232438;CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2ccc(Cl)cc2)c1;IC50;'=';10.0;nM;8.00;;405243;UO_0000065;8.13;0.17;-3.49;6.57;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;10.0
CHEMBL2030859;;None;728.87;2;6.21;BDBM50384324;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(CO)nn1-c1ccccc1;IC50;'=';10.0;nM;8.00;;405256;UO_0000065;10.98;0.21;1.79;5.64;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;10.0
CHEMBL3703610;;None;999.64;3;7.91;BDBM156390;N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCN(CCO)CC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';16.0;nM;7.80;;363139;UO_0000065;7.80;0.16;-0.11;4.71;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;16.0
CHEMBL3703601;;None;959.57;3;8.65;BDBM156380;CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';0.5;nM;9.30;;363130;UO_0000065;9.69;0.20;0.65;5.95;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.5
CHEMBL5291477;;None;518.33;2;6.37;171b;COc1ccc2nc(-c3ccc(Br)cc3)cc(-c3nnc(Nc4ccc([N+](=O)[O-])cc4)o3)c2c1;IC50;'=';150.0;nM;6.82;;;UO_0000065;13.17;0.27;0.45;5.87;0;CHEMBL5232571;Displacement of biotinylated Bim peptide from Bcl-2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5230155;1;Scientific Literature;Eur J Med Chem;2021;None;;BINDING AGENT;;0.15
CHEMBL2030848;;None;770.91;2;7.54;3e;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(OC)cc1;IC50;'=';1790.0;nM;5.75;;;UO_0000065;7.46;0.14;-1.79;4.20;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;1.79
CHEMBL2030861;;None;672.92;None;None;3r;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)CC[Si](C)(C)C)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccccc1;IC50;'=';190.0;nM;6.72;;;UO_0000065;9.99;None;None;None;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.19
CHEMBL2031004;;None;740.33;2;7.03;4f;CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';160.0;nM;6.80;;;UO_0000065;9.18;0.18;-0.23;5.12;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.16
CHEMBL2031012;;None;740.33;2;7.35;12;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';32.0;nM;7.50;;;UO_0000065;10.12;0.20;0.14;6.16;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;32.0
CHEMBL2031024;;None;770.35;2;6.71;27;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';35.0;nM;7.46;;;UO_0000065;9.68;0.19;0.75;5.25;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;35.0
CHEMBL3948552;;None;639.19;2;5.38;BDBM179544;CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)OCC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';384.11;nM;6.42;;326159;UO_0000065;10.04;0.19;1.04;5.62;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;384.11
CHEMBL3937363;;None;595.77;1;4.15;BDBM179557;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(C)(=O)=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';377.2;nM;6.42;;326172;UO_0000065;10.78;0.21;2.27;5.15;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;377.205
CHEMBL2325769;;None;889.55;3;9.75;15;Cc1c(C#N)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';17.0;nM;7.77;;;UO_0000065;8.73;0.17;-1.98;5.56;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;17.0
CHEMBL2326039;;None;958.59;3;7.44;23;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NS(C)(=O)=O)ncn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';3.8;nM;8.42;;;UO_0000065;8.78;0.18;0.98;4.38;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;3.8
CHEMBL4858808;;None;430.62;1;6.87;S1g-2;N#CC1=C(NCC2CCCCC2)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O;IC50;'=';4800.0;nM;5.32;;;UO_0000065;12.35;0.23;-1.55;10.06;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;4.8
CHEMBL2031007;;None;647.80;2;6.24;4i;CCCN(CCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';150.0;nM;6.82;;;UO_0000065;10.53;0.20;0.58;6.06;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.15
CHEMBL2376835;;None;366.41;0;3.34;6c;Nn1c(SCc2cccc([N+](=O)[O-])c2)nnc1-c1c[nH]c2ccccc12;IC50;'=';1430.0;nM;5.84;;;UO_0000065;15.95;0.31;2.50;5.05;0;CHEMBL2379961;Competitive binding affinity to his-tagged Bcl-2 (unknown origin) after 1 hr by ELISA in presence of Bim peptide;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2375247;1;Scientific Literature;Bioorg Med Chem Lett;2013;None;;;;1.43
CHEMBL2030847;;None;698.85;2;6.84;3d;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccccc1;IC50;'=';61.0;nM;7.21;;;UO_0000065;10.32;0.19;0.37;5.93;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.061
CHEMBL2030862;;None;727.28;2;7.10;3s;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)CC)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1;IC50;'=';190.0;nM;6.72;;;UO_0000065;9.24;0.18;-0.38;5.14;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.19
CHEMBL2031006;;None;689.88;2;7.33;4h;CCCCN(CCCC)c1ncc(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';110.0;nM;6.96;;;UO_0000065;10.09;0.19;-0.37;6.18;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.11
CHEMBL595134;;None;331.40;0;3.01;3, S1;N#CC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13;IC50;'=';285.0;nM;6.54;;;UO_0000065;19.75;0.37;3.54;11.59;0;CHEMBL1677787;Displacement of FAM-Bid from human recombinant Bcl-2 after 30 mins by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1671783;1;Scientific Literature;J Med Chem;2011;None;;;;0.285
CHEMBL541427;;None;696.76;3;6.30;8s;Cc1cc2c(C(=O)NC3Cc4ccccc4C3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC3Cc4ccccc4C3)c(O)c(O)cc2c1O;IC50;'=';700.0;nM;6.16;;;UO_0000065;8.83;0.16;-0.15;3.43;0;CHEMBL1031851;Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1158469;1;Scientific Literature;J Med Chem;2009;None;;;;0.7
CHEMBL443684;NAVITOCLAX;3.0;974.63;3;8.83;"2; ABT-263";CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1;IC50;'=';10.3;nM;7.99;;;UO_0000065;8.20;0.17;-0.84;6.22;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;10.3
CHEMBL137246;;None;415.57;0;4.99;34;O=C(CSc1nc2ccccc2s1)c1sc2sc3ccccc3[n+]2c1O;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2326041;;None;991.68;3;9.52;10;Cc1c(C(=O)N[C@H]2C[C@@](C)(O)C2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';7.5;nM;8.12;;;UO_0000065;8.19;0.16;-1.40;4.91;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;7.5
CHEMBL2159739;;None;922.57;3;10.06;5, BM-956;CCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1;IC50;'=';2.0;nM;8.70;;;UO_0000065;9.43;0.19;-1.36;5.67;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;2.0
CHEMBL136866;;None;338.39;0;2.58;21;Cc1cc2c(cc1C)[n+]([O-])c(-c1nc3ccccc3s1)c(N)[n+]2[O-];IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL452586;;None;536.12;2;5.40;16b;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cccc(Cl)c2C(=O)N2Cc3ccccc3C[C@H]2CN)n1;IC50;'=';1070.0;nM;5.97;;;UO_0000065;11.14;0.21;0.57;7.07;0;CHEMBL1014486;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1153292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;1070.0
CHEMBL520607;;None;525.45;1;3.98;32;CCN(CC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Br;IC50;'=';3670.0;nM;5.43;;;UO_0000065;10.34;0.22;1.46;6.91;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;3.67
CHEMBL5179170;;None;345.40;0;4.16;15;Cc1ccc(C(=O)N2N=C(c3ccc(N)cc3)CC2c2ccco2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5176013;;None;387.44;0;4.54;14;CC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C)cc3)C(c3ccco3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL3966290;;None;828.46;2;8.51;BDBM156377;CN(C)CC[C@@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';0.3;nM;9.52;;298890;UO_0000065;11.49;0.23;1.01;6.56;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.3
CHEMBL340270;;None;442.15;0;4.92;10;Brc1cccc[n+]1-c1ccc2cc(-[n+]3ccccc3Br)ccc2c1;IC50;'=';11700.0;nM;4.93;;;UO_0000065;11.15;0.28;0.01;63.55;0;CHEMBL651292;In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;11.7
CHEMBL446607;;None;619.75;2;5.28;22;Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CNS(C)(=O)=O;IC50;'=';1050.0;nM;5.98;;;UO_0000065;9.65;0.18;0.70;5.72;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;1.05
CHEMBL509208;;None;606.77;2;6.68;43;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(OCC(=O)c3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';20.0;nM;7.70;;;UO_0000065;12.69;0.23;1.02;9.09;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.02
CHEMBL3701302;;None;675.23;2;7.24;BDBM161487;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';8.0;nM;8.10;;304786;UO_0000065;11.99;0.23;0.86;10.35;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;8.0
CHEMBL3701310;;None;646.75;2;5.42;BDBM161495;CNCCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C;IC50;'=';4.1;nM;8.39;;304794;UO_0000065;12.97;0.24;2.97;7.35;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.1
CHEMBL3701320;;None;593.73;2;5.39;BDBM161505;CCNC(=O)NCc1ccc(-c2cc(C(=O)N(C)c3ccc(O)cc3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2C)c1;IC50;'=';71.4;nM;7.15;;304804;UO_0000065;12.04;0.22;1.76;6.68;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;71.4
CHEMBL503783;;None;556.67;2;6.03;7 (cis atropisomer, a-R);Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2C[C@@H]1CO;IC50;'=';390.0;nM;6.41;;;UO_0000065;11.51;0.21;0.38;8.15;0;CHEMBL1014486;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1153292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;390.0
CHEMBL503783;;None;556.67;2;6.03;7 (cis atropisomer, a-R);Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2C[C@@H]1CO;IC50;'=';1100.0;nM;5.96;;;UO_0000065;10.70;0.19;-0.07;7.57;0;CHEMBL1014486;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1153292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;1100.0
CHEMBL481581;;None;536.12;2;5.40;36;CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl;IC50;'=';160.0;nM;6.80;;;UO_0000065;12.68;0.24;1.40;8.05;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.16
CHEMBL1689143;;None;869.56;3;9.30;31;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(CC5=C(c6ccc(Cl)cc6)CCC(C)(C)C5)CC4)ccc23)cc1[N+](=O)[O-];IC50;'=';12.0;nM;7.92;;;UO_0000065;9.11;0.18;-1.38;5.79;0;CHEMBL1693055;Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1687940;1;Scientific Literature;J Med Chem;2011;None;;;;12.0
CHEMBL3944567;;None;987.59;3;8.03;BDBM156402;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN2CCOC[C@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.4;nM;9.40;;298913;UO_0000065;9.52;0.19;1.37;5.68;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.4
CHEMBL3947658;;None;1025.53;None;None;BDBM156386;CN(CCOP(=O)(O)O)CC[C@@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';0.9;nM;9.05;;298897;UO_0000065;8.82;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.9
CHEMBL3701295;;None;753.35;2;8.13;BDBM161479;CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)cn2C2CC2)CC1;IC50;'=';25.6;nM;7.59;;304779;UO_0000065;10.08;0.19;-0.54;9.84;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;25.6
CHEMBL3942343;;None;1135.53;None;None;BDBM156384;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN(CCOP(=O)(O)O)CCOP(=O)(O)O)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';2.0;nM;8.70;;298895;UO_0000065;7.66;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.0
CHEMBL4866646;;None;917.02;3;9.38;24l;CC(Oc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(C(F)(F)F)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-])C1CCOCC1;IC50;'=';9.2;nM;8.04;;;UO_0000065;8.76;0.17;-1.34;4.75;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;9.2
CHEMBL3951720;;None;688.77;3;5.99;22;Cc1cc2c(c(O)c1-c1c(C)cc3c(c1O)/C(=C/NCCCC(=O)O)C(=O)C(O)=C3C(C)C)/C(=C/NCCCC(=O)O)C(=O)C(O)=C2C(C)C;IC50;'=';596.0;nM;6.22;;;UO_0000065;9.04;0.17;0.23;2.91;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.596
CHEMBL1962393;;None;716.83;3;6.77;23;Cc1cc2c(c(O)c1-c1c(C)cc3c(c1O)/C(=C/NCCCCC(=O)O)C(=O)C(O)=C3C(C)C)/C(=C/NCCCCC(=O)O)C(=O)C(O)=C2C(C)C;IC50;'=';458.0;nM;6.34;;;UO_0000065;8.84;0.17;-0.43;2.97;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.458
CHEMBL2170840;;None;1093.76;None;None;33;CCCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1;IC50;'=';78.2;nM;7.11;;;UO_0000065;6.50;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;78.2
CHEMBL2171007;;None;794.47;2;7.12;11;Cc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1;IC50;'=';689.0;nM;6.16;;;UO_0000065;7.76;0.15;-0.96;6.61;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;689.0
CHEMBL1269076;;None;642.70;2;6.79;6f;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccc(C)cc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccc(C)cc3)c2C1=O;IC50;'=';3120.0;nM;5.51;;;UO_0000065;8.57;0.16;-1.28;3.69;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;3.12
CHEMBL344184;;None;300.31;0;3.24;6;COc1ccc2c(c1)CCc1cc(OC)ccc1/[N+]([O-])=[N+]\2[O-];IC50;'=';10400.0;nM;4.98;;;UO_0000065;16.59;0.31;1.74;7.06;0;CHEMBL651292;In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;10.4
CHEMBL1962390;;None;632.67;2;4.43;20;Cc1cc2c(c(O)c1-c1c(C)cc3c(c1O)/C(=C/NCC(=O)O)C(=O)C(O)=C3C(C)C)/C(=C/NCC(=O)O)C(=O)C(O)=C2C(C)C;IC50;'=';573.0;nM;6.24;;;UO_0000065;9.87;0.19;1.81;2.92;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.573
CHEMBL2312471;;None;414.53;1;5.44;7b;CCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(OC)cc4)ccc2c13;IC50;'=';356.0;nM;6.45;;;UO_0000065;15.56;0.29;1.01;12.72;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;356.0
CHEMBL2312470;;None;461.59;1;5.85;6d;Nc1ccc(Sc2ccc3c4c(cccc24)C2=NC(=O)C(NCCCc4ccccc4)=C23)cc1;IC50;'=';20.0;nM;7.70;;;UO_0000065;16.68;0.31;1.85;11.41;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;20.0
CHEMBL337147;;None;210.24;0;0.49;32;O=C1c2ccc[n+]3c2-c2c1ccc[n+]2CC3;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL335140;;None;244.21;0;-0.79;30;Nc1nc(N)c2c(n1)[n+]([O-])c1ccccc1[n+]2[O-];IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL3908169;;None;666.82;2;5.90;BDBM179550;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1539.27;nM;5.81;;326153;UO_0000065;8.72;0.16;-0.09;5.09;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1539.27
CHEMBL3918229;;None;532.69;1;4.79;BDBM179555;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';470.04;nM;6.33;;326158;UO_0000065;11.88;0.22;1.54;7.20;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;470.04
CHEMBL3953351;;None;699.87;2;5.70;BDBM179583;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';447.69;nM;6.35;;326197;UO_0000065;9.07;0.17;0.65;4.53;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;447.69
CHEMBL3701337;;None;656.78;2;6.26;BDBM161522;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';43.5;nM;7.36;;304821;UO_0000065;11.21;0.21;1.10;7.07;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;43.5
CHEMBL3703620;;None;987.58;3;8.03;BDBM156401;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOC[C@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.4;nM;9.40;;363150;UO_0000065;9.52;0.19;1.37;5.68;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.4
CHEMBL3703622;;None;1042.71;None;None;BDBM156403;CCN(CC)CC1CN(CC[C@H](CSc2ccccc2)Nc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC([C@@H](O)c5ccccc5-c5ccc(Cl)cc5)CC4)cc3)cc2S(=O)(=O)C(F)(F)F)CCO1;IC50;'=';0.4;nM;9.40;;363152;UO_0000065;9.01;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.4
CHEMBL538616;;None;700.79;3;7.58;8r;Cc1cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c1O;IC50;'=';320.0;nM;6.50;;;UO_0000065;9.27;0.17;-1.09;3.62;0;CHEMBL1031851;Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1158469;1;Scientific Literature;J Med Chem;2009;None;;;;0.32
CHEMBL376055;;None;679.82;1;3.78;7;CN(CCCc1ccccc1)S(=O)(=O)c1cc(C(=O)N2CCc3ccc(S(=O)(=O)NCCc4ccccc4)cc3C2)c(O)c(O)c1O;IC50;'=';330.0;nM;6.48;;;UO_0000065;9.53;0.19;2.70;3.94;0;CHEMBL918623;Displacement of biotinylated Bim BH3 peptide from recombinant His-tagged Bcl2 by ELISA assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1144472;1;Scientific Literature;J Med Chem;2007;None;;;;0.33
CHEMBL3703616;;None;1042.71;None;None;BDBM156397;CCN(CC)C[C@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';0.3;nM;9.52;;298908;UO_0000065;9.13;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.3
CHEMBL2398249;;None;443.53;1;5.10;63a;CCN1CC/C(=N/Nc2nc3ccccc3s2)c2cc(-c3cccc(C(=O)O)n3)ccc21;IC50;'>';10000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2399234;Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2396645;1;Scientific Literature;J Med Chem;2013;None;;;;10.0
CHEMBL2398173;;None;414.49;1;5.21;59b;O=C(O)c1cccc(-c2ccc3c(c2)/C(=N\Nc2nc4ccccc4s2)CCC3)n1;IC50;'>';10000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2399234;Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2396645;1;Scientific Literature;J Med Chem;2013;None;;;;10.0
CHEMBL269836;;None;272.30;0;3.16;5;CC(C)c1cc(C(=O)c2ccccc2)c(O)c(O)c1O;IC50;'=';41600.0;nM;4.38;;;UO_0000065;16.09;0.30;1.22;5.63;0;CHEMBL932183;Inhibition of human Bcl-2 protein by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1141593;1;Scientific Literature;J Med Chem;2008;None;;;;41.6
CHEMBL3311494;;None;944.52;3;6.83;20;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ncc(Cl)cn3)CC2)cc1;IC50;'=';21.0;nM;7.68;;;UO_0000065;8.13;0.17;0.85;4.98;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.021
CHEMBL219775;;None;510.61;1;3.65;6;CC(C)c1cc(C(=O)N2CCc3ccc(S(=O)(=O)NCCc4ccccc4)cc3C2)c(O)c(O)c1O;IC50;'=';6600.0;nM;5.18;;;UO_0000065;10.15;0.20;1.53;4.07;0;CHEMBL918623;Displacement of biotinylated Bim BH3 peptide from recombinant His-tagged Bcl2 by ELISA assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1144472;1;Scientific Literature;J Med Chem;2007;None;;;;6.6
CHEMBL1269110;;None;655.49;2;7.09;BDBM142757;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccc(Cl)cc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccc(Cl)cc3)c2C1=O;IC50;'=';340.0;nM;6.47;;278909;UO_0000065;9.87;0.19;-0.62;4.34;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;340.0
CHEMBL343734;;None;282.35;0;1.46;37;CS1(C)=NC(=O)C2=C(N=1)c1ccccc1S2(=O)=O;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2030850;;None;832.98;2;9.32;3g;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2ccccc2)cc1;IC50;'=';100.0;nM;7.00;;;UO_0000065;8.40;0.16;-2.32;5.11;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.1
CHEMBL2030851;;None;790.94;2;8.64;3h;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccccc2)cc1;IC50;'=';130.0;nM;6.89;;;UO_0000065;8.71;0.16;-1.75;5.26;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.13
CHEMBL2030855;;None;774.94;2;8.51;3l;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(-c2ccccc2)cc1;IC50;'=';7.0;nM;8.15;;;UO_0000065;10.52;0.20;-0.36;6.71;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.007
CHEMBL2030860;;None;727.89;2;6.17;3q;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(CO)nn1-c1ccccc1;IC50;'=';24.0;nM;7.62;;;UO_0000065;10.47;0.20;1.45;5.16;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.024
CHEMBL2030866;;None;710.30;2;7.67;4b;CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';120.0;nM;6.92;;;UO_0000065;9.74;0.19;-0.75;6.15;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.12
CHEMBL2031010;;None;750.48;2;9.52;3;O=C(c1ccc(CN(Cc2ccc(F)cc2)S(=O)(=O)c2cc(Cl)cc(Cl)c2O)cc1)N(Cc1ccc(F)cc1)Cc1cc(Cl)cc(Cl)c1;IC50;'=';35.0;nM;7.46;;;UO_0000065;9.93;0.21;-2.06;9.57;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.035
CHEMBL2031011;;None;747.14;2;7.89;4;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3O)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';910.0;nM;6.04;;;UO_0000065;8.09;0.17;-1.85;4.84;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.91
CHEMBL2031015;;None;869.48;2;7.06;15;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCN5CCOCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';400.0;nM;6.40;;;UO_0000065;7.36;0.14;-0.66;4.46;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;400.0
CHEMBL2031027;;None;769.37;2;6.67;30;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl;IC50;'=';9.0;nM;8.05;;;UO_0000065;10.46;0.20;1.38;5.45;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;9.0
CHEMBL437858;;None;3160.54;None;None;5 (Bad BH3-26 (R2));CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O;IC50;'=';49.0;nM;7.31;;;UO_0000065;2.31;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;0.049
CHEMBL3703605;;None;1039.55;None;None;BDBM156385;CCN(CCOP(=O)(O)O)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';0.9;nM;9.05;;363134;UO_0000065;8.70;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.9
CHEMBL3703617;;None;1042.71;None;None;BDBM156398;CCN(CC)C[C@@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';0.3;nM;9.52;;298909;UO_0000065;9.13;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.3
CHEMBL3898420;;None;1000.63;None;None;BDBM156376;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN2CCN(CCO)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'<';1.0;nM;;;298889;UO_0000065;;;;;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.0
CHEMBL3931032;;None;1051.57;None;None;BDBM156407;COP(=O)(O)O[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';1.0;nM;9.00;;298917;UO_0000065;8.56;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.0
CHEMBL3918448;;None;716.83;4;6.16;16;COC(=O)CCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21;IC50;'=';375.0;nM;6.43;;;UO_0000065;8.96;0.17;0.27;3.35;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.375
CHEMBL2325758;;None;895.51;3;8.67;25;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)O)nn(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';7.1;nM;8.15;;;UO_0000065;9.10;0.18;-0.52;4.90;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;7.1
CHEMBL2326038;;None;838.46;3;9.22;22;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cnoc5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';350.0;nM;6.46;;;UO_0000065;7.70;0.15;-2.76;4.71;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;350.0
CHEMBL2325768;;None;932.53;2;10.90;14;Cc1c(C(F)(F)F)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';271.0;nM;6.57;;;UO_0000065;7.04;0.14;-4.33;5.66;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;271.0
CHEMBL3701345;;None;607.69;2;6.15;BDBM161531;COc1cc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)cc1F;IC50;'=';14.3;nM;7.84;;304829;UO_0000065;12.91;0.24;1.69;8.45;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;14.3
CHEMBL3701347;;None;722.85;2;6.49;BDBM161533;Cc1c(C(=O)N(c2ccccc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';21.9;nM;7.66;;304831;UO_0000065;10.60;0.19;1.17;8.12;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;21.9
CHEMBL3701358;;None;702.81;2;5.53;BDBM161547;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN1CCOCC1;IC50;'=';13.5;nM;7.87;;304845;UO_0000065;11.20;0.21;2.34;6.87;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;13.5
CHEMBL3701372;;None;735.29;2;6.40;BDBM161561;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CCOC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';5.3;nM;8.28;;304859;UO_0000065;11.26;0.21;1.88;7.86;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.3
CHEMBL3701391;;None;706.78;2;5.19;BDBM161581;Cc1c(C(=O)N(c2ccc(O)c(F)c2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';15.7;nM;7.80;;304879;UO_0000065;11.04;0.20;2.61;6.81;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;15.7
CHEMBL3704788;;None;720.80;2;5.53;BDBM161622;COc1ncc(N(C(=O)c2cc(-c3cc(F)c(OC)cc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1;IC50;'=';6.1;nM;8.21;;304920;UO_0000065;11.40;0.21;2.68;6.71;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.1
CHEMBL3701398;;None;702.22;2;5.90;BDBM161589;Cc1c(C(=O)N(c2ccc(O)cc2)c2ccnc(C#N)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';24.4;nM;7.61;;304887;UO_0000065;10.84;0.20;1.71;5.96;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;24.4
CHEMBL2398263;;None;414.49;1;5.21;74b;O=C(O)c1cc(-c2ccc3c(c2)/C(=N\Nc2nc4ccccc4s2)CCC3)ccn1;IC50;'=';5000.0;nM;5.30;;;UO_0000065;12.79;0.24;0.09;6.06;0;CHEMBL2399234;Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2396645;1;Scientific Literature;J Med Chem;2013;None;;;;5.0
CHEMBL2030846;;None;712.83;2;7.05;3c;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)O)nn1-c1ccccc1;IC50;'=';170.0;nM;6.77;;;UO_0000065;9.50;0.18;-0.28;4.88;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.17
CHEMBL2030853;;None;825.39;2;9.29;3j;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1;IC50;'=';8.0;nM;8.10;;;UO_0000065;9.81;0.19;-1.19;6.19;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.008
CHEMBL2325773;;None;837.47;3;8.75;19;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5ccnn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';110.0;nM;6.96;;;UO_0000065;8.31;0.16;-1.79;5.40;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;110.0
CHEMBL2325771;;None;928.96;3;9.92;17;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)O)c(Cl)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';1.5;nM;8.82;;;UO_0000065;9.50;0.19;-1.10;5.76;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;1.5
CHEMBL3701306;;None;698.82;2;6.36;BDBM161491;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCO3)n1C;IC50;'=';6.6;nM;8.18;;304790;UO_0000065;11.71;0.21;1.82;8.46;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.6
CHEMBL3701315;;None;589.70;2;6.01;BDBM161500;COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c1;IC50;'=';7.2;nM;8.14;;304799;UO_0000065;13.81;0.25;2.13;8.77;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7.2
CHEMBL3701319;;None;656.78;2;6.26;BDBM161504;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)COc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';50.0;nM;7.30;;304803;UO_0000065;11.12;0.20;1.04;7.01;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;50.0
CHEMBL3701335;;None;655.80;2;6.57;BDBM161520;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)NCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';26.7;nM;7.57;;304819;UO_0000065;11.55;0.21;1.00;7.08;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;26.7
CHEMBL3701389;;None;759.35;2;7.40;BDBM161579;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C;IC50;'=';2.5;nM;8.60;;304877;UO_0000065;11.33;0.21;1.20;9.11;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.5
CHEMBL3704790;;None;701.27;2;7.05;BDBM161624;Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccccc2)cc(C#N)n1C;IC50;'=';3.5;nM;8.46;;304922;UO_0000065;12.06;0.23;1.41;9.75;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.5
CHEMBL3948036;;None;710.73;2;7.22;BDBM179581;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Cl)c3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';493.55;nM;6.31;;326195;UO_0000065;8.87;0.18;-0.91;5.54;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;493.545
CHEMBL337140;;None;442.43;1;5.28;25;O=C1c2ccccc2C(=O)c2c1ccc1nc3c(ccc4c(O)c5ccccc5c(O)c43)nc21;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL136016;;None;270.33;0;2.40;27;CN1COc2ccc3ccc4c(c3c2C1)CN(C)CO4;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2326747;;None;942.60;3;9.00;19;CC(c1ccccc1-c1ccc(Cl)cc1)N1CCC(N2CCc3c(ncnc3NS(=O)(=O)c3ccc(N[C@H](CCN(C)C)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)C2)CC1;IC50;'=';35.0;nM;7.46;;;UO_0000065;7.91;0.16;-1.54;5.83;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;35.0
CHEMBL2326746;;None;946.56;3;8.58;18;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3c2CCN(C2CCN(Cc4cc(F)ccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F;IC50;'=';33.0;nM;7.48;;;UO_0000065;7.90;0.16;-1.10;5.85;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;33.0
CHEMBL2322020;;None;960.54;3;8.22;20;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3c2CCN(C2CCN(Cc4cc(F)ccc4-c4ccc(Cl)cc4)CC2)C3=O)cc1S(=O)(=O)C(F)(F)F;IC50;'=';142.0;nM;6.85;;;UO_0000065;7.13;0.15;-1.37;4.73;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;142.0
CHEMBL3900017;;None;1013.63;None;None;BDBM156412;NCC(=O)N[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';38.0;nM;7.42;;298920;UO_0000065;7.32;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;38.0
CHEMBL3893949;;None;870.49;3;8.28;BDBM156393;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.8;nM;9.10;;298904;UO_0000065;10.45;0.21;0.82;5.89;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.8
CHEMBL427653;;None;3101.51;None;None;7 (Bad BH3-26 (A22));CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O;IC50;'=';800.0;nM;6.10;;;UO_0000065;1.97;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;0.8
CHEMBL3701311;;None;660.77;2;5.76;BDBM161496;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN(C)C;IC50;'=';5.2;nM;8.28;;304795;UO_0000065;12.54;0.23;2.52;7.87;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.2
CHEMBL3701349;;None;662.77;2;5.46;BDBM161535;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';6.1;nM;8.21;;304901;UO_0000065;12.39;0.23;2.75;8.55;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.1
CHEMBL3701411;;None;700.82;2;6.24;BDBM161604;Cc1c(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C;IC50;'=';2.5;nM;8.60;;304902;UO_0000065;12.27;0.23;2.36;8.04;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.5
CHEMBL3704776;;None;713.81;2;6.60;BDBM161610;COc1ccc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc1C#N;IC50;'=';2.2;nM;8.66;;304908;UO_0000065;12.13;0.22;2.06;7.78;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.2
CHEMBL3914781;;None;518.66;1;4.49;BDBM179554;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';278.4;nM;6.55;;326157;UO_0000065;12.64;0.24;2.07;6.63;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;278.405
CHEMBL2312474;;None;410.52;1;6.20;8b;CCCCNC1=C2C(=NC1=O)c1cccc3c(Oc4ccc(C(C)C)cc4)ccc2c13;IC50;'=';322.0;nM;6.49;;;UO_0000065;15.81;0.29;0.29;12.81;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;322.0
CHEMBL449546;;None;640.23;2;7.26;39;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)Cc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';270.0;nM;6.57;;;UO_0000065;10.26;0.20;-0.69;7.50;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.27
CHEMBL454406;;None;515.70;2;5.06;10a;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cccc(C)c2C(=O)N2Cc3ccccc3C[C@H]2CN)n1;IC50;'=';175.0;nM;6.76;;;UO_0000065;13.10;0.24;1.70;8.00;0;CHEMBL1014486;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1153292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;175.0
CHEMBL510332;;None;583.69;2;5.86;21;CC(=O)NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C;IC50;'=';730.0;nM;6.14;;;UO_0000065;10.51;0.19;0.28;7.01;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.73
CHEMBL137740;;None;348.38;0;3.72;29;COc1cc2ccc3c4cc5c(cc4c[n+](C)c3c2cc1OC)OCO5;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL137744;;None;334.36;0;0.90;31;Cn1c(=O)c2nc(-[n+]3ccc(-c4ccccc4)cc3)[nH]c2n(C)c1=O;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL3701338;;None;772.91;2;7.85;BDBM161523;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(CNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';18.0;nM;7.75;;304822;UO_0000065;10.02;0.18;-0.11;6.35;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;18.0
CHEMBL3704802;;None;731.30;2;7.24;BDBM161639;CCn1c(C#N)cc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1C;IC50;'=';2.5;nM;8.60;;304936;UO_0000065;11.76;0.22;1.36;8.04;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.5
CHEMBL2325764;;None;1013.71;None;None;32, BM-1074;Cc1c(C(=O)NS(C)(=O)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C;IC50;'=';1.8;nM;8.74;;;UO_0000065;8.63;None;None;None;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;1.8
CHEMBL3701368;;None;734.30;2;5.66;BDBM161557;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN3CCOC[C@@H]3C2)n1C;IC50;'=';3.6;nM;8.44;;304855;UO_0000065;11.50;0.22;2.78;8.50;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.6
CHEMBL3701369;;None;734.30;2;5.66;BDBM161558;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN3CCOC[C@H]3C2)n1C;IC50;'=';3.4;nM;8.47;;304856;UO_0000065;11.53;0.22;2.81;8.53;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.4
CHEMBL2031001;;None;801.75;2;7.63;4c;CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';140.0;nM;6.85;;;UO_0000065;8.55;0.19;-0.78;6.09;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.14
CHEMBL2031009;;None;746.72;2;6.91;4k;CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';9.0;nM;8.05;;;UO_0000065;10.77;0.22;1.14;6.06;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.009
CHEMBL2063886;;None;1047.74;None;None;10, BM-748;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(C#Cc3cccc(-c4c(-c5ccc(Cl)cc5)cn(CC[C@H](O)CO)c4C(=O)NCCCN4CCN(C)CC4)c3)cc2)cc1[N+](=O)[O-];IC50;'=';6.6;nM;8.18;;;UO_0000065;7.81;None;None;None;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;6.6
CHEMBL2170843;;None;858.53;2;6.22;19;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(S(C)(=O)=O)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';2543.0;nM;5.59;;;UO_0000065;6.52;0.13;-0.63;4.39;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;2543.0
CHEMBL480009;;None;464.57;1;5.05;15;CCN(C(=O)c1cc(C)n(-c2ccccc2C(=O)N2CCc3ccccc3C2)n1)c1ccccc1;IC50;'=';1900.0;nM;5.72;;;UO_0000065;12.32;0.22;0.67;9.79;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;1.9
CHEMBL480010;;None;478.60;1;5.43;16;Cc1cc(C(=O)N(c2ccccc2)C(C)C)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1;IC50;'=';7700.0;nM;5.11;;;UO_0000065;10.68;0.19;-0.32;8.75;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;7.7
CHEMBL500574;;None;569.71;2;6.29;25;Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C;IC50;'=';150.0;nM;6.82;;;UO_0000065;11.98;0.22;0.53;11.06;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.15
CHEMBL449546;;None;640.23;2;7.26;39;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)Cc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';40.0;nM;7.40;;;UO_0000065;11.56;0.22;0.14;8.45;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.04
CHEMBL460173;;None;577.08;2;6.37;30;Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO;IC50;'=';480.0;nM;6.32;;;UO_0000065;10.95;0.21;-0.05;8.03;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.48
CHEMBL2063888;;None;1107.84;None;None;12;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4ccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';33.9;nM;7.47;;;UO_0000065;6.74;None;None;None;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;33.9
CHEMBL3932880;;None;987.59;3;8.03;BDBM156399;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN2CCO[C@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.6;nM;9.22;;298910;UO_0000065;9.34;0.19;1.19;5.57;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.6
CHEMBL3342332;A-1155463;None;669.80;2;6.33;EUB0000262b;CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1;IC50;'=';382.0;nM;6.42;;;UO_0000065;9.58;0.19;0.09;5.95;0;CHEMBL5213794;Selectivity interaction (TR-FRET assay) EUB0000262b BCL2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;Protein family: Apoptosis regulator;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5212743;65;EUbOPEN Chemogenomic Library Literature Data;;2023;None;"Selectivity Comments: CellTiter-Glo Luminescent Cell Viability Assay (BCL-XL dependent cell line MOLT-4): EC50 = 214 nM, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1155463; | Selectivity Remarks: In-vitro potency | Selectivity Source Knowledge: https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1155463";;;382.0
CHEMBL3930883;;None;999.64;3;7.91;BDBM156390;N[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCN(CCO)CC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';16.0;nM;7.80;;298901;UO_0000065;7.80;0.16;-0.11;4.71;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;16.0
CHEMBL2170841;;None;838.52;2;7.60;17;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(OC(C)C)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';2021.0;nM;5.69;;;UO_0000065;6.79;0.13;-1.91;5.56;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;2021.0
CHEMBL2031029;;None;839.46;2;7.05;32;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(C)c1Cl;IC50;'=';14.0;nM;7.85;;;UO_0000065;9.36;0.18;0.80;5.85;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;14.0
CHEMBL2063887;;None;1081.81;None;None;11, BM-987;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(NCCNc3cccc(-c4c(-c5ccc(Cl)cc5)cn(CC[C@H](O)CO)c4C(=O)NCCCN4CCN(C)CC4)c3)cc2)cc1[N+](=O)[O-];IC50;'=';60.6;nM;7.22;;;UO_0000065;6.67;None;None;None;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;60.6
CHEMBL2063891;;None;584.77;1;4.33;15;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCNCC3)cc2)cc1[N+](=O)[O-];IC50;'=';534000.0;nM;;Outside typical range;;UO_0000065;;;;;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;534.0
CHEMBL2398262;;None;415.48;0;4.60;74a;O=C(O)c1ccnc(-c2ccc3c(c2)/C(=N\Nc2nc4ccccc4s2)CCC3)n1;IC50;'>';10000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2399234;Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2396645;1;Scientific Literature;J Med Chem;2013;None;;;;10.0
CHEMBL5180902;;None;442.52;1;5.42;31;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3cccnc3)C(c3ccccc3)C2)cc1;IC50;'=';14500.0;nM;4.84;;;UO_0000065;10.93;0.20;-0.58;5.77;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;14.5
CHEMBL137800;;None;289.72;0;2.59;8;COc1ccc2c(c1)C(=O)C1C=C([N+]#N)C=CC1N2.[Cl-];IC50;'=';10400.0;nM;4.98;;;UO_0000065;19.60;0.36;2.39;7.50;0;CHEMBL651292;In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;10.4
CHEMBL1269072;;None;642.62;2;5.45;BDBM142749;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)Cc3ccccc3)c2C1=O;IC50;'=';220.0;nM;6.66;;278910;UO_0000065;10.36;0.19;1.21;3.63;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;220.0
CHEMBL4530348;;None;587.54;2;7.08;15a;CC(C)(C)c1ccc(C(=O)NCCN2C(=O)c3cccc4c(Sc5ccc(Br)cc5)ccc(c34)C2=O)cc1;IC50;'=';2110.0;nM;5.68;;;UO_0000065;9.66;0.20;-1.40;8.54;0;CHEMBL5234941;Inhibition of Bcl-2 (unknown origin) by ELISA analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5233252;1;Scientific Literature;Eur J Med Chem;2020;None;;INHIBITOR;;2.11
CHEMBL5174227;;None;476.37;1;5.14;56;CN(C)C(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';5910.0;nM;5.23;;;UO_0000065;10.98;0.23;0.09;9.87;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;5.91
CHEMBL5202594;;None;506.40;2;6.40;35;CC(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';881.0;nM;6.05;;;UO_0000065;;;;;0;CHEMBL5149882;Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;T;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.8809999999999999
CHEMBL1269072;;None;642.62;2;5.45;7;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)Cc3ccccc3)c2C1=O;IC50;'=';220.0;nM;6.66;;;UO_0000065;10.36;0.19;1.21;3.63;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;0.22
CHEMBL4861551;;None;550.83;1;4.23;VER-155008;O[C@@H]1[C@H](O)[C@@H](COCc2ccc(Cl)cc2)O[C@H]1n1c(NCc2ccc(Cl)c(Cl)c2)nc2cncnc21;IC50;'>';20000.0;nM;;;;UO_0000065;;;;;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;;;20.0
CHEMBL4852727;;None;405.52;0;4.16;S1g-5;N#CC1=C(NCCC(N)=O)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O;IC50;'=';13500.0;nM;4.87;;;UO_0000065;12.01;0.23;0.71;5.07;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;13.5
CHEMBL509788;;None;621.54;2;6.48;29;Cc1c(Br)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO;IC50;'=';210.0;nM;6.68;;;UO_0000065;10.74;0.22;0.20;8.49;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.21
CHEMBL451856;;None;621.78;2;6.44;46;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';510.0;nM;6.29;;;UO_0000065;10.12;0.19;-0.15;6.50;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.51
CHEMBL453380;;None;541.66;2;5.69;19;Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN;IC50;'=';110.0;nM;6.96;;;UO_0000065;12.85;0.23;1.27;8.24;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.11
CHEMBL446480;;None;584.68;2;6.29;23;CCOC(=O)[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C;IC50;'=';5610.0;nM;5.25;;;UO_0000065;8.98;0.16;-1.04;6.20;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;5.61
CHEMBL1269073;;None;570.64;2;6.07;BDBM142751;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC3CCCC3)C2=O)C(=O)c2cc(O)c(O)c(CC3CCCC3)c2C1=O;IC50;'=';2270.0;nM;5.64;;278905;UO_0000065;9.89;0.18;-0.43;3.78;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2270.0
CHEMBL500866;;None;555.68;2;5.95;26;CNC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C;IC50;'=';140.0;nM;6.85;;;UO_0000065;12.33;0.22;0.90;9.73;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.14
CHEMBL1269012;;None;756.81;3;5.67;8c;CCc1ccc(CCNC(=O)c2c(O)c(O)cc3c2C(=O)C(C)=C(C2=C(C)C(=O)c4c(cc(O)c(O)c4C(=O)NCCc4ccc(CC)cc4)C2=O)C3=O)cc1;IC50;'=';210.0;nM;6.68;;;UO_0000065;8.82;0.16;1.01;3.22;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;0.21
CHEMBL1094366;(S)-1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-((S)-2-PHENYLPROPYL)-N5'-((S)-2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE (ATROPISOMERIC MIX);None;700.79;3;7.58;(S, +, S)-14;Cc1cc2c(C(=O)NC[C@@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@@H](C)c3ccccc3)c(O)c(O)cc2c1O;IC50;'=';430.0;nM;6.37;;;UO_0000065;9.08;0.17;-1.21;3.55;0;CHEMBL1106537;Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157826;1;Scientific Literature;J Med Chem;2010;None;;;;0.43
CHEMBL1094250;1,1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-((R)-2-PHENYLPROPYL)-N5'-((R)-2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE (ATROPISOMERIC MIX);None;700.79;3;7.58;(R, +, R)-12;Cc1cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c1O;IC50;'=';1140.0;nM;5.94;;;UO_0000065;8.48;0.16;-1.64;3.31;0;CHEMBL1106537;Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157826;1;Scientific Literature;J Med Chem;2010;None;;;;1.14
CHEMBL5179160;;None;486.53;1;5.93;25;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc([N+](=O)[O-])cc3)C(c3ccccc3)C2)cc1;IC50;'=';439.0;nM;6.36;;;UO_0000065;13.07;0.24;0.43;5.57;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.439
CHEMBL5193361;;None;497.64;1;7.32;28;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C(C)(C)C)cc3)C(c3ccccc3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5204089;;None;454.46;0;3.55;6;CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc([N+](=O)[O-])cc3)C(c3ccco3)C2)cc1;IC50;'=';1970.0;nM;5.71;;;UO_0000065;12.55;0.24;2.16;4.22;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;1.97
CHEMBL5182854;;None;492.37;1;6.01;34;CCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';32.8;nM;7.48;;;UO_0000065;15.20;0.32;1.47;10.54;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.0328
CHEMBL3309311;;None;1043.65;None;None;25;CN(C)C(=O)COc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';45.0;nM;7.35;;;UO_0000065;7.04;None;None;None;0;CHEMBL3369471;Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;FDC-P1;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.045
CHEMBL3311329;;None;942.55;3;8.04;1;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';11.0;nM;7.96;;;UO_0000065;8.44;0.17;-0.08;6.20;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.011
CHEMBL3311487;;None;959.60;3;9.48;12;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(Sc3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';61.0;nM;7.21;;;UO_0000065;7.52;0.16;-2.27;5.77;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.061
CHEMBL3309310;;None;946.54;3;6.77;24;Cn1ncc(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1-c1ccc(Cl)cc1;IC50;'<';10.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.01
CHEMBL1269076;;None;642.70;2;6.79;BDBM142754;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccc(C)cc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccc(C)cc3)c2C1=O;IC50;'=';3120.0;nM;5.51;;278903;UO_0000065;8.57;0.16;-1.28;3.69;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3120.0
CHEMBL473446;;None;546.67;1;4.89;44;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(OCC(=O)O)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';10.0;nM;8.00;;;UO_0000065;14.63;0.27;3.11;7.62;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.01
CHEMBL453466;;None;584.68;2;6.29;24;COC(=O)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C;IC50;'=';280.0;nM;6.55;;;UO_0000065;11.21;0.20;0.26;7.73;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.28
CHEMBL509788;;None;621.54;2;6.48;29;Cc1c(Br)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO;IC50;'=';40.0;nM;7.40;;;UO_0000065;11.90;0.24;0.92;9.40;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.04
CHEMBL344184;;None;300.31;0;3.24;6;COc1ccc2c(c1)CCc1cc(OC)ccc1/[N+]([O-])=[N+]\2[O-];IC50;'=';4000.0;nM;5.40;;;UO_0000065;17.97;0.34;2.16;7.65;0;CHEMBL649021;Inhibitory activity against Bcl-2 using bromide assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;4.0
CHEMBL137267;;None;546.49;2;7.98;14;O=C1c2cc([N+](=O)[O-])ccc2-c2ccc3c4ccc5c6c(ccc(c7ccc1c2c73)c64)C(=O)c1cc([N+](=O)[O-])ccc1-5;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2312469;;None;427.57;1;5.80;6c;CCCCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13;IC50;'=';80.0;nM;7.10;;;UO_0000065;16.60;0.31;1.30;10.52;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;80.0
CHEMBL2312483;;None;439.58;0;4.67;5h;O=C1N=C2C(=C1NCCCc1ccccc1)c1ccc(N3CCSCC3)c3cccc2c13;IC50;'=';49.0;nM;7.31;;;UO_0000065;16.63;0.31;2.64;16.35;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;49.0
CHEMBL411219;;None;2561.87;None;None;4 (Bad BH3-C-AEM);CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O;IC50;'=';17500.0;nM;4.76;;;UO_0000065;1.86;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;17.5
CHEMBL4292460;;None;968.02;3;7.40;27a;C[C@@H]1CC[C@H]2C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)=C(C(F)(F)F)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4;IC50;'=';6.2;nM;8.21;;;UO_0000065;8.48;0.16;0.81;3.93;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;6.2
CHEMBL4294191;;None;930.09;3;6.64;28c;C[C@H]1[C@@H](OCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24O3;IC50;'=';2.2;nM;8.66;;;UO_0000065;9.31;0.18;2.02;4.14;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;2.2
CHEMBL214965;;None;335.36;0;3.65;3;O=C(Nc1ccccc1)c1cc(Cc2ccccc2)c(O)c(O)c1O;IC50;'=';5000.0;nM;5.30;;;UO_0000065;;;;;0;CHEMBL909448;Inhibition of growth of human PC3 cell overexpressing Bcl2;F;BAO_0000219;cell-based format;Homo sapiens;None;None;PC-3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;CHEMBL3307570;;;;5.0
CHEMBL4858569;;None;901.02;3;8.55;24c;CN1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1;IC50;'=';2.4;nM;8.62;;;UO_0000065;9.57;0.18;0.07;5.19;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;2.4
CHEMBL3311483;;None;975.51;3;8.22;8;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(P2(=O)CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'>';1100.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;1.1
CHEMBL3311485;;None;943.53;3;8.76;10;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(Oc3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';250.0;nM;6.60;;;UO_0000065;7.00;0.14;-2.16;4.91;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.25
CHEMBL3311492;;None;1013.62;None;None;18;CCOC(=O)C1(Cc2ccccc2-c2ccc(Cl)cc2)CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';17.0;nM;7.77;;;UO_0000065;7.67;None;None;None;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.017
CHEMBL3309311;;None;1043.65;None;None;25;CN(C)C(=O)COc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'<';10.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.01
CHEMBL2312475;;None;438.57;1;6.98;8c;CCCCCCNC1=C2C(=NC1=O)c1cccc3c(Oc4ccc(C(C)C)cc4)ccc2c13;IC50;'=';184.0;nM;6.74;;;UO_0000065;15.36;0.28;-0.24;13.29;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;184.0
CHEMBL3704811;;None;698.82;2;5.62;BDBM60405;Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)OCO3)n1C;IC50;'=';8.5;nM;8.07;;198900;UO_0000065;11.55;0.21;2.45;7.79;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;8.5
CHEMBL3950997;;None;958.59;3;8.61;BDBM156389;CCN(CCO)CC[C@@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';3.0;nM;8.52;;298900;UO_0000065;8.89;0.18;-0.09;5.26;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.0
CHEMBL2063890;;None;500.65;1;4.92;14;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccccc2)cc1[N+](=O)[O-];IC50;'>';100000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;100.0
CHEMBL1269077;;None;642.70;2;6.95;BDBM142755;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCCc3ccccc3)c2C1=O;IC50;'=';2170.0;nM;5.66;;278908;UO_0000065;8.81;0.16;-1.29;3.80;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2170.0
CHEMBL106708;;None;216.21;0;3.19;1;O=C(O)c1ccc(-c2ccc(F)cc2)cc1;IC50;;;;;;Not Determined;;;;;;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;
CHEMBL3311329;;None;942.55;3;8.04;1;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';14.0;nM;7.85;;;UO_0000065;8.33;0.17;-0.19;6.12;0;CHEMBL3369471;Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;FDC-P1;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.014
CHEMBL3311480;;None;944.52;3;6.83;5;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1cnc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)nc1;IC50;'=';340.0;nM;6.47;;;UO_0000065;6.85;0.14;-0.36;4.20;0;CHEMBL3369471;Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;FDC-P1;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.34
CHEMBL3921948;;None;957.56;3;8.66;BDBM156392;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';3.0;nM;8.52;;298903;UO_0000065;8.90;0.18;-0.14;5.86;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.0
CHEMBL3923681;;None;567.13;2;5.44;BDBM179553;CCCCN(CCCC)C(=O)c1nn(-c2ccc(OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';1529.09;nM;5.82;;326156;UO_0000065;10.25;0.20;0.38;6.62;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1529.09
CHEMBL3914781;;None;518.66;1;4.49;BDBM179554;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';246.94;nM;6.61;;326169;UO_0000065;12.74;0.24;2.12;6.68;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;246.945
CHEMBL3959104;;None;722.91;2;6.88;BDBM179563;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(-c4ccccc4)noc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';835.86;nM;6.08;;326178;UO_0000065;8.41;0.16;-0.80;4.35;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;835.86
CHEMBL3974550;;None;738.91;2;5.15;BDBM179566;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCN3C(=O)c4ccccc4C3=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';296.11;nM;6.53;;326181;UO_0000065;8.84;0.17;1.38;4.32;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;296.105
CHEMBL3912231;;None;721.93;2;6.32;BDBM179588;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(-c4ccn(C)n4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';5299.7;nM;5.28;;326202;UO_0000065;7.31;0.14;-1.04;4.01;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5299.7
CHEMBL3903272;;None;959.58;3;8.65;BDBM156380;CCN(CCO)CC[C@@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';0.5;nM;9.30;;298892;UO_0000065;9.69;0.20;0.65;5.95;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.5
CHEMBL3899842;;None;975.57;3;7.62;BDBM156382;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN(CCO)CCO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.8;nM;9.10;;298893;UO_0000065;9.32;0.19;1.48;5.15;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.8
CHEMBL2159738;;None;864.54;2;9.88;7;Cc1cc(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';99.0;nM;7.00;;;UO_0000065;8.10;0.16;-2.88;6.04;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;99.0
CHEMBL1272170;;None;490.51;0;4.85;6a;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(C)C)C2=O)C(=O)c2cc(O)c(O)c(C(C)C)c2C1=O;IC50;'=';370.0;nM;6.43;;;UO_0000065;13.11;0.24;1.58;4.31;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;0.37
CHEMBL4102399;;None;321.30;0;3.87;8a;O=[N+]([O-])c1ccccc1Nc1nnc(-c2c[nH]c3ccccc23)o1;IC50;'=';1240.0;nM;5.91;;;UO_0000065;18.38;0.34;2.04;5.38;0;CHEMBL4001923;Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4000233;1;Scientific Literature;Bioorg Med Chem Lett;2017;None;;;;1.24
CHEMBL3943276;;None;747.96;2;8.02;BDBM179592;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(C)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'>';16000.0;nM;;;326206;UO_0000065;;;;;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;16000.0
CHEMBL3900742;;None;735.93;3;5.77;BDBM179594;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3scc(C(=O)OC)c3OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';632.21;nM;6.20;;326208;UO_0000065;8.42;0.17;0.43;4.15;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;632.205
CHEMBL3959636;;None;748.79;2;7.24;BDBM179570;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)cc3CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1832.24;nM;5.74;;326230;UO_0000065;7.66;0.16;-1.50;5.04;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.832.245
CHEMBL3942106;;None;724.75;2;7.37;BDBM179577;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1980.97;nM;5.70;;326236;UO_0000065;7.87;0.16;-1.67;5.01;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1980.97
CHEMBL3977288;;None;733.33;2;6.53;BDBM179580;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(NC(C)=O)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';254.5;nM;6.59;;326239;UO_0000065;8.99;0.18;0.06;4.62;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;254.5
CHEMBL3946968;;None;705.90;2;5.77;BDBM179600;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccsc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';292.9;nM;6.53;;326259;UO_0000065;9.26;0.18;0.76;4.66;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;292.905
CHEMBL3922113;;None;987.59;3;8.03;BDBM156401;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN2CCOC[C@@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.4;nM;9.40;;298912;UO_0000065;9.52;0.19;1.37;5.68;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.4
CHEMBL2322021;;None;963.01;3;9.09;21;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nc(Cl)nc3c2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F;IC50;'=';32.0;nM;7.50;;;UO_0000065;7.78;0.16;-1.60;5.86;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;32.0
CHEMBL3311488;;None;975.60;3;8.49;13;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([S@@+]([O-])c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';434.0;nM;6.36;;;UO_0000065;6.52;0.14;-2.13;4.29;0;CHEMBL3369471;Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;FDC-P1;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.434
CHEMBL3311484;;None;975.51;3;9.10;9;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCP(=O)(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';54.0;nM;7.27;;;UO_0000065;7.45;0.16;-1.83;5.11;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.054
CHEMBL3799447;;None;591.66;2;7.86;6e;CC(C)Oc1ccc(C(=O)Nc2c(C(=O)O)nn(-c3ccc(Oc4ccccc4)cc3)c2-c2ccc(OC(C)C)cc2)cc1;IC50;'=';5000.0;nM;5.30;;;UO_0000065;8.96;0.16;-2.56;4.74;0;CHEMBL3801206;Inhibition of Bcl2 in human DMS53 cells assessed as growth inhibition;B;BAO_0000219;cell-based format;Homo sapiens;None;None;DMS-53;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3797039;1;Scientific Literature;J Med Chem;2016;CHEMBL3308726;;;;5.0
CHEMBL1689145;;None;956.62;3;9.69;33;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(CC5=C(c6ccc(Cl)cc6)CCC(C)(C)C5)CC4)ccc23)cc1S(=O)(=O)C(F)(F)F;IC50;'=';5.0;nM;8.30;;;UO_0000065;8.68;0.18;-1.39;6.49;0;CHEMBL1693055;Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1687940;1;Scientific Literature;J Med Chem;2011;None;;;;5.0
CHEMBL335782;;None;334.40;0;4.00;39;COc1ccc2c(c1)c[n+](C)c1c3cc(OC)c(OC)cc3ccc21;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2326040;;None;907.56;3;8.98;9;Cc1c(C(N)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';19.0;nM;7.72;;;UO_0000065;8.51;0.17;-1.26;4.85;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;19.0
CHEMBL2159736;;None;921.59;3;9.24;8;CNC(=O)c1c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n(C)c1C;IC50;'=';5.0;nM;8.30;;;UO_0000065;9.01;0.18;-0.94;5.72;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;5.0
CHEMBL2159737;;None;908.55;3;9.58;4, BM-903;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';1.3;nM;8.89;;;UO_0000065;9.78;0.19;-0.69;5.80;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;1.3
CHEMBL3701399;;None;682.83;2;6.10;BDBM161590;Cc1c(N(C(=O)c2cc(-c3ccccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C;IC50;'=';4.2;nM;8.38;;304888;UO_0000065;12.27;0.22;2.28;7.83;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.2
CHEMBL3701403;;None;696.85;2;5.97;BDBM161594;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';9.9;nM;8.00;;304892;UO_0000065;11.49;0.21;2.03;8.48;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;9.9
CHEMBL3704783;;None;714.84;2;6.11;BDBM161617;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';3.5;nM;8.46;;304915;UO_0000065;11.83;0.22;2.35;8.96;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.5
CHEMBL3701339;;None;722.88;2;6.41;BDBM161524;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNS(=O)(=O)CCc3ccc(F)cc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';209.6;nM;6.68;;304823;UO_0000065;9.24;0.18;0.27;5.97;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;209.6
CHEMBL3701342;;None;655.80;2;6.93;BDBM161527;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';133.3;nM;6.88;;304826;UO_0000065;10.48;0.19;-0.05;6.43;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;133.3
CHEMBL3701344;;None;600.68;2;6.40;BDBM161530;Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C;IC50;'=';4.5;nM;8.35;;304828;UO_0000065;13.90;0.25;1.95;8.59;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.5
CHEMBL3701392;;None;707.23;2;6.04;BDBM161582;COc1ncc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1;IC50;'=';4.5;nM;8.35;;304880;UO_0000065;11.80;0.22;2.31;7.37;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.5
CHEMBL3701407;;None;703.24;2;6.45;BDBM161598;Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2)c2ccc(O)cc2)cc(C#N)n1C;IC50;'=';3.8;nM;8.42;;304896;UO_0000065;11.97;0.23;1.97;7.87;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.8
CHEMBL3893085;;None;719.95;2;7.25;BDBM179584;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCc3cccc4ccccc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';529.08;nM;6.28;;326243;UO_0000065;8.72;0.16;-0.97;5.52;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;529.08
CHEMBL3704810;;None;670.81;2;6.59;BDBM55855;COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c(C)n2C)c1;IC50;'=';6.0;nM;8.22;;198899;UO_0000065;12.26;0.22;1.63;9.40;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.0
CHEMBL3704816;;None;731.30;2;6.07;BDBM60412;Cc1c(C(=O)N(C2=CC3C(C=CN3C)N=C2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';2.0;nM;8.70;;201221;UO_0000065;11.90;0.22;2.63;9.27;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.0
CHEMBL2322026;;None;827.44;3;7.00;5;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)cnn23)cc1[N+](=O)[O-];IC50;'=';25.0;nM;7.60;;;UO_0000065;9.19;0.18;0.60;4.93;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;25.0
CHEMBL1689141;;None;924.54;3;8.89;29;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)cc1S(=O)(=O)C(F)(F)F;IC50;'=';13.0;nM;7.89;;;UO_0000065;8.53;0.17;-1.00;6.17;0;CHEMBL1693055;Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1687940;1;Scientific Literature;J Med Chem;2011;None;;;;13.0
CHEMBL3927241;;None;576.69;1;4.25;BDBM179548;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';84.81;nM;7.07;;326163;UO_0000065;12.26;0.23;2.82;5.65;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;84.805
CHEMBL258819;;None;483.50;1;5.67;9, TM 179;O=C(c1ccc(Oc2ccccc2)cc1)c1cc(C(=O)c2nc3ccccc3s2)c(O)c(O)c1O;IC50;'=';170.0;nM;6.77;;;UO_0000065;14.00;0.26;1.10;5.79;0;CHEMBL932183;Inhibition of human Bcl-2 protein by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1141593;1;Scientific Literature;J Med Chem;2008;None;;;;0.17
CHEMBL2326744;;None;931.57;3;7.74;9;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nnc3n2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)CC3)cc1S(=O)(=O)C(F)(F)F;IC50;'=';25.0;nM;7.60;;;UO_0000065;8.16;0.17;-0.14;5.73;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;25.0
CHEMBL481775;;None;522.09;2;5.66;37;CCCCN(CCCC)C(=O)c1nn(-c2ccc(N)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';90.0;nM;7.05;;;UO_0000065;13.50;0.26;1.39;8.34;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.09
CHEMBL2312472;;None;442.58;1;6.22;7c;CCCCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(OC)cc4)ccc2c13;IC50;'=';206.0;nM;6.69;;;UO_0000065;15.11;0.29;0.47;13.19;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;206.0
CHEMBL539481;;None;741.62;3;8.80;8k;Cc1cc2c(C(=O)NC(C)c3ccc(Cl)cc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC(C)c3ccc(Cl)cc3)c(O)c(O)cc2c1O;IC50;'=';490.0;nM;6.31;;;UO_0000065;8.51;0.17;-2.49;3.51;0;CHEMBL1031851;Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1158469;1;Scientific Literature;J Med Chem;2009;None;;;;0.49
CHEMBL1098324;;None;630.72;2;5.61;13;COc1ccc(C2C3=C(N=c4s/c(=C\c5ccc(OCc6cccc(C(=O)O)c6)c(OC)c5)c(=O)n42)c2ccccc2CC3)cc1;IC50;'=';3200.0;nM;5.50;;;UO_0000065;8.71;0.16;-0.12;5.53;0;CHEMBL1120826;Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157133;1;Scientific Literature;J Med Chem;2010;None;;;;3.2
CHEMBL2325762;;None;950.63;3;10.84;30;CCCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1;IC50;'=';23.0;nM;7.64;;;UO_0000065;8.03;0.16;-3.20;4.98;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;23.0
CHEMBL520607;;None;525.45;1;3.98;32;CCN(CC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Br;IC50;'=';17300.0;nM;4.76;;;UO_0000065;9.06;0.19;0.78;6.05;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;17.3
CHEMBL446802;;None;626.20;2;7.33;38;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)c3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';5660.0;nM;5.25;;;UO_0000065;8.38;0.16;-2.08;5.99;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;5.66
CHEMBL4287383;;None;976.12;3;5.93;34a;C[C@@H]1CC[C@H]2[C@@H](C)C(OCCN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)C[C@H]3CO)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4;IC50;'=';67.1;nM;7.17;;;UO_0000065;7.35;0.14;1.24;3.01;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;67.1
CHEMBL553474;;None;741.62;3;7.76;8p;Cc1cc2c(C(=O)NCCc3cccc(Cl)c3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCCc3cccc(Cl)c3)c(O)c(O)cc2c1O;IC50;'=';4400.0;nM;5.36;;;UO_0000065;7.22;0.14;-2.40;2.98;0;CHEMBL1031851;Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1158469;1;Scientific Literature;J Med Chem;2009;None;;;;4.4
CHEMBL467229;;None;537.10;2;5.44;35;CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';100.0;nM;7.00;;;UO_0000065;13.03;0.25;1.56;8.90;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.1
CHEMBL502066;;None;637.85;2;7.15;45;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NC(=O)CSc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';600.0;nM;6.22;;;UO_0000065;9.75;0.18;-0.93;7.11;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.6
CHEMBL518649;;None;551.14;1;4.98;8;CCCCN(CCCC)C(=O)c1nn(-c2ccc(N)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl;IC50;'=';380.0;nM;6.42;;;UO_0000065;11.65;0.22;1.44;5.81;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.38
CHEMBL137543;;None;260.32;0;3.25;38;Cc1cc(-c2ccccc2)[nH]c2nc3ccccc3[n+]1-2;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2170851;;None;1023.62;None;None;27;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CC(O)C6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';7.7;nM;8.11;;;UO_0000065;7.93;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;7.7
CHEMBL513318;;None;472.63;1;5.42;34;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccccc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';2010.0;nM;5.70;;;UO_0000065;12.05;0.22;0.28;9.75;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;2.01
CHEMBL503783;;None;556.67;2;6.03;7 (trans atropisomer, a-R);Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2C[C@@H]1CO;IC50;'=';6100.0;nM;5.21;;;UO_0000065;9.37;0.17;-0.82;6.63;0;CHEMBL1014486;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1153292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;6100.0
CHEMBL516633;;None;518.66;2;6.36;17;Cc1cc(C(=O)N(c2ccccc2)C2CCCCC2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1;IC50;'=';1400.0;nM;5.85;;;UO_0000065;11.29;0.20;-0.51;10.02;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;1.4
CHEMBL503454;;None;576.10;2;6.34;31;Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN;IC50;'=';30.0;nM;7.52;;;UO_0000065;13.06;0.24;1.18;8.91;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.03
CHEMBL552287;;None;672.73;3;6.46;8n;Cc1cc2c(C(=O)NCCc3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCCc3ccccc3)c(O)c(O)cc2c1O;IC50;'=';150.0;nM;6.82;;;UO_0000065;10.14;0.19;0.36;3.80;0;CHEMBL1031851;Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1158469;1;Scientific Literature;J Med Chem;2009;None;;;;0.15
CHEMBL4584015;;None;746.84;3;5.47;9;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)c(S(=O)(=O)F)c2)cc1;IC50;'=';9700.0;nM;5.01;;;UO_0000065;6.71;0.14;-0.46;3.04;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;9.7
CHEMBL1269074;;None;626.75;2;7.63;6d;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCC3CCCCC3)C2=O)C(=O)c2cc(O)c(O)c(CCC3CCCCC3)c2C1=O;IC50;'=';6730.0;nM;5.17;;;UO_0000065;8.25;0.15;-2.46;3.47;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;6.73
CHEMBL1269075;;None;614.65;2;6.17;6e;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccccc3)c2C1=O;IC50;'=';2570.0;nM;5.59;;;UO_0000065;9.09;0.17;-0.58;3.75;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;2.57
CHEMBL220055;;None;327.38;0;3.13;4;CC(C)c1cc(C(=O)N2CCc3ccccc3C2)c(O)c(O)c1O;IC50;'=';38200.0;nM;4.42;;;UO_0000065;13.49;0.25;1.29;5.45;1;CHEMBL932183;Inhibition of human Bcl-2 protein by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1141593;1;Scientific Literature;J Med Chem;2008;None;;;;38.2
CHEMBL1095309;;None;560.63;2;5.29;12h;COc1ccc(C2C3=C(N=c4s/c(=C\c5ccc(-c6cccc(C(=O)O)c6)o5)c(=O)n42)c2ccccc2CC3)cc1;IC50;'=';11100.0;nM;4.96;;;UO_0000065;8.84;0.17;-0.34;5.27;0;CHEMBL1120826;Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157133;1;Scientific Literature;J Med Chem;2010;None;;;;11.1
CHEMBL1095310;;None;560.63;2;5.29;12i;COc1cccc(C2C3=C(N=c4s/c(=C\c5ccc(-c6cccc(C(=O)O)c6)o5)c(=O)n42)c2ccccc2CC3)c1;IC50;'=';19400.0;nM;4.71;;;UO_0000065;8.41;0.16;-0.58;5.01;0;CHEMBL1120826;Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157133;1;Scientific Literature;J Med Chem;2010;None;;;;19.4
CHEMBL3704807;;None;576.10;2;7.54;BDBM161645;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2CCc3ccccc3C2)n1C;IC50;'=';19.2;nM;7.72;;304941;UO_0000065;13.39;0.25;0.18;11.73;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;19.2
CHEMBL3701298;;None;702.83;2;6.57;BDBM161483;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1CCCO;IC50;'=';14.2;nM;7.85;;304782;UO_0000065;11.17;0.21;1.28;7.97;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;14.2
CHEMBL3701301;;None;702.78;2;6.45;BDBM161486;Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';12.6;nM;7.90;;304785;UO_0000065;11.24;0.21;1.45;8.17;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;12.6
CHEMBL3701303;;None;728.85;2;6.16;BDBM161488;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCN2CCOCC2)OCO3)n1CCO;IC50;'=';3.9;nM;8.41;;304787;UO_0000065;11.54;0.21;2.25;7.19;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.9
CHEMBL3701305;;None;702.81;2;5.09;BDBM161490;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCO3)n1C;IC50;'=';4.7;nM;8.33;;304789;UO_0000065;11.85;0.22;3.24;7.27;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.7
CHEMBL3701316;;None;642.76;2;6.86;BDBM161501;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)Oc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';13.3;nM;7.88;;304800;UO_0000065;12.25;0.22;1.02;7.57;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;13.3
CHEMBL3701333;;None;740.86;2;5.70;BDBM161518;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';4.0;nM;8.40;;304817;UO_0000065;11.34;0.21;2.70;7.44;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.0
CHEMBL3701376;;None;744.87;2;6.12;BDBM161565;COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnc4c(c3)CCN4C)c(C)n2C)cc1F;IC50;'=';8.8;nM;8.06;;304863;UO_0000065;10.81;0.20;1.94;7.77;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;8.8
CHEMBL3982160;;None;723.90;2;6.28;BDBM179589;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4noc(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';843.13;nM;6.07;;326203;UO_0000065;8.39;0.16;-0.21;3.98;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;843.135
CHEMBL3938600;;None;676.28;2;6.57;BDBM179569;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';714.5;nM;6.15;;326184;UO_0000065;9.09;0.18;-0.42;5.40;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;714.5
CHEMBL3967288;;None;694.27;2;6.71;BDBM179572;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(Cl)ccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';957.15;nM;6.02;;326187;UO_0000065;8.67;0.17;-0.69;5.29;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;957.155
CHEMBL3915540;;None;1027.65;None;None;BDBM156411;CNCC(=O)N[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';27.0;nM;7.57;;298919;UO_0000065;7.36;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;27.0
CHEMBL2325759;;None;895.51;3;8.67;26;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)nn(C)c5C(=O)O)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';3.7;nM;8.43;;;UO_0000065;9.42;0.19;-0.24;5.07;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;3.7
CHEMBL2312482;;None;405.57;0;4.62;5e;CCCCCCNC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13;IC50;'=';96.0;nM;7.02;;;UO_0000065;17.30;0.33;2.40;15.70;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;96.0
CHEMBL3957283;;None;688.77;4;5.38;15;COC(=O)CCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21;IC50;'=';286.0;nM;6.54;;;UO_0000065;9.50;0.18;1.16;3.41;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.286
CHEMBL3287283;;None;420.52;1;5.27;2;O=C(O)c1csc(-c2ccc3c(c2)/C(=N/Nc2nc4ccccc4s2)CCC3)n1;IC50;'=';5000.0;nM;5.30;;;UO_0000065;12.61;0.25;0.03;6.06;0;CHEMBL3291800;Antagonist activity at Bcl-2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3286340;1;Scientific Literature;ACS Med Chem Lett;2014;None;;;;5.0
CHEMBL454411;;None;550.15;2;5.71;10b;CCCCN(CCCC)C(=O)c1nn(-c2cccc(C)c2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl;IC50;'=';42.0;nM;7.38;;;UO_0000065;13.41;0.26;1.67;8.73;0;CHEMBL1014486;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1153292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;42.0
CHEMBL4063192;;None;290.33;0;4.27;8h;Cc1ccc(Nc2nnc(-c3c[nH]c4ccccc34)o2)cc1;IC50;'=';21120.0;nM;4.67;;;UO_0000065;16.10;0.29;0.41;7.01;0;CHEMBL4001923;Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4000233;1;Scientific Literature;Bioorg Med Chem Lett;2017;None;;;;21.12
CHEMBL259033;;None;392.41;0;4.67;7;CC(C)C(=O)c1cc(C(=O)c2ccc(Oc3ccccc3)cc2)c(O)c(O)c1O;IC50;'=';2600.0;nM;5.58;;;UO_0000065;14.23;0.26;0.92;5.37;0;CHEMBL932183;Inhibition of human Bcl-2 protein by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1141593;1;Scientific Literature;J Med Chem;2008;None;;;;2.6
CHEMBL2322027;;None;874.51;3;7.19;6;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC2=NS(=O)(=O)c3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc32)cc1[N+](=O)[O-];IC50;'=';17.0;nM;7.77;;;UO_0000065;8.88;0.18;0.58;4.93;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;17.0
CHEMBL4446373;;None;742.87;3;5.22;11;CS(=O)(=O)c1cc(C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c([N+](=O)[O-])c2)ccc1-c1ccc(F)cc1;IC50;'>';99000.0;nM;;;;UO_0000065;;;;;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;99.0
CHEMBL3929718;;None;646.69;4;5.20;14;COC(=O)CN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21;IC50;'=';103.0;nM;6.99;;;UO_0000065;10.80;0.20;1.79;3.64;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.103
CHEMBL3971530;;None;772.94;4;7.73;18;COC(=O)CCCCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21;IC50;'=';840.0;nM;6.08;;;UO_0000065;7.86;0.15;-1.65;3.17;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.84
CHEMBL3704813;;None;685.78;2;5.71;BDBM60408;Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';8.0;nM;8.10;;198902;UO_0000065;11.81;0.22;2.39;7.39;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;8.0
CHEMBL4207006;;None;895.46;3;6.27;54;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5(CN6CCOCC6)COC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1;IC50;'=';14.5;nM;7.84;;;UO_0000065;8.75;0.18;1.57;5.82;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;14.5
CHEMBL4206829;;None;892.51;2;7.45;53;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@@H](CC5CC5)CN5CCOCC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1;IC50;'=';20.7;nM;7.68;;;UO_0000065;8.61;0.17;0.23;5.99;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;20.7
CHEMBL3701377;;None;688.80;2;6.25;BDBM161566;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';6.3;nM;8.20;;304864;UO_0000065;11.91;0.22;1.95;8.54;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.3
CHEMBL3704797;;None;676.79;2;5.76;BDBM161634;Cc1c(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cnn1C;IC50;'=';6.9;nM;8.16;;304931;UO_0000065;12.06;0.22;2.40;8.50;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.9
CHEMBL3704801;;None;717.27;2;6.76;BDBM161638;Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn(C)c1C#N;IC50;'=';10.5;nM;7.98;;304935;UO_0000065;11.12;0.21;1.22;7.46;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;10.5
CHEMBL3701384;;None;731.30;2;6.62;BDBM161573;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';3.6;nM;8.44;;304871;UO_0000065;11.55;0.22;1.82;8.95;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.6
CHEMBL3701386;;None;713.28;2;7.42;BDBM161575;Cc1c(C(=O)N(c2ccccc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';21.2;nM;7.67;;304873;UO_0000065;10.76;0.20;0.25;10.12;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;21.2
CHEMBL3701397;;None;718.83;2;5.88;BDBM161587;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn([C@H]3CCOC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';24.2;nM;7.62;;304886;UO_0000065;10.60;0.20;1.74;7.23;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;24.2
CHEMBL3701415;;None;713.81;2;6.60;BDBM161608;COc1cc(C#N)cc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1;IC50;'=';4.2;nM;8.38;;304906;UO_0000065;11.74;0.22;1.78;7.53;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.2
CHEMBL3920752;;None;611.14;1;4.90;BDBM179545;CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';134.92;nM;6.87;;326160;UO_0000065;11.24;0.22;1.97;5.49;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;134.92
CHEMBL4863897;;None;936.45;3;9.68;17a;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2C(F)(F)F)C1;IC50;'=';0.86;nM;9.07;;;UO_0000065;9.68;0.19;-0.61;5.27;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;0.86
CHEMBL4862150;;None;887.98;3;8.64;24e;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1;IC50;'=';4.7;nM;8.33;;;UO_0000065;9.38;0.18;-0.31;4.84;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;4.7
CHEMBL4851700;;None;902.01;3;8.52;24m;CN1CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1;IC50;'=';0.75;nM;9.12;;;UO_0000065;10.12;0.19;0.60;5.59;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;0.75
CHEMBL1672080;;None;408.53;1;6.30;6g;CCC(C)(C)c1ccc(Sc2ccc3c4c(cccc24)C2=NC(=O)C(C#N)=C23)cc1;IC50;'=';342.0;nM;6.47;;;UO_0000065;15.83;0.29;0.17;12.15;0;CHEMBL1677787;Displacement of FAM-Bid from human recombinant Bcl-2 after 30 mins by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1671783;1;Scientific Literature;J Med Chem;2011;None;;;;0.342
CHEMBL2170838;;None;1079.73;None;None;31;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C;IC50;'=';4.0;nM;8.40;;;UO_0000065;7.78;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;4.0
CHEMBL2170845;;None;884.57;2;6.75;21;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(S(=O)(=O)C6CC6)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';844.0;nM;6.07;;;UO_0000065;6.87;0.14;-0.68;4.77;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;844.0
CHEMBL1096755;;None;548.60;2;5.42;12c;O=C(O)c1cccc(-c2ccc(/C=c3\sc4n(c3=O)C(c3cccc(F)c3)C3=C(N=4)c4ccccc4CC3)o2)c1;IC50;'=';8000.0;nM;5.10;;;UO_0000065;9.29;0.17;-0.32;6.01;0;CHEMBL1120826;Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157133;1;Scientific Literature;J Med Chem;2010;None;;;;8.0
CHEMBL3701354;;None;702.81;2;5.53;BDBM161543;CCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C;IC50;'=';8.4;nM;8.08;;304841;UO_0000065;11.49;0.21;2.55;7.05;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;8.4
CHEMBL3701357;;None;738.79;2;5.77;BDBM161546;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1CC(F)F;IC50;'=';7.0;nM;8.15;;304844;UO_0000065;11.04;0.21;2.38;7.12;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7.0
CHEMBL3923262;;None;944.56;3;8.22;BDBM156388;CN(CCO)CC[C@@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';4.0;nM;8.40;;298899;UO_0000065;8.89;0.18;0.18;5.18;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.0
CHEMBL3943506;;None;1123.67;None;None;BDBM156405;CC(C)(C)OP(=O)(O)OCO[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';4.0;nM;8.40;;298915;UO_0000065;7.47;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.0
CHEMBL464268;;None;476.58;0;4.58;2;Cc1cc(C(=O)N2CCc3ccccc3C2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1;IC50;'=';1500.0;nM;5.82;;;UO_0000065;12.22;0.22;1.24;9.97;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;1.5
CHEMBL464440;;None;436.52;0;4.63;9;Cc1cc(C(=O)Nc2ccccc2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1;IC50;'=';50000.0;nM;4.30;;;UO_0000065;9.85;0.18;-0.33;6.40;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;50.0
CHEMBL504480;;None;656.23;2;7.09;40;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';40.0;nM;7.40;;;UO_0000065;11.27;0.21;0.31;7.64;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.04
CHEMBL473446;;None;546.67;1;4.89;44;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(OCC(=O)O)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';130.0;nM;6.89;;;UO_0000065;12.60;0.24;2.00;6.56;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.13
CHEMBL3704793;;None;695.20;2;6.17;BDBM161628;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc(F)cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';7.8;nM;8.11;;304925;UO_0000065;11.66;0.22;1.94;7.79;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7.8
CHEMBL3701361;;None;704.83;2;5.78;BDBM161550;COCCN(C)CCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C;IC50;'=';6.4;nM;8.19;;304848;UO_0000065;11.63;0.22;2.41;7.15;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.4
CHEMBL4592343;;None;927.52;3;9.08;7g;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCCCCCC(=O)NO)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'=';250.0;nM;6.60;;;UO_0000065;7.12;0.14;-2.48;3.11;0;CHEMBL4332203;Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4330103;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;0.25
CHEMBL2322028;;None;959.58;3;7.47;7;O=S(=O)(Nc1nnc2n1CCN(C1CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC1)C2)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1;IC50;'<';5.0;nM;;;;UO_0000065;;;;;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;5.0
CHEMBL5187447;;None;449.30;1;5.14;52;O=C(O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL3924348;;None;1032.65;None;None;BDBM156383;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN2CCN(C[C@@H](O)CF)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';1.0;nM;9.00;;298894;UO_0000065;8.72;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.0
CHEMBL1097075;;None;524.60;1;3.79;1;COc1ccccc1C1C2=C(N=c3s/c(=C\c4cccc(OCC(=O)O)c4)c(=O)n31)c1ccccc1CC2;IC50;'=';3100.0;nM;5.51;;;UO_0000065;10.50;0.20;1.72;6.11;0;CHEMBL1120826;Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157133;1;Scientific Literature;J Med Chem;2010;None;;;;3.1
CHEMBL4091074;;None;306.33;0;3.97;8i;COc1ccc(Nc2nnc(-c3c[nH]c4ccccc34)o2)cc1;IC50;'=';29050.0;nM;4.54;;;UO_0000065;14.81;0.27;0.57;5.97;0;CHEMBL4001923;Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4000233;1;Scientific Literature;Bioorg Med Chem Lett;2017;None;;;;29.05
CHEMBL5196601;;None;521.42;2;6.18;21;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccn3)C2)cc1;IC50;'=';650.0;nM;6.19;;;UO_0000065;11.87;0.25;0.01;7.38;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.65
CHEMBL5201208;;None;423.49;0;3.95;1;Cc1ccc(C(=O)N2N=C(c3ccc(NS(C)(=O)=O)cc3)CC2c2ccco2)cc1;IC50;'=';15900.0;nM;4.80;;;UO_0000065;11.33;0.22;0.85;5.22;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;15.9
CHEMBL551288;APOGOSSYPOL;None;462.54;2;6.76;2, Apogossypol;Cc1cc2c(C(C)C)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)cc2c1O;IC50;'=';80000.0;nM;4.10;;;UO_0000065;8.86;0.16;-2.66;3.38;0;CHEMBL1031851;Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1158469;1;Scientific Literature;J Med Chem;2009;None;;;;80.0
CHEMBL2325772;;None;837.47;3;8.75;18;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cncn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';46.0;nM;7.34;;;UO_0000065;8.76;0.17;-1.41;5.69;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;46.0
CHEMBL2325770;;None;962.52;3;10.29;16;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)O)c(C(F)(F)F)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';1.1;nM;8.96;;;UO_0000065;9.31;0.19;-1.33;5.84;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;1.1
CHEMBL2312476;;None;472.59;1;7.03;8d;CC(C)c1ccc(Oc2ccc3c4c(cccc24)C2=NC(=O)C(NCCCc4ccccc4)=C23)cc1;IC50;'=';42.0;nM;7.38;;;UO_0000065;15.61;0.28;0.35;14.55;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;42.0
CHEMBL554545;;None;728.84;3;8.22;8j;Cc1cc(C)c(CNC(=O)c2c(O)c(O)cc3c(O)c(-c4c(C)cc5c(C(=O)NCc6c(C)cc(C)cc6C)c(O)c(O)cc5c4O)c(C)cc23)c(C)c1;IC50;'=';700.0;nM;6.16;;;UO_0000065;8.44;0.16;-2.07;3.43;0;CHEMBL1031851;Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1158469;1;Scientific Literature;J Med Chem;2009;None;;;;0.7
CHEMBL3976266;;None;699.87;2;5.69;BDBM179587;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc4c(c3)OCCO4)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';511.57;nM;6.29;;326246;UO_0000065;8.99;0.17;0.60;4.76;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;511.57
CHEMBL3932360;;None;729.94;2;7.58;BDBM179591;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc4ccc(F)cc4c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';834.15;nM;6.08;;326250;UO_0000065;8.33;0.16;-1.50;5.34;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;834.155
CHEMBL4453237;;None;872.49;2;7.48;J1H;C[N+](C)(CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-])CC(=O)O;IC50;'=';500.0;nM;6.30;;;UO_0000065;7.22;0.14;-1.18;3.88;0;CHEMBL4378481;Displacement of fluorescein labelled Puma-BH3 peptide from human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4376822;1;Scientific Literature;J Med Chem;2020;None;;;;0.5
CHEMBL2312479;;None;411.53;0;4.24;5g;O=C1N=C2C(=C1NCc1ccccc1)c1ccc(N3CCSCC3)c3cccc2c13;IC50;'>';10000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;10.0
CHEMBL2063881;;None;424.55;0;2.77;5, BM-955;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(N)(=O)=O)cc1[N+](=O)[O-];IC50;'>';100000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;100.0
CHEMBL2325765;;None;977.65;3;9.09;11;Cc1c(C(=O)N2CC(C)(O)C2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';5.6;nM;8.25;;;UO_0000065;8.44;0.17;-0.84;5.27;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;5.6
CHEMBL1689146;;None;998.66;3;9.46;34;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc4c(NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)ncnc4c3)CC2)C1;IC50;'=';84.0;nM;7.08;;;UO_0000065;7.09;0.14;-2.38;5.16;0;CHEMBL1693055;Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1687940;1;Scientific Literature;J Med Chem;2011;None;;;;84.0
CHEMBL4858527;;None;919.06;3;9.71;24k;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCSCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1;IC50;'=';1.65;nM;8.78;;;UO_0000065;9.56;0.19;-0.93;5.49;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;1.65
CHEMBL3311488;;None;975.60;3;8.49;13;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([S@@+]([O-])c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';19.0;nM;7.72;;;UO_0000065;7.91;0.16;-0.77;5.21;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.019
CHEMBL3309262;;None;1043.65;None;None;26;CN(C)C(=O)COc1ccc(-c2ccc(Cl)cc2)c(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1;IC50;'=';187.0;nM;6.73;;;UO_0000065;6.45;None;None;None;0;CHEMBL3369471;Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;FDC-P1;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.187
CHEMBL2170839;;None;1079.73;None;None;32;CCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1;IC50;'=';30.1;nM;7.52;;;UO_0000065;6.97;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;30.1
CHEMBL4075044;;None;310.74;0;4.61;8e;Clc1cccc(Nc2nnc(-c3c[nH]c4ccccc34)o2)c1;IC50;'=';660.0;nM;6.18;;;UO_0000065;19.89;0.38;1.57;9.26;0;CHEMBL4001923;Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4000233;1;Scientific Literature;Bioorg Med Chem Lett;2017;None;;;;0.66
CHEMBL4066452;;None;321.30;0;3.87;8c;O=[N+]([O-])c1ccc(Nc2nnc(-c3c[nH]c4ccccc34)o2)cc1;IC50;'=';3830.0;nM;5.42;;;UO_0000065;16.86;0.31;1.55;4.93;0;CHEMBL4001923;Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4000233;1;Scientific Literature;Bioorg Med Chem Lett;2017;None;;;;3.83
CHEMBL217223;;None;475.52;0;4.48;4;O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)c1cc(Cc2ccccc2)c(O)c(O)c1O;IC50;'=';1600.0;nM;5.80;;;UO_0000065;12.19;0.23;1.32;4.68;0;CHEMBL909445;Binding affinity to human Bcl2 by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;None;;;;1.6
CHEMBL2170849;;None;1021.65;None;None;25;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';8.3;nM;8.08;;;UO_0000065;7.91;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;8.3
CHEMBL259034;;None;476.48;1;6.21;8;O=C(c1ccc(Oc2ccccc2)cc1)c1cc(C(=O)c2cccc3ccccc23)c(O)c(O)c1O;IC50;'=';290.0;nM;6.54;;;UO_0000065;13.72;0.25;0.33;6.28;0;CHEMBL932183;Inhibition of human Bcl-2 protein by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1141593;1;Scientific Literature;J Med Chem;2008;None;;;;0.29
CHEMBL3977288;;None;733.33;2;6.53;BDBM179580;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(NC(C)=O)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';427.08;nM;6.37;;326194;UO_0000065;8.69;0.17;-0.16;4.46;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;427.085
CHEMBL3890556;;None;645.83;1;4.65;BDBM179571;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cn(C)cn3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';639.96;nM;6.19;;326186;UO_0000065;9.59;0.18;1.54;4.71;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;639.955
CHEMBL2312467;;None;392.48;0;3.44;4b;CCCOC(=O)C1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13;IC50;'=';2100.0;nM;5.68;;;UO_0000065;14.47;0.28;2.24;9.63;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;2.1
CHEMBL1672071;;None;364.40;1;5.38;8a;CC(C)c1ccc(Oc2ccc3c4c(cccc24)C2=NC(=O)C(C#N)=C23)cc1;IC50;'=';739.0;nM;6.13;;;UO_0000065;16.83;0.30;0.75;9.82;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;739.0
CHEMBL2322022;;None;996.57;3;9.46;22;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nc(C(F)(F)F)nc3c2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F;IC50;'=';46.0;nM;7.34;;;UO_0000065;7.36;0.15;-2.12;5.74;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;46.0
CHEMBL4438456;;None;501.68;1;4.75;J1Q;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1;IC50;'=';1300.0;nM;5.89;;;UO_0000065;11.73;0.22;1.14;6.97;0;CHEMBL4378481;Displacement of fluorescein labelled Puma-BH3 peptide from human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4376822;1;Scientific Literature;J Med Chem;2020;None;;;;1.3
CHEMBL4529727;;None;746.84;3;5.47;7;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)c(S(=O)(=O)F)c1;IC50;'=';2000.0;nM;5.70;;;UO_0000065;7.63;0.16;0.23;3.45;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;2.0
CHEMBL2325766;;None;985.65;3;8.57;12;Cc1c(C(=O)NS(C)(=O)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';0.9;nM;9.05;;;UO_0000065;9.18;0.18;0.48;5.05;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;0.9
CHEMBL4868427;;None;902.01;3;9.03;17b;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1;IC50;'=';1.5;nM;8.82;;;UO_0000065;9.78;0.19;-0.21;5.13;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;1.5
CHEMBL4855736;;None;902.99;3;8.99;24j;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1;IC50;'=';3.0;nM;8.52;;;UO_0000065;9.44;0.18;-0.47;5.04;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;3.0
CHEMBL4873467;;None;864.04;3;8.02;17c;COc1ccc(C2=C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)CCC(C)(C)C2)cc1;IC50;'=';3.8;nM;8.42;;;UO_0000065;9.75;0.19;0.40;4.65;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;3.8
CHEMBL3309313;;None;1029.67;None;None;28;CN(C)CCOc1ccc(-c2ccc(Cl)cc2)c(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1;IC50;'=';22.0;nM;7.66;;;UO_0000065;7.44;None;None;None;0;CHEMBL3369471;Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;FDC-P1;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.022
CHEMBL3311486;;None;955.54;3;8.81;11;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(C(=O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';65.0;nM;7.19;;;UO_0000065;7.52;0.15;-1.62;5.05;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.065
CHEMBL3311489;;None;975.60;3;8.49;14;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([S@+]([O-])c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';545.0;nM;6.26;;;UO_0000065;6.42;0.13;-2.23;4.23;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.545
CHEMBL3311479;;None;944.52;3;6.83;4;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)nn1;IC50;'=';270.0;nM;6.57;;;UO_0000065;6.95;0.14;-0.26;4.26;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.27
CHEMBL3309307;;None;943.54;3;7.43;21;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccncc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'<';10.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.01
CHEMBL3309312;;None;1029.67;None;None;27;CN(C)CCOc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';4.0;nM;8.40;;;UO_0000065;8.16;None;None;None;0;CHEMBL3369471;Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;FDC-P1;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.004
CHEMBL3704784;;None;714.80;2;6.00;BDBM161618;COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)ccn3)c(C)n2C)cc1F;IC50;'=';14.9;nM;7.83;;304916;UO_0000065;10.95;0.20;1.83;6.30;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;14.9
CHEMBL3701383;;None;419.85;0;4.51;BDBM161572;CC(Nc1ncnc(N)c1C#N)c1cc(Cl)c2ccnnc2c1-c1cccc(F)c1;IC50;'=';20.6;nM;7.69;;304870;UO_0000065;18.31;0.35;3.18;6.78;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;20.6
CHEMBL3640002;;None;729.28;2;7.12;BDBM161576;Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';30.3;nM;7.52;;304874;UO_0000065;10.31;0.19;0.40;7.83;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;30.3
CHEMBL3701387;;None;703.28;2;8.02;BDBM161577;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C;IC50;'=';3.8;nM;8.42;;304875;UO_0000065;11.97;0.23;0.40;10.76;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.8
CHEMBL3701393;;None;700.24;2;7.11;BDBM161583;Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';3.9;nM;8.41;;304881;UO_0000065;12.01;0.23;1.30;8.24;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.9
CHEMBL3701401;;None;712.85;2;6.11;BDBM161592;COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c1;IC50;'=';5.4;nM;8.27;;304890;UO_0000065;11.60;0.21;2.16;7.11;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.4
CHEMBL3704782;;None;668.80;2;5.79;BDBM161616;Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';2.6;nM;8.59;;304914;UO_0000065;12.84;0.23;2.80;8.03;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.6
CHEMBL3957281;;None;670.88;2;5.81;BDBM179596;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(N)ccc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';530.64;nM;6.28;;326255;UO_0000065;9.35;0.18;0.47;4.49;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;530.645
CHEMBL4111735;;None;715.96;2;6.25;BDBM179598;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])C[C@]34CC[C@H](CC3=O)C4(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';726.27;nM;6.14;;326257;UO_0000065;8.57;0.16;-0.11;4.69;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;726.275
CHEMBL4861266;;None;289.29;0;2.24;S1e;N#CC1=C(C#N)c2ccc(NCCO)c3cccc(c23)C1=O;IC50;'>';20000.0;nM;;;;UO_0000065;;;;;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;;;20.0
CHEMBL4877337;;None;390.55;1;6.09;S1g-3;CCCCNC1=C(C#N)C(=O)c2cccc3c(SC4CCCCC4)ccc1c23;IC50;'=';16000.0;nM;4.80;;;UO_0000065;12.28;0.23;-1.29;9.07;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;16.0
CHEMBL4867128;;None;936.45;3;9.68;17f;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)c(Cl)c2)C1;IC50;'=';0.8;nM;9.10;;;UO_0000065;9.71;0.19;-0.58;5.29;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;0.8
CHEMBL4847514;;None;971.12;3;9.49;24d;CC(C)C(=O)N1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1;IC50;'=';2.4;nM;8.62;;;UO_0000065;8.88;0.17;-0.87;4.71;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;2.4
CHEMBL4474764;;None;815.89;2;6.09;13;C#CCN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(-c3ccc(F)cc3)c(S(=O)(=O)F)c2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';1300.0;nM;5.89;;;UO_0000065;7.21;0.15;-0.20;4.01;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;1.3
CHEMBL4279468;;None;944.08;3;5.55;29b;C[C@H]1[C@@H](CC(=O)N2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@]3(C)O[C@]24[C@H]1CC[C@@H](C)[C@@H]4C[C@H]3O;IC50;'=';50.1;nM;7.30;;;UO_0000065;7.73;0.15;1.75;3.08;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;50.1
CHEMBL4473013;;None;746.84;3;5.47;8;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2S(=O)(=O)F)cc1;IC50;'=';27600.0;nM;4.56;;;UO_0000065;6.10;0.12;-0.91;2.76;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;27.6
CHEMBL4565306;;None;941.86;2;4.69;C5;O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCOCCOCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O;IC50;'=';4940.0;nM;5.31;;;UO_0000065;5.63;0.12;0.62;2.53;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;4.94
CHEMBL3701346;;None;644.18;2;7.81;BDBM161532;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';5.1;nM;8.29;;304830;UO_0000065;12.87;0.24;0.48;9.92;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.1
CHEMBL3701402;;None;694.84;2;6.47;BDBM161593;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';12.2;nM;7.91;;304891;UO_0000065;11.39;0.21;1.44;8.24;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;12.2
CHEMBL3701405;;None;745.32;2;7.54;BDBM161596;Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CCCN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C;IC50;'=';3.1;nM;8.51;;304894;UO_0000065;11.42;0.22;0.97;7.95;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.1
CHEMBL3701408;;None;712.85;2;6.11;BDBM161600;COc1ccc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c1;IC50;'=';3.0;nM;8.52;;304898;UO_0000065;11.96;0.22;2.41;7.33;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.0
CHEMBL3704780;;None;693.25;2;6.28;BDBM161614;Cc1nn(C)cc1N(C(=O)c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1;IC50;'=';3.0;nM;8.52;;304912;UO_0000065;12.29;0.23;2.24;8.87;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.0
CHEMBL4277317;;None;944.08;3;6.51;27g;C[C@H]1[C@@H](CC(=O)N2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3;IC50;'=';11.9;nM;7.92;;;UO_0000065;8.39;0.16;1.41;3.51;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;11.9
CHEMBL4280705;;None;962.09;3;5.68;27e;C[C@@H]1CC[C@H]2[C@@](C)(O)[C@@H](OCCN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4;IC50;'=';86.5;nM;7.06;;;UO_0000065;7.34;0.14;1.38;2.96;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;86.5
CHEMBL4851332;;None;930.06;3;9.30;24n;CCN1CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1;IC50;'=';0.5;nM;9.30;;;UO_0000065;10.00;0.19;0.00;5.70;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;0.5
CHEMBL1689140;;None;879.51;3;8.28;28;O=[N+]([O-])c1cc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)ccc1N[C@H](CCN1CCOCC1)CSc1ccccc1;IC50;'=';21.0;nM;7.68;;;UO_0000065;8.73;0.17;-0.60;5.26;0;CHEMBL1693055;Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1687940;1;Scientific Literature;J Med Chem;2011;None;;;;21.0
CHEMBL4572199;;None;279.37;0;2.70;1a;CCc1sc2ncnc(N[C@@H](C)C(=O)O)c2c1CC;IC50;'=';164000.0;nM;;Outside typical range;;UO_0000065;;;;;0;CHEMBL4375085;Displacement of N-terminal fluorescein labelled Puma-BH3 peptide from human N-terminal thrombin cleavage site-fused/His6-tagged Bcl-2 expressed in Escherichia coliBL21(DE3) pLysS cells by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4373699;1;Scientific Literature;J Med Chem;2019;None;;;;164.0
CHEMBL481775;;None;522.09;2;5.66;37;CCCCN(CCCC)C(=O)c1nn(-c2ccc(N)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';700.0;nM;6.16;;;UO_0000065;11.79;0.23;0.49;7.29;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.7
CHEMBL3984880;;None;1039.55;None;None;BDBM156385;CCN(CCOP(=O)(O)O)CC[C@@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';0.9;nM;9.05;;298896;UO_0000065;8.70;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.9
CHEMBL1269074;;None;626.75;2;7.63;BDBM142752;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCC3CCCCC3)C2=O)C(=O)c2cc(O)c(O)c(CCC3CCCCC3)c2C1=O;IC50;'=';6730.0;nM;5.17;;278906;UO_0000065;8.25;0.15;-2.46;3.47;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6730.0
CHEMBL2170842;;None;912.50;2;7.11;18;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';153.0;nM;6.82;;;UO_0000065;7.47;0.15;-0.29;5.35;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;153.0
CHEMBL4211496;;None;951.62;3;9.13;16;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3sc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3C2)C1;IC50;'=';57.9;nM;7.24;;;UO_0000065;7.61;0.16;-1.89;5.78;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;57.9
CHEMBL3929521;;None;686.25;2;6.45;BDBM179546;CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)Nc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';455.26;nM;6.34;;326149;UO_0000065;9.24;0.18;-0.11;5.42;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;455.265
CHEMBL3932621;;None;669.80;2;5.94;BDBM179551;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1716.45;nM;5.76;;326166;UO_0000065;8.61;0.16;-0.17;4.93;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.716.455
CHEMBL343743;;None;314.18;0;3.90;20;NCC(=O)c1ccc2cc(Br)c3ccccc3c2c1;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL3958535;;None;1093.65;None;None;BDBM156406;CCOP(=O)(OCC)O[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';30.0;nM;7.52;;298916;UO_0000065;6.88;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;30.0
CHEMBL270268;;None;364.40;0;4.95;6;CC(C)c1cc(C(=O)c2ccc(Oc3ccccc3)cc2)c(O)c(O)c1O;IC50;'=';3400.0;nM;5.47;;;UO_0000065;15.01;0.28;0.52;6.29;0;CHEMBL932183;Inhibition of human Bcl-2 protein by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1141593;1;Scientific Literature;J Med Chem;2008;None;;;;3.4
CHEMBL480008;;None;468.53;0;4.79;14;Cc1cc(C(=O)N(C)c2ccccc2F)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1;IC50;'=';3000.0;nM;5.52;;;UO_0000065;11.79;0.22;0.73;9.45;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;3.0
CHEMBL541004;;None;656.78;3;7.13;8m;Cc1cc2c(C(=O)NCC3CCCCC3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCC3CCCCC3)c(O)c(O)cc2c1O;IC50;'=';710.0;nM;6.15;;;UO_0000065;9.36;0.17;-0.98;3.42;0;CHEMBL1031851;Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1158469;1;Scientific Literature;J Med Chem;2009;None;;;;0.71
CHEMBL3137309;VENETOCLAX;4.0;868.46;3;8.66;ABT-199;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'<';1.0;nM;;;;UO_0000065;;;;;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.001
CHEMBL1689139;;None;837.47;3;8.51;21;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)cc1[N+](=O)[O-];IC50;'=';8.7;nM;8.06;;;UO_0000065;9.62;0.19;-0.45;5.89;0;CHEMBL1693055;Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1687940;1;Scientific Literature;J Med Chem;2011;None;;;;8.7
CHEMBL214839;;None;287.32;0;3.18;2;CC(C)c1cc(C(=O)Nc2ccccc2)c(O)c(O)c1O;IC50;'=';53100.0;nM;4.28;;;UO_0000065;14.88;0.28;1.09;4.76;0;CHEMBL909445;Binding affinity to human Bcl2 by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;None;;;;53.1
CHEMBL216213;;None;615.79;2;7.81;6;COc1c(Cc2ccccc2C(C)C)cc(C(=O)Nc2ccc(S(=O)(=O)c3ccccc3C(C)(C)C)cc2)c(OC)c1OC;IC50;'>';100000.0;nM;;;;UO_0000065;;;;;0;CHEMBL909448;Inhibition of growth of human PC3 cell overexpressing Bcl2;F;BAO_0000219;cell-based format;Homo sapiens;None;None;PC-3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;CHEMBL3307570;;;;100.0
CHEMBL1269107;;None;586.60;2;5.78;6i;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O;IC50;'=';290.0;nM;6.54;;;UO_0000065;11.14;0.20;0.76;4.38;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;0.29
CHEMBL469305;;None;468.53;0;4.79;12;Cc1cc(C(=O)N(C)c2ccc(F)cc2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1;IC50;'=';10700.0;nM;4.97;;;UO_0000065;10.61;0.19;0.18;8.51;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;10.7
CHEMBL517577;;None;512.61;2;6.36;18;Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1;IC50;'=';800.0;nM;6.10;;;UO_0000065;11.89;0.21;-0.26;10.43;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.8
CHEMBL514298;;None;526.64;2;6.75;27;Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1C;IC50;'=';110.0;nM;6.96;;;UO_0000065;13.21;0.24;0.21;11.91;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.11
CHEMBL513318;;None;472.63;1;5.42;34;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccccc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';230.0;nM;6.64;;;UO_0000065;14.05;0.26;1.22;11.36;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.23
CHEMBL450954;;None;676.28;2;7.02;41;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NS(=O)(=O)Cc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';250.0;nM;6.60;;;UO_0000065;9.76;0.19;-0.42;6.31;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.25
CHEMBL498873;;None;642.25;2;6.41;47;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NCc3ccncc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl;IC50;'=';650.0;nM;6.19;;;UO_0000065;9.63;0.18;-0.22;5.66;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.65
CHEMBL3931799;;None;966.57;3;9.24;BDBM156394;N#C[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';2.0;nM;8.70;;298905;UO_0000065;9.00;0.18;-0.54;5.84;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.0
CHEMBL2171010;;None;864.43;2;7.71;14;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(OC(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';763.0;nM;6.12;;;UO_0000065;7.08;0.14;-1.59;5.97;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;763.0
CHEMBL2171011;;None;824.49;2;7.21;16;CCOc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1;IC50;'=';1624.0;nM;5.79;;;UO_0000065;7.02;0.14;-1.42;5.65;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;1624.0
CHEMBL2030858;;None;728.87;2;6.34;3o;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1cccc(CO)c1;IC50;'=';71.0;nM;7.15;;;UO_0000065;9.81;0.18;0.81;5.04;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.071
CHEMBL2030865;;None;675.85;2;7.02;4a;CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';700.0;nM;6.16;;;UO_0000065;9.11;0.17;-0.87;5.47;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.7
CHEMBL4209752;;None;864.45;2;6.81;50;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5(CN6CCOCC6)CC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1;IC50;'=';40.7;nM;7.39;;;UO_0000065;8.55;0.17;0.58;5.76;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;40.7
CHEMBL4849303;;None;327.39;0;4.58;S1i;N#CC1=C(C#N)c2ccc(NC3CCCCC3)c3cccc(c23)C1=O;IC50;'>';20000.0;nM;;;;UO_0000065;;;;;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;;;20.0
CHEMBL137528;;None;477.48;1;5.72;19;CN1C(=O)c2ccc3c4ccc5c(=O)n6c7ccccc7nc6c6ccc(c7ccc(c2c37)C1=O)c4c56;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL1269073;;None;570.64;2;6.07;6c;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC3CCCC3)C2=O)C(=O)c2cc(O)c(O)c(CC3CCCC3)c2C1=O;IC50;'=';2270.0;nM;5.64;;;UO_0000065;9.89;0.18;-0.43;3.78;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;2.27
CHEMBL4111735;;None;715.96;2;6.25;BDBM179598;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])C[C@]34CC[C@H](CC3=O)C4(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';806.98;nM;6.09;;326212;UO_0000065;8.51;0.16;-0.16;4.66;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;806.98
CHEMBL3948036;;None;710.73;2;7.22;BDBM179581;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Cl)c3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';370.43;nM;6.43;;326240;UO_0000065;9.05;0.18;-0.79;5.65;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;370.43
CHEMBL3904990;;None;721.93;2;6.32;BDBM179575;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccn(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';855.19;nM;6.07;;326189;UO_0000065;8.41;0.16;-0.25;4.61;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;855.19
CHEMBL3948609;;None;683.83;2;5.45;BDBM179590;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4nonc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';271.77;nM;6.57;;326204;UO_0000065;9.60;0.18;1.12;4.30;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;271.77
CHEMBL3985364;;None;659.83;2;6.06;BDBM179582;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';314.95;nM;6.50;;326241;UO_0000065;9.85;0.19;0.44;5.72;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;314.95
CHEMBL4206007;;None;801.30;2;6.99;39;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N5CC(F)(F)C5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1;IC50;'=';46.6;nM;7.33;;;UO_0000065;9.15;0.19;0.34;6.85;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;46.6
CHEMBL1672077;;None;368.42;0;4.62;7a;COc1ccc(Sc2ccc3c4c(cccc24)C2=NC(=O)C(C#N)=C23)cc1;IC50;'=';945.0;nM;6.03;;;UO_0000065;16.35;0.30;1.40;9.65;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;945.0
CHEMBL2312481;;None;377.51;0;3.84;5c;CCCCNC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13;IC50;'=';198.0;nM;6.70;;;UO_0000065;17.76;0.34;2.86;15.00;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;198.0
CHEMBL137796;;None;290.34;0;3.75;28;COc1cc2ccc3c[n+]4ccccc4cc3c2cc1OC;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2325757;;None;958.59;3;7.44;24;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NS(C)(=O)=O)cnn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';5.4;nM;8.27;;;UO_0000065;8.62;0.17;0.83;4.30;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;5.4
CHEMBL137306;;None;282.35;0;3.47;15;c1cc[n+]2cc3ccc4c[n+]5ccccc5cc4c3cc2c1;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL3701341;;None;654.81;2;6.47;BDBM161526;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)Cc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';80.0;nM;7.10;;304825;UO_0000065;10.84;0.20;0.63;7.48;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;80.0
CHEMBL3701351;;None;751.89;2;6.11;BDBM161537;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)OCO3)n1C;IC50;'=';5.3;nM;8.28;;304835;UO_0000065;11.01;0.20;2.17;7.62;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.3
CHEMBL3701355;;None;732.84;3;5.16;BDBM161544;COCCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C;IC50;'=';19.7;nM;7.71;;304842;UO_0000065;10.51;0.19;2.55;6.23;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;19.7
CHEMBL3701360;;None;656.78;2;7.02;BDBM161549;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN(C)C;IC50;'=';7.6;nM;8.12;;304847;UO_0000065;12.36;0.23;1.10;9.28;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7.6
CHEMBL2312468;;None;378.45;0;3.05;4a;CCOC(=O)C1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13;IC50;'=';2200.0;nM;5.66;;;UO_0000065;14.95;0.29;2.61;9.59;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;2.2
CHEMBL3890069;;None;799.63;2;7.44;BDBM179562;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)c(Br)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';473.64;nM;6.33;;326222;UO_0000065;7.91;0.18;-1.12;5.56;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;473.64
CHEMBL214839;;None;287.32;0;3.18;2;CC(C)c1cc(C(=O)Nc2ccccc2)c(O)c(O)c1O;IC50;'=';7000.0;nM;5.16;;;UO_0000065;;;;;0;CHEMBL909448;Inhibition of growth of human PC3 cell overexpressing Bcl2;F;BAO_0000219;cell-based format;Homo sapiens;None;None;PC-3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;CHEMBL3307570;;;;7.0
CHEMBL4290795;;None;946.09;3;5.61;29a;C[C@H]1[C@@H](OCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@]3(C)O[C@]24[C@H]1CC[C@@H](C)[C@@H]4C[C@H]3O;IC50;'=';31.9;nM;7.50;;;UO_0000065;7.92;0.15;1.89;3.27;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;31.9
CHEMBL4295247;;None;944.12;3;7.37;27c;C[C@H]1[C@@H](CCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3;IC50;'=';1.2;nM;8.92;;;UO_0000065;9.45;0.18;1.55;4.27;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;1.2
CHEMBL3704809;;None;684.79;2;6.31;BDBM54890;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';11.1;nM;7.96;;198898;UO_0000065;11.62;0.21;1.64;8.23;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;11.1
CHEMBL3704815;;None;782.90;3;6.08;BDBM60411;COCCc1c(C(=O)N(c2ccc(O)cc2)c2cnc3ccn(C)c3c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';15.9;nM;7.80;;201220;UO_0000065;9.96;0.18;1.72;6.30;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;15.9
CHEMBL3957281;;None;670.88;2;5.81;BDBM179596;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(N)ccc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';660.5;nM;6.18;;326210;UO_0000065;9.21;0.18;0.37;4.42;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;660.495
CHEMBL3926618;;None;608.81;1;4.33;BDBM179578;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])N(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1735.78;nM;5.76;;326237;UO_0000065;9.46;0.18;1.43;4.92;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.735.775
CHEMBL3902056;;None;751.93;2;7.85;BDBM179586;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(F)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';3533.03;nM;5.45;;326245;UO_0000065;7.25;0.14;-2.40;4.43;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.533.025
CHEMBL3912231;;None;721.93;2;6.32;BDBM179588;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(-c4ccn(C)n4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';3558.82;nM;5.45;;326247;UO_0000065;7.55;0.14;-0.87;4.14;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.558.815
CHEMBL3948609;;None;683.83;2;5.45;BDBM179590;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4nonc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';257.15;nM;6.59;;326249;UO_0000065;9.64;0.18;1.14;4.32;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;257.155
CHEMBL3701318;;None;693.22;2;7.38;BDBM161503;Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';8.2;nM;8.09;;304802;UO_0000065;11.66;0.22;0.71;10.33;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;8.2
CHEMBL3701365;;None;703.24;2;6.45;BDBM161554;Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';3.9;nM;8.41;;304852;UO_0000065;11.96;0.23;1.96;7.86;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.9
CHEMBL3701410;;None;683.78;2;6.59;BDBM161602;Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';2.8;nM;8.55;;304900;UO_0000065;12.51;0.23;1.96;8.38;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.8
CHEMBL2322029;;None;956.58;3;8.17;8;O=S(=O)(Nc1ncnc2c1CN(C1CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC1)C2)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1;IC50;'=';740.0;nM;6.13;;;UO_0000065;6.41;0.13;-2.04;4.47;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;740.0
CHEMBL2322025;;None;841.46;3;7.24;4;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nn(C)c3nc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ncc23)cc1[N+](=O)[O-];IC50;'=';8500.0;nM;5.07;;;UO_0000065;6.03;0.12;-2.17;3.28;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;8500.0
CHEMBL2322023;;None;877.53;2;9.49;2;O=[N+]([O-])c1cc(S(=O)(=O)Nc2cccc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)ccc1N[C@H](CCN1CCOCC1)CSc1ccccc1;IC50;'>';4000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;4000.0
CHEMBL2312480;;None;467.64;1;5.45;5j;O=C1N=C2C(=C1NCCCCCc1ccccc1)c1ccc(N3CCSCC3)c3cccc2c13;IC50;'=';1300.0;nM;5.89;;;UO_0000065;12.59;0.24;0.44;13.17;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;1.3
CHEMBL1672082;;None;353.41;0;4.19;6a;N#CC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13;IC50;'=';331.0;nM;6.48;;;UO_0000065;18.34;0.34;2.29;8.18;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;331.0
CHEMBL4861424;;None;902.01;3;9.03;17e;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccccc2C(F)(F)F)C1;IC50;'=';1.7;nM;8.77;;;UO_0000065;9.72;0.19;-0.26;5.10;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;1.7
CHEMBL217354;;None;573.71;2;6.90;5, TW-37;CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(S(=O)(=O)c3ccccc3C(C)(C)C)cc2)c(O)c(O)c1O;IC50;'=';700.0;nM;6.16;;;UO_0000065;10.73;0.21;-0.75;4.97;0;CHEMBL909445;Binding affinity to human Bcl2 by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;None;;;;0.7
CHEMBL4285268;;None;959.14;3;6.48;27f;C[C@H]1[C@H](N(C)CCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3;IC50;'=';16.7;nM;7.78;;;UO_0000065;8.11;0.16;1.30;3.67;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;16.7
CHEMBL2170835;;None;1051.68;None;None;28;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';10.2;nM;7.99;;;UO_0000065;7.60;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;10.2
CHEMBL2170850;;None;1035.68;None;None;26;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCCCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';15.6;nM;7.81;;;UO_0000065;7.54;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;15.6
CHEMBL3701394;;None;697.21;2;6.11;BDBM161584;Cc1c(C(=O)N(c2ccc(O)c(F)c2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';9.9;nM;8.00;;304882;UO_0000065;11.48;0.22;1.89;8.33;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;9.9
CHEMBL3701412;;None;644.78;2;5.32;BDBM161605;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';9.2;nM;8.04;;304903;UO_0000065;12.46;0.23;2.72;8.36;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;9.2
CHEMBL3704785;;None;706.27;2;7.17;BDBM161619;Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(C#N)s2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';49.1;nM;7.31;;304917;UO_0000065;10.35;0.20;0.14;7.16;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;49.1
CHEMBL466801;;None;450.54;0;4.66;10;Cc1cc(C(=O)N(C)c2ccccc2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1;IC50;'=';2500.0;nM;5.60;;;UO_0000065;12.43;0.23;0.94;9.59;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;2.5
CHEMBL481581;;None;536.12;2;5.40;36;CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl;IC50;'=';20.0;nM;7.70;;;UO_0000065;14.36;0.28;2.30;9.12;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.02
CHEMBL503454;;None;576.10;2;6.34;31;Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN;IC50;'=';100.0;nM;7.00;;;UO_0000065;12.15;0.23;0.66;8.29;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.1
CHEMBL450954;;None;676.28;2;7.02;41;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NS(=O)(=O)Cc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';3150.0;nM;5.50;;;UO_0000065;8.14;0.16;-1.52;5.26;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;3.15
CHEMBL4102399;;None;321.30;0;3.87;11j;O=[N+]([O-])c1ccccc1Nc1nnc(-c2c[nH]c3ccccc23)o1;IC50;'=';4270.0;nM;5.37;;;UO_0000065;16.71;0.31;1.50;4.89;0;CHEMBL5234938;Binding affinity to Bcl-2 (unknown origin) by ELISA analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5233252;1;Scientific Literature;Eur J Med Chem;2020;None;;INHIBITOR;;4.27
CHEMBL2371929;;None;3269.70;None;None;Bim BH3 peptide;CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O;IC50;'=';11.0;nM;7.96;;;UO_0000065;2.43;None;None;None;0;CHEMBL909445;Binding affinity to human Bcl2 by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;None;;;;0.011
CHEMBL3701381;;None;712.83;2;6.61;BDBM161570;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';5.7;nM;8.24;;304868;UO_0000065;11.57;0.21;1.63;8.58;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.7
CHEMBL3701388;;None;757.34;2;7.90;BDBM161578;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C;IC50;'=';2.1;nM;8.68;;304876;UO_0000065;11.46;0.22;0.78;9.03;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.1
CHEMBL3701396;;None;718.23;2;7.25;BDBM161586;Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)c(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';8.0;nM;8.10;;304884;UO_0000065;11.27;0.21;0.85;7.94;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;8.0
CHEMBL2312473;;None;478.57;1;6.12;7d;O=C1N=C2C(=C1NCCCc1ccccc1)c1ccc(Sc3ccc(OO)cc3)c3cccc2c13;IC50;'=';57.0;nM;7.24;;;UO_0000065;15.14;0.28;1.12;10.21;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;57.0
CHEMBL135315;;None;332.34;0;3.43;26;C[n+]1cc2c3cc4c(cc3ccc2c2ccc3c(c21)OCO3)OCO4;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL214965;;None;335.36;0;3.65;3;O=C(Nc1ccccc1)c1cc(Cc2ccccc2)c(O)c(O)c1O;IC50;'=';7200.0;nM;5.14;;;UO_0000065;15.33;0.28;1.49;5.73;0;CHEMBL909445;Binding affinity to human Bcl2 by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;None;;;;7.2
CHEMBL217223;;None;475.52;0;4.48;4;O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)c1cc(Cc2ccccc2)c(O)c(O)c1O;IC50;'=';4000.0;nM;5.40;;;UO_0000065;;;;;0;CHEMBL909448;Inhibition of growth of human PC3 cell overexpressing Bcl2;F;BAO_0000219;cell-based format;Homo sapiens;None;None;PC-3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;CHEMBL3307570;;;;4.0
CHEMBL2063894;;None;850.51;2;9.57;18;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cn(C)cc5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';82.6;nM;7.08;;;UO_0000065;8.33;0.16;-2.49;6.11;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;82.6
CHEMBL414287;;None;1834.13;None;None;12 (Bax BH3);CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O;IC50;'=';29070.0;nM;4.54;;;UO_0000065;2.47;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;29.07
CHEMBL2326037;;None;851.50;3;8.97;21;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cn(C)nc5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';140.0;nM;6.85;;;UO_0000065;8.05;0.16;-2.12;5.32;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;140.0
CHEMBL2325774;;None;851.50;3;8.97;20;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cnn(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';210.0;nM;6.68;;;UO_0000065;7.84;0.15;-2.29;5.18;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;210.0
CHEMBL2325767;;None;898.98;2;10.53;13;Cc1c(Cl)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';260.0;nM;6.58;;;UO_0000065;7.32;0.15;-3.94;5.68;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;260.0
CHEMBL269555;;None;2584.87;None;None;3 (N-AEM-Bad BH3);CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)O;IC50;'=';5600.0;nM;5.25;;;UO_0000065;2.03;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;5.6
CHEMBL3701353;;None;688.78;2;5.26;BDBM161542;C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(CN3CCOCC3)n1C)OCO2;IC50;'=';19.5;nM;7.71;;304840;UO_0000065;11.19;0.21;2.45;6.73;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;19.5
CHEMBL3701413;;None;704.80;2;5.49;BDBM161606;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3COC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';11.7;nM;7.93;;304904;UO_0000065;11.25;0.21;2.44;7.53;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;11.7
CHEMBL3916642;;None;1042.71;None;None;BDBM156403;CCN(CC)CC1CN(CC[C@@H](CSc2ccccc2)Nc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC([C@H](O)c5ccccc5-c5ccc(Cl)cc5)CC4)cc3)cc2S(=O)(=O)C(F)(F)F)CCO1;IC50;'=';0.4;nM;9.40;;298914;UO_0000065;9.01;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.4
CHEMBL2031014;;None;869.48;2;7.06;14;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCCN5CCOCC5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';110.0;nM;6.96;;;UO_0000065;8.00;0.16;-0.10;4.85;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;110.0
CHEMBL2031026;;None;841.48;2;7.29;29;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCN(C)C)c(C)c1Cl;IC50;'=';37.0;nM;7.43;;;UO_0000065;8.83;0.17;0.14;5.54;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;37.0
CHEMBL3701336;;None;593.73;2;5.39;BDBM161521;CCNC(=O)NCc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(C)c3ccc(O)cc3)c(C)n2C)c1;IC50;'=';28.9;nM;7.54;;304820;UO_0000065;12.70;0.23;2.15;7.05;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;28.9
CHEMBL3701350;;None;593.66;2;5.85;BDBM161536;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)c(O)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';2.1;nM;8.68;;304834;UO_0000065;14.62;0.27;2.83;8.36;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.1
CHEMBL3701359;;None;698.82;2;6.80;BDBM161548;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN1CCOCC1;IC50;'=';19.0;nM;7.72;;304846;UO_0000065;11.05;0.20;0.92;7.98;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;19.0
CHEMBL3704778;;None;730.84;2;6.25;BDBM161612;COc1cc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)cc1F;IC50;'=';3.1;nM;8.51;;304910;UO_0000065;11.64;0.22;2.26;7.32;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.1
CHEMBL137369;;None;408.42;1;5.58;24;O=c1c2ccccc2c2nc3ccc4c(=O)c5ccccc5c5nc6ccc1c2c6c3c45;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2325763;;None;999.68;3;9.05;31, BM-1075;CCn1c(C)c(C(=O)NS(C)(=O)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1;IC50;'=';1.8;nM;8.74;;;UO_0000065;8.75;0.18;-0.31;4.88;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;1.8
CHEMBL2063883;;None;1107.84;None;None;7, BM-907;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';1.3;nM;8.89;;;UO_0000065;8.02;None;None;None;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;1.3
CHEMBL220055;;None;327.38;0;3.13;5;CC(C)c1cc(C(=O)N2CCc3ccccc3C2)c(O)c(O)c1O;IC50;'=';38200.0;nM;4.42;;;UO_0000065;13.49;0.25;1.29;5.45;0;CHEMBL918623;Displacement of biotinylated Bim BH3 peptide from recombinant His-tagged Bcl2 by ELISA assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1144472;1;Scientific Literature;J Med Chem;2007;None;;;;38.2
CHEMBL342944;;None;303.39;0;2.56;35;O=C(CSc1ccccn1)c1sc2cccc[n+]2c1O;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL609717;;None;370.79;0;3.66;36;COc1cc2cc[n+]3c4ccc([N+](=O)[O-])cc4ccc3c2cc1OC.[Cl-];IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL5185435;;None;510.39;2;6.38;18;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccoc3)C2)cc1;IC50;'=';3820.0;nM;5.42;;;UO_0000065;10.62;0.22;-0.96;6.44;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;3.82
CHEMBL5201389;;None;445.52;1;5.93;16;Cc1ccc(C(=O)N2N=C(c3ccc(NC(=O)OC(C)(C)C)cc3)CC2c2ccco2)cc1;IC50;'=';3290.0;nM;5.48;;;UO_0000065;12.31;0.23;-0.45;6.52;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;3.29
CHEMBL5209197;;None;519.44;2;6.36;44;CC(C)(C)NC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';9220.0;nM;5.04;;;UO_0000065;9.69;0.20;-1.32;6.82;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;9.22
CHEMBL2063893;;None;907.56;3;8.93;17;CNC(=O)c1c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)cn1C;IC50;'=';5.3;nM;8.28;;;UO_0000065;9.12;0.18;-0.65;5.70;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;5.3
CHEMBL2325761;;None;936.60;3;10.45;29;CCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1;IC50;'=';10.0;nM;8.00;;;UO_0000065;8.54;0.17;-2.45;5.22;0;CHEMBL2330000;Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321752;1;Scientific Literature;J Med Chem;2013;None;;;;10.0
CHEMBL5196783;;None;344.42;0;4.14;129;CCCn1cc(/C=N/N=C2\C(=O)Nc3ccc(C)cc32)c2ccccc21;IC50;'=';460.0;nM;6.34;;;UO_0000065;18.40;0.33;2.20;10.79;0;CHEMBL5228637;Inhibition of Bcl-2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5226338;1;Scientific Literature;Eur J Med Chem;2021;None;;INHIBITOR;;0.46
CHEMBL3701330;;None;670.81;2;6.31;BDBM161515;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';76.6;nM;7.12;;304814;UO_0000065;10.61;0.19;0.81;6.83;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;76.6
CHEMBL3701362;;None;692.79;2;5.76;BDBM161551;COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2[nH]c(C)c(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c2C)cc1F;IC50;'=';22.9;nM;7.64;;304849;UO_0000065;11.03;0.20;1.88;6.58;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;22.9
CHEMBL3701364;;None;742.32;2;7.04;BDBM161553;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)n1C;IC50;'=';2.0;nM;8.70;;304851;UO_0000065;11.72;0.22;1.66;9.66;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.0
CHEMBL3701395;;None;734.25;2;6.42;BDBM161585;COC(=O)c1ccnc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1;IC50;'=';49.0;nM;7.31;;304883;UO_0000065;9.96;0.19;0.89;6.22;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;49.0
CHEMBL3704806;;None;730.27;2;6.52;BDBM161644;Cc1c(C(=O)N(c2cnc3c(ccn3C)c2)c2ccc(O)cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';36.6;nM;7.44;;304940;UO_0000065;10.18;0.19;0.92;6.82;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;36.6
CHEMBL3701343;;None;708.86;2;6.37;BDBM161528;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNS(=O)(=O)CCc3ccc(F)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';134.0;nM;6.87;;304827;UO_0000065;9.70;0.18;0.50;6.14;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;134.0
CHEMBL3701352;;None;729.28;2;7.12;BDBM161538;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';6.1;nM;8.21;;304836;UO_0000065;11.26;0.21;1.09;8.55;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.1
CHEMBL3704808;;None;737.86;2;6.80;BDBM51910;Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';3.7;nM;8.43;;198897;UO_0000065;11.43;0.21;1.63;8.30;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.7
CHEMBL3704817;;None;662.77;2;5.46;BDBM60413;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2ccc(F)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';447.0;nM;6.35;;201222;UO_0000065;9.58;0.18;0.89;6.61;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;447.0
CHEMBL1672082;;None;353.41;0;4.19;6h;N#CC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13;IC50;'=';302.0;nM;6.52;;;UO_0000065;18.45;0.34;2.33;8.23;0;CHEMBL1677787;Displacement of FAM-Bid from human recombinant Bcl-2 after 30 mins by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1671783;1;Scientific Literature;J Med Chem;2011;None;;;;0.302
CHEMBL1689144;;None;911.59;3;9.07;32;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc4c(NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c([N+](=O)[O-])c5)ncnc4c3)CC2)C1;IC50;'=';21.0;nM;7.68;;;UO_0000065;8.42;0.17;-1.39;5.26;0;CHEMBL1693055;Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1687940;1;Scientific Literature;J Med Chem;2011;None;;;;21.0
CHEMBL3890050;;None;673.88;2;5.27;BDBM179579;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(C)nn(C)c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';651.76;nM;6.19;;326193;UO_0000065;9.18;0.18;0.92;4.70;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;651.765
CHEMBL4278369;;None;930.09;3;6.98;27b;C[C@H]1[C@@H](CCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3;IC50;'=';9.7;nM;8.01;;;UO_0000065;8.62;0.17;1.03;3.83;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;9.7
CHEMBL2030849;;None;832.98;2;9.32;3f;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1cccc(Oc2ccccc2)c1;IC50;'=';140.0;nM;6.85;;;UO_0000065;8.23;0.15;-2.47;5.01;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.14
CHEMBL552735;;None;586.68;3;8.08;12e;Cc1cc2c(CCc3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(CCc3ccccc3)c(O)c(O)cc2c1O;IC50;'=';480.0;nM;6.32;;;UO_0000065;10.77;0.20;-1.76;5.21;0;CHEMBL1031851;Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1158469;1;Scientific Literature;J Med Chem;2009;None;;;;0.48
CHEMBL540363;;None;365.82;0;4.73;11;Cl.N=C(N)c1ccc(/N=N/c2c(O)ccc3c2[nH]c2ccccc23)cc1;IC50;'=';5800.0;nM;5.24;;;UO_0000065;15.90;0.29;0.51;4.73;0;CHEMBL651292;In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;5.8
CHEMBL137177;;None;198.27;0;1.33;23;c1cc[n+]2c(c1)-c1cccc[n+]1CCC2;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2063895;;None;922.57;3;9.75;19;CCOC(=O)c1c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)cn1C;IC50;'=';45.8;nM;7.34;;;UO_0000065;7.96;0.16;-2.41;5.16;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;45.8
CHEMBL3309313;;None;1029.67;None;None;28;CN(C)CCOc1ccc(-c2ccc(Cl)cc2)c(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1;IC50;'<';10.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.01
CHEMBL3895678;;None;553.10;2;5.14;BDBM179552;CCCCN(CCCC)C(=O)c1nn(-c2ccc(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';421.88;nM;6.38;;326167;UO_0000065;11.53;0.22;1.23;6.45;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;421.875
CHEMBL3927241;;None;576.69;1;4.25;BDBM179548;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';102.02;nM;6.99;;326151;UO_0000065;12.12;0.23;2.74;5.58;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;102.02
CHEMBL3897154;;None;666.85;2;5.79;BDBM179595;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(C#N)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';672.58;nM;6.17;;326209;UO_0000065;9.26;0.18;0.38;4.49;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;672.575
CHEMBL3959104;;None;722.91;2;6.88;BDBM179563;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(-c4ccccc4)noc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';664.26;nM;6.18;;326223;UO_0000065;8.55;0.16;-0.70;4.42;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;664.26
CHEMBL3917653;;None;694.90;2;6.41;BDBM179576;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4ccn(C)c34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1053.17;nM;5.98;;326235;UO_0000065;8.60;0.16;-0.43;5.04;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.053.175
CHEMBL3932621;;None;669.80;2;5.94;BDBM179551;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';2943.39;nM;5.53;;326154;UO_0000065;8.26;0.15;-0.41;4.73;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2943.39
CHEMBL538616;;None;700.79;3;7.58;rac-4;Cc1cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c1O;IC50;'=';660.0;nM;6.18;;;UO_0000065;8.82;0.16;-1.40;3.44;0;CHEMBL1106537;Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157826;1;Scientific Literature;J Med Chem;2010;None;;;;0.66
CHEMBL1094366;(S)-1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-((S)-2-PHENYLPROPYL)-N5'-((S)-2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE (ATROPISOMERIC MIX);None;700.79;3;7.58;(S, +, S)-14;Cc1cc2c(C(=O)NC[C@@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@@H](C)c3ccccc3)c(O)c(O)cc2c1O;IC50;'=';430.0;nM;6.37;;;UO_0000065;9.08;0.17;-1.21;3.55;0;CHEMBL1106537;Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157826;1;Scientific Literature;J Med Chem;2010;None;;;;0.43
CHEMBL2030845;;None;740.88;2;7.53;3b;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccccc1;IC50;'=';660.0;nM;6.18;;;UO_0000065;8.34;0.16;-1.35;4.84;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.66
CHEMBL2030854;;None;770.95;2;8.02;3k;CCCCOc1ccc(-n2nc(CO)c(-c3ccc(C(=O)NS(=O)(=O)c4ccc5ccccc5c4)cc3C(=O)N3CCc4ccccc4C3)c2CCCC)cc1;IC50;'=';45.0;nM;7.35;;;UO_0000065;9.53;0.18;-0.67;5.62;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.045
CHEMBL2030864;;None;859.83;2;9.94;3u;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1;IC50;'=';6.0;nM;8.22;;;UO_0000065;9.56;0.19;-1.72;6.28;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.006
CHEMBL4854644;;None;368.42;0;5.00;S1d;COc1ccc(Sc2ccc3c4c(cccc24)C(=O)C(C#N)=C3C#N)cc1;IC50;'=';6100.0;nM;5.21;;;UO_0000065;14.15;0.26;0.21;7.06;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;6.1
CHEMBL4853795;;None;417.99;0;1.89;MKT-077;CC[n+]1ccccc1/C=c1\s/c(=C2/Sc3ccccc3N2C)c(=O)n1C.[Cl-];IC50;'>';20000.0;nM;;;;UO_0000065;;;;;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;;;20.0
CHEMBL1689142;;None;966.57;3;8.66;30;O=S(=O)(Nc1ncnc2cc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)ccc12)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1;IC50;'=';81.0;nM;7.09;;;UO_0000065;7.34;0.15;-1.57;5.17;0;CHEMBL1693055;Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1687940;1;Scientific Literature;J Med Chem;2011;None;;;;81.0
CHEMBL3311493;;None;971.59;3;8.54;19;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(CO)(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';59.0;nM;7.23;;;UO_0000065;7.44;0.15;-1.31;4.97;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.059
CHEMBL2063896;;None;894.52;3;9.27;20;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(C)c5C(=O)O)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';1.7;nM;8.77;;;UO_0000065;9.80;0.19;-0.50;5.72;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;1.7
CHEMBL3924533;;None;984.63;3;9.23;BDBM156413;CN(C)[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';24.0;nM;7.62;;298921;UO_0000065;7.74;0.16;-1.61;5.94;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;24.0
CHEMBL3980026;;None;1080.61;None;None;BDBM156387;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN2CCN(CCOP(=O)(O)O)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.7;nM;9.15;;298898;UO_0000065;8.47;None;None;None;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.7
CHEMBL3311490;;None;966.57;3;9.07;16;N#CC1(Cc2ccccc2-c2ccc(Cl)cc2)CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';545.0;nM;6.26;;;UO_0000065;6.48;0.13;-2.81;4.21;0;CHEMBL3369471;Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;FDC-P1;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.545
CHEMBL3311331;;None;982.61;3;8.64;3;O=S(=O)(NC(=C1COC1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1;IC50;'>';1000.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;1.0
CHEMBL3309283;;None;991.60;3;8.16;15;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(S(=O)(=O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';87.0;nM;7.06;;;UO_0000065;7.12;0.15;-1.10;4.43;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.087
CHEMBL3309309;;None;932.51;3;6.76;23;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3cn[nH]c3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';40.0;nM;7.40;;;UO_0000065;7.93;0.16;0.64;4.71;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.04
CHEMBL3309312;;None;1029.67;None;None;27;CN(C)CCOc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'<';10.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.01
CHEMBL2398292;;None;377.43;1;5.09;12a;C/C(=N\Nc1nc2ccccc2s1)c1ccc(-c2cccc(C(=O)O)c2)o1;IC50;'>';10000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2399234;Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2396645;1;Scientific Literature;J Med Chem;2013;None;;;;10.0
CHEMBL4202464;;None;870.41;2;7.43;51;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5(CN6CC(F)(F)C6)CC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1;IC50;'=';34.8;nM;7.46;;;UO_0000065;8.57;0.18;0.03;6.26;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;34.8
CHEMBL3287282;;None;414.49;1;5.21;1;O=C(O)c1cccc(-c2ccc3c(c2)/C(=N/Nc2nc4ccccc4s2)CCC3)n1;IC50;'>';10000.0;nM;;;;UO_0000065;;;;;0;CHEMBL3291800;Antagonist activity at Bcl-2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3286340;1;Scientific Literature;ACS Med Chem Lett;2014;None;;;;10.0
CHEMBL4218253;;None;582.17;1;4.98;37;Cn1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)n1;IC50;'=';67.4;nM;7.17;;;UO_0000065;12.32;0.24;2.19;8.19;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;67.4
CHEMBL4204650;;None;516.11;1;4.82;35;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(C)(=O)=O)cc3)CC2)C1;IC50;'=';495.0;nM;6.30;;;UO_0000065;12.22;0.25;1.49;9.04;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;495.0
CHEMBL4204583;;None;999.64;3;9.18;29;CC1(C)CCC(c2ccc(Cl)cc2)=C(CNC2(Cn3cnc4ccc(C(=O)NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc43)CC2)C1;IC50;'>';1000.0;nM;;;;UO_0000065;;;;;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;1000.0
CHEMBL4216380;;None;952.61;3;8.53;20;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3nc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)sc3C2)C1;IC50;'=';38.1;nM;7.42;;;UO_0000065;7.79;0.16;-1.11;5.38;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;38.1
CHEMBL376408;ABT 737;1.0;813.45;2;7.88;ABT-737;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'<';1.0;nM;;;;UO_0000065;;;;;0;CHEMBL2050128;Inhibition of Bcl2;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2046328;1;Scientific Literature;Bioorg Med Chem;2012;None;;;;1.0
CHEMBL4855086;;None;888.97;3;8.60;24i;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1;IC50;'=';4.4;nM;8.36;;;UO_0000065;9.40;0.18;-0.24;4.94;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;4.4
CHEMBL3911725;;None;945.55;3;8.26;BDBM156378;CN(CCO)CC[C@@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'<';0.3;nM;;;298891;UO_0000065;;;;;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;0.3
CHEMBL3899315;;None;957.56;3;8.66;BDBM156391;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';253.0;nM;6.60;;298902;UO_0000065;6.89;0.14;-2.06;4.54;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;253.0
CHEMBL3931799;;None;966.57;3;9.24;BDBM156394;N#C[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';7.0;nM;8.15;;298906;UO_0000065;8.44;0.17;-1.09;5.48;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7.0
CHEMBL4218405;;None;999.64;3;9.18;28;CC1(C)CCC(c2ccc(Cl)cc2)=C(CNC2(Cn3cnc4cc(C(=O)NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)ccc43)CC2)C1;IC50;'=';108.0;nM;6.97;;;UO_0000065;6.97;0.14;-2.21;4.59;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;108.0
CHEMBL4209621;;None;783.34;2;5.97;40;CN(CCO)c1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';46.0;nM;7.34;;;UO_0000065;9.37;0.19;1.37;5.76;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;46.0
CHEMBL1269070;;None;728.75;3;5.67;BDBM142746;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)NCC(C)c3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)NCC(C)c3ccccc3)c2C1=O;IC50;'=';230.0;nM;6.64;;278911;UO_0000065;9.11;0.17;0.97;3.20;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;230.0
CHEMBL460173;;None;577.08;2;6.37;30;Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO;IC50;'=';50.0;nM;7.30;;;UO_0000065;12.65;0.24;0.93;9.28;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.05
CHEMBL446802;;None;626.20;2;7.33;38;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)c3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';810.0;nM;6.09;;;UO_0000065;9.73;0.18;-1.24;6.96;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.81
CHEMBL467229;;None;537.10;2;5.44;35;CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';780.0;nM;6.11;;;UO_0000065;11.37;0.22;0.67;7.76;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.78
CHEMBL504480;;None;656.23;2;7.09;40;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';130.0;nM;6.89;;;UO_0000065;10.49;0.20;-0.20;7.12;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.13
CHEMBL509208;;None;606.77;2;6.68;43;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(OCC(=O)c3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';330.0;nM;6.48;;;UO_0000065;10.68;0.20;-0.20;7.65;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.33
CHEMBL508392;;None;685.27;2;6.42;42;CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl;IC50;'=';30.0;nM;7.52;;;UO_0000065;10.98;0.21;1.10;6.13;0;CHEMBL1019894;Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.03
CHEMBL3899211;;None;651.81;2;5.80;BDBM179549;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1286.87;nM;5.89;;326164;UO_0000065;9.04;0.17;0.09;5.03;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1286.87
CHEMBL3943276;;None;747.96;2;8.02;BDBM179592;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(C)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'>';16000.0;nM;;;326251;UO_0000065;;;;;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;16000.0
CHEMBL3962105;;None;815.46;2;7.56;BDBM179585;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(CNC(=O)c4ccc(Cl)cc4)s3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';2626.68;nM;5.58;;326199;UO_0000065;6.84;0.14;-1.98;3.91;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.626.685
CHEMBL3936310;;None;966.57;3;9.24;BDBM156396;N#C[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';1195.0;nM;5.92;;298907;UO_0000065;6.13;0.12;-3.32;3.98;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1195.0
CHEMBL4862537;;None;378.50;0;4.28;S1g-4;N#CC1=C(NCCO)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O;IC50;'=';9600.0;nM;5.02;;;UO_0000065;13.26;0.25;0.74;6.86;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;9.6
CHEMBL5198074;;None;443.91;0;4.30;3;CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Cl)cc3)C(c3ccco3)C2)cc1;IC50;'=';2720.0;nM;5.57;;;UO_0000065;12.54;0.25;1.27;6.05;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;2.72
CHEMBL5176214;;None;463.33;1;5.23;53;COC(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';1640.0;nM;5.79;;;UO_0000065;12.49;0.26;0.56;9.81;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;1.64
CHEMBL4216466;;None;945.59;2;9.07;13;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3cc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)ccc3C2)C1;IC50;'=';12.6;nM;7.90;;;UO_0000065;8.35;0.17;-1.17;6.31;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;12.6
CHEMBL3311480;;None;944.52;3;6.83;5;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1cnc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)nc1;IC50;'=';18.0;nM;7.75;;;UO_0000065;8.20;0.17;0.91;5.02;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.018
CHEMBL3311481;;None;949.56;3;7.49;6;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1csc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)n1;IC50;'=';119.0;nM;6.92;;;UO_0000065;7.29;0.15;-0.57;4.90;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.119
CHEMBL3311482;;None;954.56;3;8.04;7;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CC3(CN(Cc4ccccc4-c4ccc(Cl)cc4)C3)C2)cc1;IC50;'>';468.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.468
CHEMBL3311490;;None;966.57;3;9.07;16;N#CC1(Cc2ccccc2-c2ccc(Cl)cc2)CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'<';10.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.01
CHEMBL3950403;;None;747.96;2;8.02;BDBM179565;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccccc4C)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'>';16000.0;nM;;;326180;UO_0000065;;;;;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;16000.0
CHEMBL3909422;;None;657.84;2;5.58;BDBM179556;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)c3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';518.88;nM;6.29;;326216;UO_0000065;9.55;0.18;0.70;5.03;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;518.875
CHEMBL3900418;;None;623.82;1;4.93;BDBM179558;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)C(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';90.44;nM;7.04;;326218;UO_0000065;11.29;0.22;2.11;5.64;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;90.435
CHEMBL3974550;;None;738.91;2;5.15;BDBM179566;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCN3C(=O)c4ccccc4C3=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';253.16;nM;6.60;;326226;UO_0000065;8.93;0.17;1.45;4.36;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;253.155
CHEMBL4572365;;None;805.71;2;5.57;H2;N#CC1=C(NCCC(=O)NCCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O;IC50;'=';9710.0;nM;5.01;;;UO_0000065;6.22;0.13;-0.56;2.82;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;9.71
CHEMBL2326745;;None;928.57;3;8.44;10;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3c2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F;IC50;'=';19.0;nM;7.72;;;UO_0000065;8.32;0.17;-0.72;6.04;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;19.0
CHEMBL342179;;None;466.45;1;5.42;18;O=C1NC(=O)c2ccc3c4ccc5c6c(ccc(c7ccc1c2c73)c64)C(=O)N(c1ccccc1)C5=O;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL2063892;;None;1033.77;None;None;16;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(C)c5C(=O)NCCCN5CCN(C)CC5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';0.6;nM;9.22;;;UO_0000065;8.92;None;None;None;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;0.6
CHEMBL4560793;;None;937.91;2;7.00;C6;O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCCCCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O;IC50;'=';7660.0;nM;5.12;;;UO_0000065;5.45;0.11;-1.88;2.68;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;7.66
CHEMBL2063880;;None;525.09;1;3.59;4, BM-501;CN1CCN(CCCNC(=O)c2c(-c3ccccc3)c(-c3ccc(Cl)cc3)cn2CC[C@H](O)CO)CC1;IC50;'=';213000.0;nM;;Outside typical range;;UO_0000065;;;;;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;213.0
CHEMBL1269077;;None;642.70;2;6.95;6g;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCCc3ccccc3)c2C1=O;IC50;'=';2170.0;nM;5.66;;;UO_0000065;8.81;0.16;-1.29;3.80;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;2.17
CHEMBL3701294;;None;741.34;2;7.82;BDBM161478;CCn1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cc1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1;IC50;'=';25.2;nM;7.60;;304778;UO_0000065;10.25;0.19;-0.22;9.84;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;25.2
CHEMBL3701325;;None;617.68;2;7.14;BDBM161510;Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C;IC50;'=';10.0;nM;8.00;;304809;UO_0000065;12.95;0.24;0.86;9.50;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;10.0
CHEMBL3701331;;None;688.79;2;5.05;BDBM161516;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';5.9;nM;8.23;;304815;UO_0000065;11.95;0.22;3.18;7.19;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.9
CHEMBL3701321;;None;655.80;2;6.57;BDBM161506;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)NCc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';60.4;nM;7.22;;304805;UO_0000065;11.01;0.20;0.65;6.75;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;60.4
CHEMBL3701329;;None;656.78;2;7.30;BDBM161514;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCN(C(=O)O)c3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';38.9;nM;7.41;;304813;UO_0000065;11.28;0.21;0.11;6.97;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;38.9
CHEMBL2171005;;None;859.33;2;7.58;9;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(Br)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';255.0;nM;6.59;;;UO_0000065;7.67;0.16;-0.99;7.08;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;255.0
CHEMBL5201820;;None;521.42;2;6.18;23;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccncc3)C2)cc1;IC50;'=';2780.0;nM;5.56;;;UO_0000065;10.66;0.22;-0.62;6.62;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;2.78
CHEMBL3701309;;None;679.22;2;5.97;BDBM161494;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';2.9;nM;8.54;;304897;UO_0000065;12.57;0.24;2.57;8.89;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.9
CHEMBL3701348;;None;656.78;2;7.17;BDBM161534;Cc1ccc(OC(=O)NCc2ccc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c(C)n3C)c(C(=O)N3Cc4ccccc4C[C@H]3C)c2)cc1;IC50;'=';16.9;nM;7.77;;304832;UO_0000065;11.83;0.22;0.60;7.47;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;16.9
CHEMBL3701373;;None;715.30;2;6.92;BDBM161562;Cc1c(C(=O)N(c2ccccc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';18.1;nM;7.74;;304860;UO_0000065;10.82;0.20;0.82;10.44;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;18.1
CHEMBL3704796;;None;676.79;2;5.76;BDBM161633;Cc1nn(C)cc1N(C(=O)c1cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1;IC50;'=';8.3;nM;8.08;;304930;UO_0000065;11.94;0.22;2.32;8.41;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;8.3
CHEMBL3704804;;None;729.32;2;7.83;BDBM161641;Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CCCN3CCOCC3)n(C)c2C)c2ccccc2)cc(C#N)n1C;IC50;'=';3.1;nM;8.51;;304938;UO_0000065;11.67;0.22;0.68;9.81;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.1
CHEMBL3704805;;None;680.21;2;6.53;BDBM161642;Cc1cc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)no1;IC50;'=';13.3;nM;7.88;;304939;UO_0000065;11.58;0.22;1.35;7.55;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;13.3
CHEMBL4862718;;None;330.41;0;4.87;S1f;N#CC1=C(C#N)c2ccc(SC3CCCC3)c3cccc(c23)C1=O;IC50;'=';8400.0;nM;5.08;;;UO_0000065;15.36;0.29;0.21;7.85;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;8.4
CHEMBL2170848;;None;1007.62;None;None;24;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';7.5;nM;8.12;;;UO_0000065;8.06;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;7.5
CHEMBL2170846;;None;995.61;3;9.96;22;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';9.2;nM;8.04;;;UO_0000065;8.07;0.16;-1.92;5.57;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;9.2
CHEMBL2171004;;None;814.88;2;7.47;8;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(Cl)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';660.0;nM;6.18;;;UO_0000065;7.58;0.15;-1.29;6.63;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;660.0
CHEMBL3701349;;None;662.77;2;5.46;BDBM161535;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';12.5;nM;7.90;;304833;UO_0000065;11.92;0.22;2.44;8.23;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;12.5
CHEMBL3701356;;None;720.80;2;5.48;BDBM161545;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1CCF;IC50;'=';8.6;nM;8.07;;304843;UO_0000065;11.19;0.21;2.59;7.04;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;8.6
CHEMBL3923681;;None;567.13;2;5.44;BDBM179553;CCCCN(CCCC)C(=O)c1nn(-c2ccc(OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';892.38;nM;6.05;;326168;UO_0000065;10.67;0.21;0.61;6.88;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;892.385
CHEMBL3937363;;None;595.77;1;4.15;BDBM179557;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(C)(=O)=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';294.71;nM;6.53;;326217;UO_0000065;10.96;0.21;2.38;5.23;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;294.715
CHEMBL4294620;;None;976.12;3;5.93;34b;C[C@@H]1CC[C@H]2[C@@H](C)C(OCCN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)C[C@@H]3CO)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4;IC50;'=';28.7;nM;7.54;;;UO_0000065;7.73;0.15;1.61;3.16;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;28.7
CHEMBL4282932;;None;928.08;3;6.58;28d;C[C@H]1[C@@H](CC(=O)N2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24O3;IC50;'=';3.5;nM;8.46;;;UO_0000065;9.11;0.17;1.88;3.90;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;3.5
CHEMBL1272224;;None;518.56;1;5.00;BDBM142750;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC(C)C)C2=O)C(=O)c2cc(O)c(O)c(CC(C)C)c2C1=O;IC50;'=';250.0;nM;6.60;;278902;UO_0000065;12.73;0.24;1.60;4.42;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;250.0
CHEMBL2398170;;None;394.48;0;4.95;48;C/C(=N\Nc1nc2ccccc2s1)c1ccc(-c2cccc(C(=O)O)n2)s1;IC50;'>';10000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2399234;Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2396645;1;Scientific Literature;J Med Chem;2013;None;;;;10.0
CHEMBL2171009;;None;836.55;2;8.11;13;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(C(C)(C)C)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';1908.0;nM;5.72;;;UO_0000065;6.84;0.13;-2.39;6.14;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;1908.0
CHEMBL2171006;;None;848.44;2;7.83;10;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';582.0;nM;6.24;;;UO_0000065;7.35;0.14;-1.59;6.69;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;582.0
CHEMBL2171003;;None;798.43;2;6.95;7;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';977.0;nM;6.01;;;UO_0000065;7.53;0.15;-0.94;6.45;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;977.0
CHEMBL2170852;;None;825.44;2;6.72;5, BM-916;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';117.0;nM;6.93;;;UO_0000065;8.40;0.16;0.21;5.09;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;117.0
CHEMBL3701367;;None;701.23;2;6.50;BDBM161556;Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)ccn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';8.5;nM;8.07;;304854;UO_0000065;11.51;0.22;1.57;7.02;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;8.5
CHEMBL481409;;None;290.36;0;4.28;12;Oc1cc(Cc2ccccc2)c(Cc2ccccc2)cc1O;IC50;'=';4700.0;nM;5.33;;;UO_0000065;18.35;0.33;1.05;13.17;0;CHEMBL1107438;Displacement of FITC-conjugated BH3-Bim peptide from human recombinant Bcl-2 expressed in Escherichia coli BL21 (DE3) by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157820;1;Scientific Literature;J Med Chem;2010;None;;;;4.7
CHEMBL441574;;None;2952.32;None;None;13 (Bax BH3-26);CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O;IC50;'=';2880.0;nM;5.54;;;UO_0000065;1.88;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;2.88
CHEMBL2063882;;None;1135.85;None;None;6, BM-977;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)c4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';8.7;nM;8.06;;;UO_0000065;7.10;None;None;None;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;8.7
CHEMBL2063885;;None;1075.75;None;None;9, BM-593;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(C#Cc3cccc(-c4c(-c5ccc(Cl)cc5)cn(CC[C@H](O)CO)c4C(=O)NCCCN4CCN(C)CC4)c3)cc2)cc1[N+](=O)[O-];IC50;'=';1.9;nM;8.72;;;UO_0000065;8.11;None;None;None;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;1.9
CHEMBL3311330;;None;941.56;3;8.22;2;N=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';19.0;nM;7.72;;;UO_0000065;8.20;0.17;-0.50;5.71;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.019
CHEMBL444140;;None;542.64;2;5.72;5;Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO;IC50;'=';190.0;nM;6.72;;;UO_0000065;12.39;0.22;1.00;8.54;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.19
CHEMBL1269012;;None;756.81;3;5.67;BDBM142748;CCc1ccc(CCNC(=O)c2c(O)c(O)cc3c2C(=O)C(C)=C(C2=C(C)C(=O)c4c(cc(O)c(O)c4C(=O)NCCc4ccc(CC)cc4)C2=O)C3=O)cc1;IC50;'=';210.0;nM;6.68;;278912;UO_0000065;8.82;0.16;1.01;3.22;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;210.0
CHEMBL409227;;None;3001.38;None;None;6 (Bad BH3-26 (A3));CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O;IC50;'=';410.0;nM;6.39;;;UO_0000065;2.13;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;0.41
CHEMBL2312478;;None;363.49;0;3.45;5f;CC(C)NC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13;IC50;'>';10000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;10.0
CHEMBL2312484;;None;399.52;1;5.02;6b;CCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13;IC50;'=';190.0;nM;6.72;;;UO_0000065;16.82;0.32;1.70;9.96;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;190.0
CHEMBL412528;;None;3041.41;None;None;8 (Bad BH3-26 (A23));CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O;IC50;'=';1360.0;nM;5.87;;;UO_0000065;1.93;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;1.36
CHEMBL411747;;None;3117.51;None;None;1 (Bad BH3-26);CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O;IC50;'=';300.0;nM;6.52;;;UO_0000065;2.09;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;0.3
CHEMBL137135;;None;411.25;0;2.09;1;CCOC(=O)C(C#N)C1c2cc(Br)ccc2OC(N)C1C(=O)OCC;IC50;'=';9000.0;nM;5.05;;;UO_0000065;12.27;0.28;2.96;4.52;0;CHEMBL651293;Inhibitory activity against Bcl-2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;9.0
CHEMBL508211;;None;556.67;2;6.03;7 (cis atropisomer, a-S);Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2C[C@H]1CO;IC50;'=';210.0;nM;6.68;;;UO_0000065;12.00;0.22;0.65;8.49;0;CHEMBL1014486;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1153292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;210.0
CHEMBL509760;;None;556.67;2;6.03;7;Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2CC1CO;IC50;'=';600.0;nM;6.22;;;UO_0000065;11.18;0.20;0.19;7.91;0;CHEMBL1014486;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1153292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;600.0
CHEMBL501871;;None;556.67;2;6.37;20;COC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C;IC50;'=';160.0;nM;6.80;;;UO_0000065;12.21;0.22;0.43;10.04;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;0.16
CHEMBL1272224;;None;518.56;1;5.00;6b;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC(C)C)C2=O)C(=O)c2cc(O)c(O)c(CC(C)C)c2C1=O;IC50;'=';250.0;nM;6.60;;;UO_0000065;12.73;0.24;1.60;4.42;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;0.25
CHEMBL1269070;;None;728.75;3;5.67;8a;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)NCC(C)c3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)NCC(C)c3ccccc3)c2C1=O;IC50;'=';230.0;nM;6.64;;;UO_0000065;9.11;0.17;0.97;3.20;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;0.23
CHEMBL541496;;None;728.84;3;7.58;8q;CCc1ccc(CCNC(=O)c2c(O)c(O)cc3c(O)c(-c4c(C)cc5c(C(=O)NCCc6ccc(CC)cc6)c(O)c(O)cc5c4O)c(C)cc23)cc1;IC50;'=';670.0;nM;6.17;;;UO_0000065;8.47;0.16;-1.41;3.44;0;CHEMBL1031851;Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1158469;1;Scientific Literature;J Med Chem;2009;None;;;;0.67
CHEMBL1269075;;None;614.65;2;6.17;BDBM142753;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccccc3)c2C1=O;IC50;'=';2570.0;nM;5.59;;278907;UO_0000065;9.09;0.17;-0.58;3.75;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2570.0
CHEMBL3920752;;None;611.14;1;4.90;BDBM179545;CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';150.9;nM;6.82;;326148;UO_0000065;11.16;0.22;1.92;5.45;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;150.9
CHEMBL3945127;;None;747.96;2;8.02;BDBM179567;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Oc4ccc(C)cc4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';4863.58;nM;5.31;;326227;UO_0000065;7.10;0.13;-2.71;4.32;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4863.58
CHEMBL3962530;;None;786.83;2;8.89;BDBM179568;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cc(Cl)cc(Cl)c4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';4210.98;nM;5.38;;326228;UO_0000065;6.83;0.14;-3.51;4.73;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.210.985
CHEMBL4284025;;None;960.12;3;7.00;34c;C[C@@H]1CC[C@H]2[C@@H](C)C(OCCNC3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4;IC50;'=';1.9;nM;8.72;;;UO_0000065;9.08;0.18;1.72;3.84;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;1.9
CHEMBL3985961;;None;656.85;2;5.50;BDBM179597;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3N)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';254.69;nM;6.59;;326256;UO_0000065;10.04;0.19;1.09;4.72;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;254.695
CHEMBL3900418;;None;623.82;1;4.93;BDBM179558;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)C(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';126.56;nM;6.90;;326173;UO_0000065;11.06;0.21;1.97;5.53;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;126.56
CHEMBL3927159;;None;683.88;2;6.12;BDBM179560;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(C)=O)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';609.25;nM;6.21;;326175;UO_0000065;9.09;0.17;0.10;4.75;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;609.245
CHEMBL3890069;;None;799.63;2;7.44;BDBM179562;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)c(Br)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';638.23;nM;6.20;;326177;UO_0000065;7.75;0.18;-1.24;5.45;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;638.23
CHEMBL3985364;;None;659.83;2;6.06;BDBM179582;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';454.15;nM;6.34;;326196;UO_0000065;9.61;0.18;0.28;5.58;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;454.155
CHEMBL3976266;;None;699.87;2;5.69;BDBM179587;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc4c(c3)OCCO4)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';631.49;nM;6.20;;326201;UO_0000065;8.86;0.17;0.51;4.69;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;631.485
CHEMBL3890050;;None;673.88;2;5.27;BDBM179579;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(C)nn(C)c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';466.35;nM;6.33;;326238;UO_0000065;9.40;0.18;1.06;4.81;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;466.345
CHEMBL3703599;;None;828.46;2;8.51;BDBM156377;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';0.3;nM;9.52;;363128;UO_0000065;11.49;0.23;1.01;6.56;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.3
CHEMBL4211198;;None;900.43;2;6.92;55;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(CN6CC(F)(F)C6)COC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1;IC50;'=';17.3;nM;7.76;;;UO_0000065;8.62;0.18;0.84;6.05;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;17.3
CHEMBL1094250;1,1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-((R)-2-PHENYLPROPYL)-N5'-((R)-2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE (ATROPISOMERIC MIX);None;700.79;3;7.58;(R, +, R)-12;Cc1cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c1O;IC50;'=';320.0;nM;6.50;;;UO_0000065;9.27;0.17;-1.09;3.62;0;CHEMBL1106537;Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157826;1;Scientific Literature;J Med Chem;2010;None;;;;0.32
CHEMBL3701291;;None;594.12;2;6.66;BDBM161473;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';5.0;nM;8.30;;304775;UO_0000065;13.97;0.26;1.64;9.93;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.0
CHEMBL3701296;;None;736.87;2;6.41;BDBM161481;CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(ccn5C)c4)cn2C)OCO3)CC1;IC50;'=';22.4;nM;7.65;;304780;UO_0000065;10.38;0.19;1.24;8.00;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;22.4
CHEMBL3701334;;None;716.80;3;5.11;BDBM161519;COc1ncc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n(C)c2C)c2ccc(O)cc2)cn1;IC50;'=';5.9;nM;8.23;;304818;UO_0000065;11.48;0.21;3.12;6.25;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.9
CHEMBL3701366;;None;701.23;2;6.50;BDBM161555;Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';91.5;nM;7.04;;304853;UO_0000065;10.04;0.19;0.54;6.12;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;91.5
CHEMBL3701371;;None;721.26;2;6.01;BDBM161560;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3COC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';4.2;nM;8.38;;304858;UO_0000065;11.61;0.22;2.37;7.96;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.2
CHEMBL3701400;;None;692.79;2;5.47;BDBM161591;COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)c(F)c3)c3cnn(C)c3)c(C)n2C)c1;IC50;'=';20.6;nM;7.69;;304889;UO_0000065;11.09;0.21;2.22;7.30;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;20.6
CHEMBL3893154;;None;888.32;2;9.50;BDBM232403;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4Cc4ccc(Cl)c(Cl)c4)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';50.0;nM;7.30;;405203;UO_0000065;8.22;0.17;-2.20;5.77;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;50.0
CHEMBL3942482;;None;857.26;2;9.10;BDBM232415;CCCCN(CCc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';30.0;nM;7.52;;405220;UO_0000065;8.78;0.18;-1.58;6.18;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;30.0
CHEMBL3894163;;None;802.70;2;7.66;BDBM232428;CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C(F)(F)F)c1Cl;IC50;'=';30.0;nM;7.52;;405233;UO_0000065;9.37;0.19;-0.14;6.03;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;30.0
CHEMBL3927392;;None;827.63;2;7.71;BDBM232434;CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';7.84;nM;8.11;;405239;UO_0000065;9.79;0.21;0.40;6.49;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;7.84
CHEMBL3927294;;None;867.42;2;9.97;BDBM232441;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2cccc(Cl)c2)cc1;IC50;'=';20.0;nM;7.70;;405247;UO_0000065;8.88;0.17;-2.27;5.62;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;20.0
CHEMBL3962772;;None;749.89;2;6.15;BDBM232448;CCCCN(CCCC)C(=O)c1cn(CC(=O)O)c(-c2ccc(C(=O)NS(=O)(=O)c3cccc4ccccc34)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';140.0;nM;6.85;;405260;UO_0000065;9.14;0.17;0.70;4.31;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;140.0
CHEMBL2031014;;None;869.48;2;7.06;BDBM50384363;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCCN5CCOCC5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';110.0;nM;6.96;;405185;UO_0000065;8.00;0.16;-0.10;4.85;1;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;110.0
CHEMBL3926219;;None;604.75;1;4.72;BDBM179547;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1265.77;nM;5.90;;326150;UO_0000065;9.75;0.18;1.18;5.16;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.265.765
CHEMBL3908169;;None;666.82;2;5.90;BDBM179550;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1282.77;nM;5.89;;326165;UO_0000065;8.84;0.16;-0.01;5.16;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1282.77
CHEMBL3909422;;None;657.84;2;5.58;BDBM179556;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)c3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';692.43;nM;6.16;;326171;UO_0000065;9.36;0.18;0.58;4.93;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;692.435
CHEMBL4592905;;None;664.78;2;5.81;10;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1;IC50;'=';6300.0;nM;5.20;;;UO_0000065;7.82;0.15;-0.61;3.97;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;6.3
CHEMBL4560892;;None;744.84;3;5.06;12;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)c(S(=O)(=O)O)c1;IC50;'=';55900.0;nM;4.25;;;UO_0000065;5.71;0.12;-0.81;2.30;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;55.9
CHEMBL3137309;VENETOCLAX;4.0;868.46;3;8.66;"6; ABT-199";CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'=';1.0;nM;9.00;;;UO_0000065;10.36;0.20;0.34;5.23;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;1.0
CHEMBL4286682;;None;916.02;3;5.87;27h;C[C@@H]1CC[C@@H]2[C@]34OO[C@](C)(CC[C@@H]13)O[C@H]4O[C@]2(C)C(=O)N1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1;IC50;'=';13.0;nM;7.89;;;UO_0000065;8.61;0.17;2.02;3.49;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;13.0
CHEMBL5202671;;None;504.38;2;6.15;36;O=C(Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1)OC1CC1;IC50;'=';44.1;nM;7.36;;;UO_0000065;14.58;0.30;1.21;10.36;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.0441
CHEMBL5174166;;None;477.36;1;5.19;40;CNC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';5530.0;nM;5.26;;;UO_0000065;11.01;0.23;0.07;7.12;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;5.53
CHEMBL5201208;;None;423.49;0;3.95;1;Cc1ccc(C(=O)N2N=C(c3ccc(NS(C)(=O)=O)cc3)CC2c2ccco2)cc1;IC50;'>';10000.0;nM;;;;UO_0000065;;;;;0;CHEMBL5149882;Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;T;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;10.0
CHEMBL5202671;;None;504.38;2;6.15;36;O=C(Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1)OC1CC1;IC50;'=';15100.0;nM;4.82;;;UO_0000065;;;;;0;CHEMBL5149882;Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;T;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;15.1
CHEMBL5170553;;None;427.46;0;3.78;11;CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3cccc(F)c3)C(c3ccco3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5205908;;None;423.49;0;3.95;10;Cc1cccc(C(=O)N2N=C(c3ccc(NS(C)(=O)=O)cc3)CC2c2ccco2)c1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5181504;;None;442.52;1;5.42;32;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccncc3)C(c3ccccc3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5197825;;None;537.54;2;6.77;29;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C(=O)C(F)(F)F)cc3)C(c3ccccc3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5201043;;None;504.43;2;5.97;57;CC(C)(C)NC(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5182854;;None;492.37;1;6.01;34;CCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';6620.0;nM;5.18;;;UO_0000065;;;;;0;CHEMBL5149882;Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;T;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;6.62
CHEMBL5183315;;None;521.42;2;6.04;50;CC(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2C)cn1;IC50;'=';157.0;nM;6.80;;;UO_0000065;;;;;0;CHEMBL5149882;Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;T;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.157
CHEMBL4519659;;None;980.16;3;8.40;J1T;COc1cc2c(cc1C(CN1CCCC1)c1ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(C[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)cc1)OCO2;IC50;'=';20.0;nM;7.70;;;UO_0000065;7.85;0.16;-0.70;5.47;0;CHEMBL4378481;Displacement of fluorescein labelled Puma-BH3 peptide from human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4376822;1;Scientific Literature;J Med Chem;2020;None;;;;0.02
CHEMBL4455274;;None;853.75;1;4.66;C1;O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O;IC50;'=';15210.0;nM;4.82;;;UO_0000065;5.64;0.12;0.16;2.52;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;15.21
CHEMBL4476628;;None;1023.02;None;None;C4;O=C(CCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O)NCCCCCCNC(=O)CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O;IC50;'=';13470.0;nM;4.87;;;UO_0000065;4.76;None;None;None;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;13.47
CHEMBL503454;;None;576.10;2;6.34;2W3L:DRO;Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN;IC50;'=';30.0;nM;7.52;;;UO_0000065;13.06;0.24;1.18;8.91;1;CHEMBL4322141;Inhibition of Bcl2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321790;1;Scientific Literature;J Med Chem;2019;None;;;;30.0
CHEMBL3703619;;None;987.58;3;8.03;BDBM156400;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCO[C@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';1.0;nM;9.00;;363149;UO_0000065;9.11;0.19;0.97;5.44;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;1.0
CHEMBL3703612;;None;957.56;3;8.66;BDBM156392;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';3.0;nM;8.52;;363141;UO_0000065;8.90;0.18;-0.14;5.86;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;3.0
CHEMBL3703625;;None;1051.57;None;None;BDBM156407;COP(=O)(O)O[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';1.0;nM;9.00;;363155;UO_0000065;8.56;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;1.0
CHEMBL3703600;;None;945.55;3;8.26;BDBM156378;CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'<';0.3;nM;;;363129;UO_0000065;;;;;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.3
CHEMBL3703607;;None;1080.61;None;None;BDBM156387;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(CCOP(=O)(O)O)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.7;nM;9.15;;363136;UO_0000065;8.47;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.7
CHEMBL3927598;;None;841.47;2;7.66;BDBM232400;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)C3CCCCC3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';250.0;nM;6.60;;405199;UO_0000065;7.85;0.15;-1.06;4.65;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;250.0
CHEMBL2031022;;None;890.33;2;9.06;BDBM50384353;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';20.0;nM;7.70;;405200;UO_0000065;8.65;0.18;-1.36;6.16;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;20.0
CHEMBL3893805;;None;835.04;2;5.76;BDBM232449;CCCCN(CCCC)C(=O)c1cn(CCN2CCOCC2)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';120.0;nM;6.92;;405261;UO_0000065;8.29;0.16;1.16;4.48;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;120.0
CHEMBL3309262;;None;1043.65;None;None;26;CN(C)C(=O)COc1ccc(-c2ccc(Cl)cc2)c(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1;IC50;'<';10.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.01
CHEMBL135934;;None;614.29;2;9.68;5;O=C1c2cc(Br)ccc2-c2ccc3c4ccc5c6c(ccc(c7ccc1c2c73)c64)C(=O)c1cc(Br)ccc1-5;IC50;'=';7700.0;nM;5.11;;;UO_0000065;8.32;0.18;-4.57;14.98;0;CHEMBL651291;In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;7.7
CHEMBL3912236;;None;844.43;2;6.01;BDBM232404;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)N3CCOCC3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';340.0;nM;6.47;;405204;UO_0000065;7.66;0.15;0.46;4.19;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;340.0
CHEMBL3960836;;None;794.30;2;7.89;BDBM232416;CCCCN(CCCC(F)(F)F)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';110.0;nM;6.96;;405221;UO_0000065;8.76;0.17;-0.93;5.72;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;110.0
CHEMBL3954559;;None;818.35;2;7.52;BDBM232418;CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1ccc2c(c1)OCCO2;IC50;'=';70.0;nM;7.16;;405223;UO_0000065;8.74;0.17;-0.37;5.11;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;70.0
CHEMBL3963735;;None;1058.48;None;None;BDBM232436;CCCCN(Cc1ccc(-c2ccc(CC(=O)O)cc2)cc1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';10.0;nM;8.00;;405241;UO_0000065;7.56;None;None;None;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;10.0
CHEMBL3899265;;None;939.75;2;11.38;BDBM232440;CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2cccc(Cl)c2)c1;IC50;'=';70.0;nM;7.16;;405245;UO_0000065;7.61;0.16;-4.23;5.88;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;70.0
CHEMBL3921891;;None;777.00;2;7.01;BDBM232447;CCCCN(CCCC)C(=O)c1cn(CCCN(C)C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';200.0;nM;6.70;;405259;UO_0000065;8.62;0.16;-0.31;5.36;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;200.0
CHEMBL3897725;;None;860.82;2;6.53;BDBM232450;CCCCN(CCCC)C(=O)c1cn(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(I)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1;IC50;'=';6.97;nM;8.16;;405262;UO_0000065;9.48;0.21;1.63;5.52;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;6.97
CHEMBL3601398;CGM-097;1.0;659.27;2;6.58;1, NVP-CGM097;COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2;IC50;'>';50000.0;nM;;;;UO_0000065;;;;;0;CHEMBL3603527;Inhibition of Bcl2 (unknown origin) assessed as inhibition of Bcl2-Bad interaction by TR-FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3600357;1;Scientific Literature;J Med Chem;2015;None;;;;50000.0
CHEMBL4552126;;None;493.38;1;5.34;1;COC(=O)CCNC1=C(C#N)C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc1c23;IC50;'=';4520.0;nM;5.34;;;UO_0000065;10.83;0.24;0.00;6.75;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;4.52
CHEMBL344254;;None;456.50;1;8.16;12;O=C1c2ccccc2-c2ccc3c4ccc5c6c(ccc(c7ccc1c2c73)c64)C(=O)c1ccccc1-5;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL3701382;;None;717.27;2;6.76;BDBM161571;Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C;IC50;'=';2.6;nM;8.59;;304869;UO_0000065;11.97;0.23;1.83;8.03;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.6
CHEMBL376408;ABT 737;1.0;813.45;2;7.88;1, ABT-737;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';2.0;nM;8.70;;;UO_0000065;10.69;0.21;0.82;6.79;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;2.0
CHEMBL3704789;;None;730.84;2;6.25;BDBM161623;COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)cc1F;IC50;'=';2.6;nM;8.59;;304921;UO_0000065;11.75;0.22;2.34;7.39;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.6
CHEMBL3701365;;None;703.24;2;6.45;BDBM161554;Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';2.4;nM;8.62;;304926;UO_0000065;12.26;0.23;2.17;8.06;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.4
CHEMBL3704795;;None;713.81;2;6.00;BDBM161632;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(cnn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';2.9;nM;8.54;;304929;UO_0000065;11.96;0.22;2.54;7.84;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.9
CHEMBL3704803;;None;763.34;2;7.18;BDBM161640;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CCOC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C;IC50;'=';2.8;nM;8.55;;304937;UO_0000065;11.20;0.21;1.37;8.12;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.8
CHEMBL3701297;;None;658.77;2;6.72;BDBM161482;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';16.2;nM;7.79;;304781;UO_0000065;11.83;0.22;1.07;9.96;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;16.2
CHEMBL3701300;;None;716.81;2;6.76;BDBM161485;Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n(C)c2C)c2ccc(O)cc2)cc1F;IC50;'=';4.4;nM;8.36;;304784;UO_0000065;11.66;0.22;1.60;8.64;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.4
CHEMBL3701309;;None;679.22;2;5.97;BDBM161494;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';4.0;nM;8.40;;304793;UO_0000065;12.36;0.23;2.43;8.74;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.0
CHEMBL3701312;;None;591.11;2;7.32;BDBM161497;Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';7.5;nM;8.12;;304796;UO_0000065;13.75;0.26;0.80;10.33;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7.5
CHEMBL3701326;;None;653.74;2;6.89;BDBM161511;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C;IC50;'=';5.2;nM;8.28;;304810;UO_0000065;12.67;0.23;1.39;8.12;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.2
CHEMBL3701328;;None;738.85;2;6.20;BDBM161513;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';3.0;nM;8.52;;304812;UO_0000065;11.54;0.21;2.32;7.44;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.0
CHEMBL3701332;;None;631.69;2;5.80;BDBM161517;COc1ncc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3C)OCO4)n(C)c2C)c2ccc(O)cc2)cn1;IC50;'=';4.4;nM;8.36;;304816;UO_0000065;13.23;0.24;2.56;7.01;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.4
CHEMBL3701340;;None;669.83;2;6.61;BDBM161525;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)NCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';75.0;nM;7.12;;304824;UO_0000065;10.64;0.19;0.51;6.66;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;75.0
CHEMBL3701293;;None;727.31;2;7.34;BDBM161477;CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)cn2C)CC1;IC50;'=';21.2;nM;7.67;;304777;UO_0000065;10.55;0.20;0.33;9.94;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;21.2
CHEMBL3701375;;None;742.85;2;6.62;BDBM161564;COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnc4c(ccn4C)c3)c(C)n2C)cc1F;IC50;'=';7.4;nM;8.13;;304862;UO_0000065;10.95;0.20;1.51;7.72;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7.4
CHEMBL3701404;;None;693.25;2;6.45;BDBM161595;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1CCN1CCOCC1;IC50;'=';5.5;nM;8.26;;304893;UO_0000065;11.91;0.23;1.81;8.60;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.5
CHEMBL3704777;;None;700.82;2;6.24;BDBM161611;Cc1c(N(C(=O)c2cc(-c3ccc(F)cc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C;IC50;'=';3.5;nM;8.46;;304909;UO_0000065;12.07;0.22;2.22;7.90;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.5
CHEMBL3704781;;None;693.25;2;6.28;BDBM161615;Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cnn1C;IC50;'=';3.4;nM;8.47;;304913;UO_0000065;12.22;0.23;2.19;8.81;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.4
CHEMBL3703614;;None;966.57;3;9.24;BDBM156394;N#C[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';2.0;nM;8.70;;363143;UO_0000065;9.00;0.18;-0.54;5.84;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;2.0
CHEMBL4591149;;None;569.48;2;5.20;2;COC(=O)CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O;IC50;'=';4780.0;nM;5.32;;;UO_0000065;9.34;0.20;0.12;5.73;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;4.78
CHEMBL4454922;;None;777.66;1;4.79;H1;N#CC1=C(NCCC(=O)NCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O;IC50;'=';10480.0;nM;4.98;;;UO_0000065;6.40;0.13;0.19;2.80;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;10.48
CHEMBL4579464;;None;865.76;2;4.83;H5;N#CC1=C(NCCC(=O)NCCOCCOCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O;IC50;'=';2240.0;nM;5.65;;;UO_0000065;6.53;0.13;0.82;2.88;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;2.24
CHEMBL3982160;;None;723.90;2;6.28;BDBM179589;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4noc(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';641.46;nM;6.19;;326248;UO_0000065;8.55;0.16;-0.09;4.06;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;641.455
CHEMBL3943273;;None;872.47;3;6.76;Table 10-B, 1;CN(CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-])CC(=O)NO;IC50;'<=';100.0;nM;;;;UO_0000065;;;;;0;CHEMBL3882095;Inhibition of recombinant human C-terminal minus Bcl-2 using 26-mer fluorescein labeled BH3 peptide as substrate after 3 hrs by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3881527;38;SureChEMBL Patent Bioactivity Data;;2008;None;;;;0.1
CHEMBL4469267;;None;913.50;3;8.69;7f;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCCCCC(=O)NO)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'=';240.0;nM;6.62;;;UO_0000065;7.25;0.14;-2.07;3.12;0;CHEMBL4332203;Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4330103;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;0.24
CHEMBL3701382;;None;717.27;2;6.76;BDBM161571;Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C;IC50;'=';1.7;nM;8.77;;304927;UO_0000065;12.23;0.23;2.01;8.20;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.7
CHEMBL2398260;;None;420.52;1;5.27;71a;O=C(O)c1csc(-c2ccc3c(c2)/C(=N\Nc2nc4ccccc4s2)CCC3)n1;IC50;'=';5000.0;nM;5.30;;;UO_0000065;12.61;0.25;0.03;6.06;0;CHEMBL2399234;Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2396645;1;Scientific Literature;J Med Chem;2013;None;;;;5.0
CHEMBL3917653;;None;694.90;2;6.41;BDBM179576;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4ccn(C)c34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1356.79;nM;5.87;;326190;UO_0000065;8.44;0.16;-0.54;4.94;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1356.79
CHEMBL4855924;;None;338.39;0;4.99;S1a;N#CC1=C(C#N)c2ccc(Sc3ccccc3)c3cccc(c23)C1=O;IC50;'=';1800.0;nM;5.75;;;UO_0000065;16.98;0.31;0.75;8.89;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;1.8
CHEMBL3704814;;None;773.86;1;4.77;BDBM60409;CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)N4CCN(C)CC4)c(C(F)(F)F)n2C)OCO3)CC1;IC50;'=';52.9;nM;7.28;;198903;UO_0000065;9.40;0.18;2.51;7.49;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;52.9
CHEMBL4208633;;None;906.49;2;6.98;52;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@@H](CC5CC5)C(=O)N5CCOCC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1;IC50;'=';68.2;nM;7.17;;;UO_0000065;7.91;0.16;0.19;4.93;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;68.2
CHEMBL2398286;;None;388.45;0;4.89;38;C/C(=N\Nc1nc2ccccc2s1)c1cccc(-c2cccc(C(=O)O)n2)c1;IC50;'>';10000.0;nM;;;;UO_0000065;;;;;0;CHEMBL2399234;Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2396645;1;Scientific Literature;J Med Chem;2013;None;;;;10.0
CHEMBL5200411;;None;491.39;1;6.00;55;CC(C)C(=O)Oc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';5450.0;nM;5.26;;;UO_0000065;10.71;0.22;-0.74;8.93;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;5.45
CHEMBL3703604;;None;1135.53;None;None;BDBM156384;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN(CCOP(=O)(O)O)CCOP(=O)(O)O)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';2.0;nM;8.70;;363133;UO_0000065;7.66;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;2.0
CHEMBL3703628;;None;1013.63;None;None;BDBM156412;NCC(=O)N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';38.0;nM;7.42;;363158;UO_0000065;7.32;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;38.0
CHEMBL3703598;;None;1000.63;None;None;BDBM156376;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(CCO)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'<';1.0;nM;;;363127;UO_0000065;;;;;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;1.0
CHEMBL2030844;;None;698.80;2;6.49;3a;CCOC(=O)c1nn(-c2ccccc2)c(C)c1-c1ccc(C(=O)NS(=O)(=O)c2ccc3ccccc3c2)cc1C(=O)N1CCc2ccccc2C1;IC50;'=';4190.0;nM;5.38;;;UO_0000065;7.70;0.14;-1.11;4.21;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;4.19
CHEMBL2030857;;None;756.92;2;6.77;3n;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(CCCO)cc1;IC50;'=';14.0;nM;7.85;;;UO_0000065;10.38;0.20;1.08;5.54;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.014
CHEMBL2030859;;None;728.87;2;6.21;3p;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(CO)nn1-c1ccccc1;IC50;'=';11.0;nM;7.96;;;UO_0000065;10.92;0.21;1.75;5.61;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.011
CHEMBL2031002;;None;825.86;2;8.74;4d;CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';120.0;nM;6.92;;;UO_0000065;8.38;0.17;-1.82;5.98;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.12
CHEMBL2031008;;None;745.73;2;6.87;4j;CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1;IC50;'=';15.0;nM;7.82;;;UO_0000065;10.49;0.21;0.95;5.65;0;CHEMBL2033942;Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029199;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;0.015
CHEMBL2031016;;None;890.46;2;8.62;16;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCc5ccc(C(=O)O)cc5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';15.0;nM;7.82;;;UO_0000065;8.79;0.17;-0.80;4.65;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;15.0
CHEMBL2031019;;None;731.32;2;6.16;19;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';32.0;nM;7.50;;;UO_0000065;10.25;0.20;1.33;5.61;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;32.0
CHEMBL2031020;;None;904.32;2;8.70;20;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)c3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';280.0;nM;6.55;;;UO_0000065;7.25;0.15;-2.15;4.62;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;280.0
CHEMBL2031030;;None;823.46;2;7.81;33;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCCC2)c(C)c1Cl;IC50;'=';47.0;nM;7.33;;;UO_0000065;8.90;0.17;-0.48;5.87;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;47.0
CHEMBL2031032;;None;741.31;2;7.17;38;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CNc3ccccc3C2)c(C)c1Cl;IC50;'=';26.0;nM;7.58;;;UO_0000065;10.23;0.20;0.42;5.67;0;CHEMBL2033953;Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2029223;1;Scientific Literature;Bioorg Med Chem Lett;2012;None;;;;26.0
CHEMBL5171960;;None;439.49;0;3.65;8;COc1ccc(C(=O)N2N=C(c3ccc(NS(C)(=O)=O)cc3)CC2c2ccco2)cc1;IC50;'=';10110.0;nM;5.00;;;UO_0000065;11.37;0.22;1.35;4.94;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;10.11
CHEMBL5183128;;None;434.48;0;3.51;7;CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C#N)cc3)C(c3ccco3)C2)cc1;IC50;'=';7440.0;nM;5.13;;;UO_0000065;11.80;0.23;1.62;4.43;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;7.44
CHEMBL5205655;;None;521.42;2;6.18;47;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)nc1;IC50;'=';372.0;nM;6.43;;;UO_0000065;12.33;0.26;0.25;7.66;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.37200000000000005
CHEMBL5196944;;None;534.45;2;7.03;48;CC1C(c2ccc(NC(=O)OC(C)(C)C)cc2)=NN(C(=O)c2ccc(Br)cc2)C1c1ccccc1;IC50;'=';27.4;nM;7.56;;;UO_0000065;14.15;0.30;0.53;10.65;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.0274
CHEMBL4878411;;None;888.97;3;8.74;24h;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1;IC50;'=';8.4;nM;8.08;;;UO_0000065;9.08;0.18;-0.66;4.77;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;8.4
CHEMBL4213316;;None;600.23;1;4.35;36;CN1CCN(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)CC1;IC50;'=';168.0;nM;6.78;;;UO_0000065;11.29;0.23;2.42;8.89;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;168.0
CHEMBL5187331;;None;504.38;2;6.18;38;C=CCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';8830.0;nM;5.05;;;UO_0000065;;;;;0;CHEMBL5149882;Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;T;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;8.83
CHEMBL5201439;;None;519.62;2;5.43;26;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(S(C)(=O)=O)cc3)C(c3ccccc3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5188416;;None;520.43;2;6.79;24;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';262.0;nM;6.58;;;UO_0000065;12.65;0.26;-0.21;9.27;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.262
CHEMBL5203263;;None;505.42;2;5.97;43;CC(C)NC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';350.0;nM;6.46;;;UO_0000065;12.77;0.27;0.49;8.75;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.35
CHEMBL5195576;;None;504.38;2;5.64;51;CC1C(c2ccc(N3CCOC3=O)cc2)=NN(C(=O)c2ccc(Br)cc2)C1c1ccccc1;IC50;'=';5160.0;nM;5.29;;;UO_0000065;10.48;0.22;-0.35;8.50;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;5.16
CHEMBL3703602;;None;975.57;3;7.62;BDBM156382;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN(CCO)CCO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.8;nM;9.10;;363131;UO_0000065;9.32;0.19;1.48;5.15;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.8
CHEMBL2171008;;None;808.49;2;7.38;12;CCc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1;IC50;'=';621.0;nM;6.21;;;UO_0000065;7.68;0.15;-1.17;6.66;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;621.0
CHEMBL2170853;;None;780.44;2;6.82;6;Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccccc5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';2200.0;nM;5.66;;;UO_0000065;7.25;0.14;-1.16;6.07;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;2200.0
CHEMBL2170847;;None;1037.65;None;None;23;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';55.2;nM;7.26;;;UO_0000065;6.99;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;55.2
CHEMBL2169898;;None;810.46;2;6.82;15;COc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1;IC50;'=';802.0;nM;6.10;;;UO_0000065;7.52;0.15;-0.72;5.95;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;802.0
CHEMBL3950260;;None;655.87;2;6.06;BDBM179601;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';474.73;nM;6.32;;326260;UO_0000065;9.64;0.18;0.26;5.56;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;474.73
CHEMBL3932360;;None;729.94;2;7.58;BDBM179591;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc4ccc(F)cc4c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1076.21;nM;5.97;;326205;UO_0000065;8.18;0.16;-1.61;5.25;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1076.21
CHEMBL3902718;;None;761.21;2;7.39;BDBM179561;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc(Cl)cc3Br)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';465.17;nM;6.33;;326221;UO_0000065;8.32;0.18;-1.06;5.57;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;465.17
CHEMBL3899521;;None;689.84;2;5.30;BDBM179573;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(=O)OC)o3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';456.67;nM;6.34;;326233;UO_0000065;9.19;0.18;1.04;4.14;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;456.67
CHEMBL3904990;;None;721.93;2;6.32;BDBM179575;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccn(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';757.03;nM;6.12;;326234;UO_0000065;8.48;0.16;-0.20;4.65;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;757.035
CHEMBL2063884;;None;1090.77;None;None;8, BM-908;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(-c3cn(-c4cccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)c4)nn3)cc2)cc1[N+](=O)[O-];IC50;'=';1.4;nM;8.85;;;UO_0000065;8.12;None;None;None;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;1.4
CHEMBL2170844;;None;872.56;2;6.61;20;CCS(=O)(=O)c1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1;IC50;'=';828.0;nM;6.08;;;UO_0000065;6.97;0.14;-0.53;4.78;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;828.0
CHEMBL3901575;;None;803.81;2;7.33;BDBM232432;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl;IC50;'=';10.0;nM;8.00;;405237;UO_0000065;9.95;0.20;0.67;5.42;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;10.0
CHEMBL3703618;;None;987.58;3;8.03;BDBM156399;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCO[C@@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.6;nM;9.22;;363148;UO_0000065;9.34;0.19;1.19;5.57;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.6
CHEMBL4437855;;None;298.27;0;2.85;4;O=C(O)c1ccc(-c2ccc(F)c(S(=O)(=O)F)c2)cc1;IC50;;;;;;Not Determined;;;;;;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;
CHEMBL4464321;;None;298.27;0;2.85;3;O=C(O)c1ccc(-c2ccc(F)cc2S(=O)(=O)F)cc1;IC50;;;;;;Not Determined;;;;;;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;
CHEMBL4278774;;None;974.10;3;6.48;27i;CO[C@H]1OC2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@]1(C)CC(=O)N1CCN(c5ccc(C(=O)NS(=O)(=O)c6ccc(NCC7CCOCC7)c([N+](=O)[O-])c6)c(Oc6cnc7[nH]ccc7c6)c5)CC1)[C@@]24OO3;IC50;'=';34.7;nM;7.46;;;UO_0000065;7.66;0.15;0.98;3.17;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;34.7
CHEMBL4849170;;None;344.44;1;5.26;S1g;N#CC1=C(C#N)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O;IC50;'=';8600.0;nM;5.07;;;UO_0000065;14.71;0.28;-0.19;7.84;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;8.6
CHEMBL4860155;;None;873.96;3;8.39;24f;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5CCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1;IC50;'=';1.9;nM;8.72;;;UO_0000065;9.98;0.19;0.33;5.07;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;1.9
CHEMBL3895678;;None;553.10;2;5.14;BDBM179552;CCCCN(CCCC)C(=O)c1nn(-c2ccc(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';623.56;nM;6.21;;326155;UO_0000065;11.22;0.22;1.07;6.27;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;623.56
CHEMBL3893085;;None;719.95;2;7.25;BDBM179584;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCc3cccc4ccccc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';709.36;nM;6.15;;326198;UO_0000065;8.54;0.16;-1.10;5.41;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;709.36
CHEMBL3902056;;None;751.93;2;7.85;BDBM179586;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(F)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';5412.52;nM;5.27;;326200;UO_0000065;7.00;0.13;-2.58;4.28;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.412.515
CHEMBL3953270;;None;987.59;3;8.03;BDBM156400;O=C(NS(=O)(=O)c1ccc(N[C@@H](CCN2CCO[C@@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';1.0;nM;9.00;;298911;UO_0000065;9.11;0.19;0.97;5.44;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.0
CHEMBL3703600;;None;945.55;3;8.26;"3; AZD4320";CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';3.9;nM;8.41;;;UO_0000065;8.89;0.18;0.15;5.38;0;CHEMBL5108715;Displacement of synthetic peptide tracer conjugated to fluorescein isothiocyanate from C-terminal 6xHis-tagged Bcl-2 (1 to 204 residues) (unknown origin) preincubated for 1 hr followed by tracer addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5107957;1;Scientific Literature;Eur J Med Chem;2022;None;TIME = 1.333 hr;INHIBITOR;;3.9
CHEMBL2031017;;None;866.22;2;7.95;BDBM50384348;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(I)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';40.0;nM;7.40;;405179;UO_0000065;8.54;0.19;-0.55;6.08;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;40.0
CHEMBL3923567;;None;765.34;2;7.22;BDBM232384;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(C#N)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';920.0;nM;6.04;;405180;UO_0000065;7.89;0.15;-1.18;4.15;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;920.0
CHEMBL3978452;;None;883.51;2;7.45;BDBM232389;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCCCN5CCOCC5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';290.0;nM;6.54;;405187;UO_0000065;7.40;0.14;-0.91;4.56;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;290.0
CHEMBL3891889;;None;853.53;2;8.57;BDBM232393;CCCCN(CCCC)C(=O)c1nn(-c2ccc(CNS(=O)(=O)c3ccc4ccc(OCCC5CCCN5C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';860.0;nM;6.07;;405191;UO_0000065;7.11;0.14;-2.50;5.18;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;860.0
CHEMBL3982550;;None;752.38;2;8.24;BDBM179564;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccc(Cl)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';7935.67;nM;5.10;;326224;UO_0000065;6.78;0.13;-3.14;4.48;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7935.67
CHEMBL408194;OBATOCLAX;3.0;317.39;0;4.49;GX015-070;COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C;IC50;'=';1110.0;nM;5.96;;;UO_0000065;18.76;0.34;1.46;11.20;1;CHEMBL4147762;Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4145520;1;Scientific Literature;Eur J Med Chem;2018;None;;;;1.11
CHEMBL3311491;;None;970.60;3;8.50;17;NCC1(Cc2ccccc2-c2ccc(Cl)cc2)CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'<';10.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.01
CHEMBL3309308;;None;943.54;3;7.43;22;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3cccnc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';26.0;nM;7.58;;;UO_0000065;8.04;0.16;0.16;5.37;0;CHEMBL3369467;Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.026
CHEMBL3984367;;None;798.41;2;8.13;BDBM232387;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OC(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';50.0;nM;7.30;;405184;UO_0000065;9.14;0.18;-0.83;5.58;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;50.0
CHEMBL3137309;VENETOCLAX;4.0;868.46;3;8.66;"3; ABT-199";CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'=';7.39;nM;8.13;;;UO_0000065;9.36;0.18;-0.53;4.73;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;7.39
CHEMBL4851461;;None;380.47;1;6.11;S1c;CC(C)c1ccc(Sc2ccc3c4c(cccc24)C(=O)C(C#N)=C3C#N)cc1;IC50;'=';2800.0;nM;5.55;;;UO_0000065;14.59;0.27;-0.56;8.59;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;2.8
CHEMBL4862583;;None;335.37;0;4.45;S1h;N#CC1=C(C#N)c2ccc(NCc3ccccc3)c3cccc(c23)C1=O;IC50;'=';14800.0;nM;4.83;;;UO_0000065;14.40;0.25;0.38;6.30;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;14.8
CHEMBL3704812;;None;729.28;2;7.12;BDBM60406;Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)ncn3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';7.7;nM;8.11;;198901;UO_0000065;11.13;0.21;0.99;8.45;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7.7
CHEMBL3924890;;None;772.03;2;7.15;BDBM179559;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc([S+]([O-])c4ccccc4)cs3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';799.39;nM;6.10;;326174;UO_0000065;7.90;0.16;-1.05;4.46;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;799.39
CHEMBL3972844;;None;756.71;2;6.96;BDBM179593;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(F)c(Br)cc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';268.82;nM;6.57;;326207;UO_0000065;8.68;0.18;-0.39;5.78;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;268.82
CHEMBL3916294;;None;708.88;2;6.57;BDBM179599;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cnco4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';884.62;nM;6.05;;326213;UO_0000065;8.54;0.16;-0.52;4.33;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;884.625
CHEMBL3946968;;None;705.90;2;5.77;BDBM179600;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccsc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';479.98;nM;6.32;;326214;UO_0000065;8.95;0.18;0.55;4.51;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;479.98
CHEMBL3924890;;None;772.03;2;7.15;BDBM179559;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc([S+]([O-])c4ccccc4)cs3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';675.4;nM;6.17;;326219;UO_0000065;7.99;0.16;-0.98;4.51;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;675.4
CHEMBL3950403;;None;747.96;2;8.02;BDBM179565;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccccc4C)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';3349.66;nM;5.47;;326225;UO_0000065;7.32;0.14;-2.55;4.45;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3349.66
CHEMBL3918855;;None;811.41;2;7.05;BDBM232399;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(C(=O)N(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';150.0;nM;6.82;;405197;UO_0000065;8.41;0.16;-0.23;4.81;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;150.0
CHEMBL3948491;;None;867.54;2;8.35;BDBM232402;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4CCSc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';50.0;nM;7.30;;405202;UO_0000065;8.42;0.17;-1.05;5.84;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;50.0
CHEMBL3947141;;None;883.25;2;7.77;BDBM232407;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)c(I)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';7.69;nM;8.11;;405207;UO_0000065;9.19;0.21;0.34;6.41;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;7.69
CHEMBL3986056;;None;820.21;2;7.65;BDBM232417;Cc1c(Cl)c(C(=O)N(CCC(F)(F)F)CCC(F)(F)F)nn1-c1ccc(C(=O)NS(=O)(=O)c2ccc3ccccc3c2)cc1C(=O)N1CCc2ccccc2C1;IC50;'=';80.0;nM;7.10;;405222;UO_0000065;8.65;0.17;-0.55;5.83;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;80.0
CHEMBL3906577;;None;907.70;2;9.07;BDBM232424;CCCCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';8.49;nM;8.07;;405229;UO_0000065;8.89;0.18;-1.00;5.69;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;8.49
CHEMBL3912240;;None;847.65;2;10.03;BDBM232454;CCCCN(Cc1ccc(Cl)c(Cl)c1)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';10.0;nM;8.00;;405266;UO_0000065;9.44;0.20;-2.03;7.11;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;10.0
CHEMBL3890556;;None;645.83;1;4.65;BDBM179571;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cn(C)cn3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';475.07;nM;6.32;;326231;UO_0000065;9.79;0.19;1.67;4.81;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;475.075
CHEMBL4852221;;None;424.57;1;6.49;S1g-1;N#CC1=C(NCc2ccccc2)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O;IC50;'=';5200.0;nM;5.28;;;UO_0000065;12.45;0.23;-1.21;9.99;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;5.2
CHEMBL51483;GOSSYPOL;3.0;518.56;3;6.38;SID26747182;Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O;IC50;'=';1191.0;nM;5.92;;;UO_0000065;11.42;0.21;-0.46;3.81;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;1.191
CHEMBL3902718;;None;761.21;2;7.39;BDBM179561;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc(Cl)cc3Br)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';562.77;nM;6.25;;326176;UO_0000065;8.21;0.18;-1.14;5.49;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;562.775
CHEMBL443684;NAVITOCLAX;3.0;974.63;3;8.83;Navitoclax, ABT-263;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1;IC50;'<';15.0;nM;;;;UO_0000065;;;;;0;CHEMBL3369471;Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;FDC-P1;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3351631;1;Scientific Literature;Bioorg Med Chem Lett;2014;None;;;;0.015
CHEMBL3953351;;None;699.87;2;5.70;BDBM179583;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';310.86;nM;6.51;;326242;UO_0000065;9.30;0.18;0.81;4.65;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;310.86
CHEMBL4860213;;None;889.01;3;8.55;24a;CN(C)CCCNc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(C(F)(F)F)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-];IC50;'=';0.89;nM;9.05;;;UO_0000065;10.18;0.20;0.50;5.45;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;0.89
CHEMBL4852442;;None;917.07;3;9.33;24b;CCN(CC)CCCNc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(C(F)(F)F)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-];IC50;'=';0.3;nM;9.52;;;UO_0000065;10.38;0.20;0.19;5.74;0;CHEMBL4828452;Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4825763;1;Scientific Literature;Bioorg Med Chem;2021;None;TIME = 0.25 hr;INHIBITOR;;0.3
CHEMBL518858;;None;468.53;0;4.79;13;Cc1cc(C(=O)N(C)c2cccc(F)c2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1;IC50;'=';2300.0;nM;5.64;;;UO_0000065;12.03;0.22;0.85;9.65;0;CHEMBL1019892;Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1139292;1;Scientific Literature;Bioorg Med Chem Lett;2009;None;;;;2.3
CHEMBL443221;;None;305.30;0;1.30;7;Nc1nc(-c2ccccc2)nc2c1[n+]([O-])c1ccccc1[n+]2[O-];IC50;'=';1600.0;nM;5.80;;;UO_0000065;18.98;0.34;4.50;5.48;0;CHEMBL651292;In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;1.6
CHEMBL5270107;;None;1127.63;None;None;SF-8-028;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCNC(=O)COc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'<';20.0;nM;;;;UO_0000065;;;;;0;CHEMBL5260438;Inhibition of BCL-2 (unknown origin) using FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 as substrate incubated for 4 hrs by fluorescence polarization competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5257141;1;Scientific Literature;ACS Med Chem Lett;2023;None;TIME = 4.0 hr;INHIBITOR;;20.0
CHEMBL5184262;;None;483.57;1;6.23;27;CC(=O)c1ccc(C(=O)N2N=C(c3ccc(NC(=O)OC(C)(C)C)cc3)CC2c2ccccc2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5184993;;None;510.39;2;6.38;17;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccco3)C2)cc1;IC50;'=';1260.0;nM;5.90;;;UO_0000065;11.56;0.24;-0.48;7.01;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;1.26
CHEMBL5204882;;None;477.46;0;4.66;5;CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C(F)(F)F)cc3)C(c3ccco3)C2)cc1;IC50;'=';2880.0;nM;5.54;;;UO_0000065;11.60;0.23;0.88;6.02;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;2.88
CHEMBL3701299;;None;712.83;2;6.61;BDBM161484;Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(cnn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';5.5;nM;8.26;;304783;UO_0000065;11.59;0.21;1.65;8.60;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.5
CHEMBL3701304;;None;586.69;2;6.68;BDBM161489;COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccncc3)c3ccc(O)cc3)c(C)n2C)c1;IC50;'=';4.9;nM;8.31;;304788;UO_0000065;14.16;0.26;1.63;9.45;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.9
CHEMBL3701307;;None;633.70;2;5.19;BDBM161492;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCO;IC50;'=';3.6;nM;8.44;;304791;UO_0000065;13.32;0.25;3.25;6.90;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.6
CHEMBL3701313;;None;721.30;2;6.98;BDBM161498;CC1=C(C(=O)N(c2ccccc2)c2ccc(O)cc2)CC(c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2COCCN2CCOCC2)N1C;IC50;'=';6.6;nM;8.18;;304797;UO_0000065;11.34;0.21;1.20;9.54;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.6
CHEMBL3701322;;None;606.12;2;6.90;BDBM161507;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1C;IC50;'=';7.5;nM;8.12;;304806;UO_0000065;13.40;0.25;1.22;9.45;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7.5
CHEMBL3701324;;None;642.76;2;6.86;BDBM161509;Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)Oc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';64.4;nM;7.19;;304808;UO_0000065;11.19;0.20;0.33;6.91;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;64.4
CHEMBL106708;;None;216.21;0;3.19;203;O=C(O)c1ccc(-c2ccc(F)cc2)cc1;IC50;'=';300000.0;nM;;Outside typical range;;UO_0000065;;;;;0;CHEMBL2208697;Binding affinity to Bcl2 by fluorescent polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2203023;1;Scientific Literature;J Med Chem;2011;None;;;;300.0
CHEMBL3701292;;None;713.28;2;7.33;BDBM161475;CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4[nH]ccc4c3)cn2C)CC1;IC50;'=';24.6;nM;7.61;;304776;UO_0000065;10.67;0.20;0.28;8.64;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;24.6
CHEMBL3701390;;None;730.26;2;7.12;BDBM161580;COc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc1C#N;IC50;'=';3.5;nM;8.46;;304878;UO_0000065;11.58;0.22;1.34;7.60;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.5
CHEMBL3701397;;None;718.83;2;5.88;BDBM161587;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn([C@H]3CCOC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';26.1;nM;7.58;;304885;UO_0000065;10.55;0.20;1.70;7.20;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;26.1
CHEMBL3701409;;None;674.80;2;5.33;BDBM161601;COc1ccc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c1;IC50;'=';10.1;nM;8.00;;304899;UO_0000065;11.85;0.22;2.67;7.59;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;10.1
CHEMBL3701414;;None;672.79;2;5.38;BDBM161607;COc1ncc(N(C(=O)c2cc(-c3ccccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1;IC50;'=';13.6;nM;7.87;;304905;UO_0000065;11.69;0.21;2.49;6.95;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;13.6
CHEMBL3704775;;None;690.78;2;5.52;BDBM161609;COc1ncc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1;IC50;'=';5.2;nM;8.28;;304907;UO_0000065;11.99;0.22;2.76;7.31;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.2
CHEMBL3704791;;None;706.27;2;7.17;BDBM161625;Cc1c(C(=O)N(c2ccc(O)cc2)c2csc(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';3.0;nM;8.52;;304923;UO_0000065;12.07;0.23;1.35;8.35;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.0
CHEMBL3704792;;None;707.23;2;6.04;BDBM161627;COc1cnc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1;IC50;'=';5.5;nM;8.26;;304924;UO_0000065;11.68;0.22;2.22;7.29;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.5
CHEMBL3704794;;None;704.23;2;5.84;BDBM161631;Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)nn2C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';2.7;nM;8.57;;304928;UO_0000065;12.17;0.23;2.73;7.15;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.7
CHEMBL3701374;;None;691.23;2;6.11;BDBM161563;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CC3(CCO3)C2)n1C;IC50;'=';4.6;nM;8.34;;304861;UO_0000065;12.06;0.23;2.23;8.68;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.6
CHEMBL3701378;;None;686.79;2;5.93;BDBM161567;Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';5.1;nM;8.29;;304865;UO_0000065;12.07;0.22;2.36;7.75;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.1
CHEMBL3704799;;None;731.30;2;7.24;BDBM161636;Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(CCN3CCOCC3)c2C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';1.9;nM;8.72;;304933;UO_0000065;11.93;0.22;1.48;8.15;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.9
CHEMBL3704800;;None;721.26;2;6.43;BDBM161637;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc(OCCN3CCOCC3)nc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C;IC50;'=';2.7;nM;8.57;;304934;UO_0000065;11.88;0.23;2.14;7.57;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.7
CHEMBL3703626;;None;956.58;3;8.63;BDBM156410;N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';30.0;nM;7.52;;363156;UO_0000065;7.86;0.16;-1.11;4.98;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;30.0
CHEMBL408194;OBATOCLAX;3.0;317.39;0;4.49;3;COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C;IC50;'=';1110.0;nM;5.96;;;UO_0000065;18.76;0.34;1.46;11.20;0;CHEMBL3822337;Inhibition of FITC-labeled Bid BH3 peptide binding to human GST-tagged BCL2 lacking C-terminal transmembrane domain expressed in Escherichia coli XL-1 Blue cells preincubated for 10 mins followed by FITC-labeled Bid BH3 peptide addition measured after 20 mins by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;XL-1;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3817778;1;Scientific Literature;Medchemcomm;2016;None;;;;1.11
CHEMBL3917011;;None;956.58;3;8.63;BDBM156410;N[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';30.0;nM;7.52;;298918;UO_0000065;7.86;0.16;-1.11;4.98;0;CHEMBL3707482;"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP') assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.";B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638929;37;BindingDB Patent Bioactivity Data;;2015;None;;;;30.0
CHEMBL3701314;;None;632.72;2;5.16;BDBM161499;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN;IC50;'=';4.7;nM;8.33;;304798;UO_0000065;13.16;0.24;3.17;6.50;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.7
CHEMBL3701317;;None;693.22;2;7.38;BDBM161502;Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';10.9;nM;7.96;;304801;UO_0000065;11.49;0.22;0.58;10.18;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;10.9
CHEMBL3701327;;None;599.69;2;7.00;BDBM161512;Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C;IC50;'=';5.1;nM;8.29;;304811;UO_0000065;13.83;0.25;1.29;9.84;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;5.1
CHEMBL3701379;;None;784.91;3;5.58;BDBM161568;COCCc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C;IC50;'=';14.8;nM;7.83;;304866;UO_0000065;9.98;0.18;2.25;6.41;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;14.8
CHEMBL3703609;;None;958.59;3;8.61;BDBM156389;CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';3.0;nM;8.52;;363138;UO_0000065;8.89;0.18;-0.09;5.26;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;3.0
CHEMBL3703606;;None;1025.53;None;None;BDBM156386;CN(CCOP(=O)(O)O)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';0.9;nM;9.05;;363135;UO_0000065;8.82;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.9
CHEMBL3703624;;None;1093.65;None;None;BDBM156406;CCOP(=O)(OCC)O[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';30.0;nM;7.52;;363154;UO_0000065;6.88;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;30.0
CHEMBL3931099;;None;714.29;2;6.29;BDBM232427;CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';60.0;nM;7.22;;405232;UO_0000065;10.11;0.20;0.93;5.78;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;60.0
CHEMBL3986556;;None;788.21;2;9.04;BDBM232452;CCCCN(CCCC)c1ccc(Br)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';10.0;nM;8.00;;405264;UO_0000065;10.15;0.21;-1.04;8.03;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;10.0
CHEMBL3945127;;None;747.96;2;8.02;BDBM179567;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Oc4ccc(C)cc4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';6630.34;nM;5.18;;326182;UO_0000065;6.92;0.13;-2.84;4.21;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6630.34
CHEMBL336901;;None;336.35;0;4.06;16;[O-][n+]1c2c([n+]([O-])c3c4ccccc4ccc31)-c1cccc3cccc-2c13;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL371861;;None;551.62;2;5.72;1;O=C(NS(=O)(=O)c1ccc(NCCSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1;IC50;'=';6300.0;nM;5.20;;;UO_0000065;9.43;0.19;-0.52;4.39;0;CHEMBL858941;Inhibitory activity against Bcl-XL in presence of HSA3 from 1% human serum;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1149415;1;Scientific Literature;J Med Chem;2006;None;;;;6.3
CHEMBL5170050;;None;527.44;2;6.24;20;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3cncs3)C2)cc1;IC50;'=';4360.0;nM;5.36;;;UO_0000065;10.16;0.22;-0.88;6.39;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;4.36
CHEMBL5181735;;None;477.46;0;4.84;13;Cc1ccc(C(=O)N2N=C(c3ccc(NS(=O)(=O)C(F)(F)F)cc3)CC2c2ccco2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5203092;;None;409.47;0;3.64;9;CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccccc3)C(c3ccco3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5183356;;None;488.36;0;4.41;4;CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccco3)C2)cc1;IC50;'=';2470.0;nM;5.61;;;UO_0000065;11.48;0.26;1.20;6.10;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;2.47
CHEMBL5187331;;None;504.38;2;6.18;38;C=CCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';31.8;nM;7.50;;;UO_0000065;14.86;0.31;1.32;10.56;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.0318
CHEMBL5188723;;None;520.43;2;6.79;45;CC(C)(C)OC(=O)Nc1cccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)c1;IC50;'=';11060.0;nM;4.96;;;UO_0000065;9.52;0.20;-1.83;6.98;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;11.06
CHEMBL376408;ABT 737;1.0;813.45;2;7.88;1, ABT-737;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';7.0;nM;8.15;;;UO_0000065;10.03;0.20;0.27;6.36;0;CHEMBL2399234;Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2396645;1;Scientific Literature;J Med Chem;2013;None;;;;0.007
CHEMBL4215940;;None;959.62;2;9.11;10;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3CC2)C1;IC50;'=';193.0;nM;6.71;;;UO_0000065;7.00;0.14;-2.40;5.37;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;193.0
CHEMBL3701308;;None;674.80;2;5.33;BDBM161493;COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c1;IC50;'=';6.2;nM;8.21;;304792;UO_0000065;12.16;0.22;2.88;7.79;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.2
CHEMBL3342332;A-1155463;None;669.80;2;6.33;EUB0000262;CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1;IC50;'=';382.0;nM;6.42;;Not Active;UO_0000065;9.58;0.19;0.09;5.95;0;CHEMBL4883619;Time-resolved fluorescence energy transfer (TR-FRET) with BCL2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;Assay publication: PMID: 25313317 | Target protein length: full length | Target protein type: recombinant protein (GST-Bcl-2);;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4507311;54;SGC Frankfurt - Donated Chemical Probes;;2021;None;Num of experiments None 3.0 None;;;382.0
CHEMBL4288614;;None;946.09;3;6.57;27d;C[C@H]1[C@@H](OCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3;IC50;'=';5.0;nM;8.30;;;UO_0000065;8.77;0.17;1.73;3.80;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;5.0
CHEMBL2031021;;None;759.37;2;6.58;BDBM50384352;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';60.0;nM;7.22;;405198;UO_0000065;9.51;0.19;0.64;5.78;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;60.0
CHEMBL2030856;;None;742.90;2;6.38;BDBM50384321;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(CCO)cc1;IC50;'=';20.0;nM;7.70;;405252;UO_0000065;10.36;0.19;1.32;5.43;1;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;20.0
CHEMBL2031027;;None;769.37;2;6.67;BDBM50384358;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl;IC50;'=';8.41;nM;8.07;;405210;UO_0000065;10.50;0.20;1.41;5.47;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;8.41
CHEMBL3963300;;None;866.53;2;7.40;BDBM232412;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CNC2CCN(C)CC2)c(C)c1Cl;IC50;'=';20.0;nM;7.70;;405216;UO_0000065;8.88;0.17;0.30;5.62;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;20.0
CHEMBL440058;;None;2879.17;None;None;10 (Bak BH3-26);CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1)[C@@H](C)O)C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)[C@@H](C)CC)[C@@H](C)CC;IC50;'=';3030.0;nM;5.52;;;UO_0000065;1.92;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;3.03
CHEMBL51483;GOSSYPOL;3.0;518.56;3;6.38;(+)-1;Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O;IC50;'=';260.0;nM;6.58;;;UO_0000065;12.70;0.24;0.21;4.23;0;CHEMBL1106537;Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157826;1;Scientific Literature;J Med Chem;2010;None;;;;0.26
CHEMBL2374449;;None;372.57;1;6.47;12;CCSCCCCC(c1ccc(O)cc1)C(C)(CC)c1ccc(O)cc1;IC50;'~';9000.0;nM;;;;UO_0000065;;;;;0;CHEMBL649854;Inhibitory activity against Bcl-2 functioning;F;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1135909;1;Scientific Literature;J Med Chem;2002;None;;;;9.0
CHEMBL436605;ANTIMYCIN A3;None;520.58;1;2.70;4;CCCC[C@H]1C(=O)O[C@H](C)[C@H](NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C;IC50;'=';2000.0;nM;5.70;;;UO_0000065;10.95;0.21;3.00;3.62;0;CHEMBL651293;Inhibitory activity against Bcl-2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;2.0
CHEMBL5190824;;None;521.42;2;6.18;22;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3cccnc3)C2)cc1;IC50;'=';1630.0;nM;5.79;;;UO_0000065;11.10;0.23;-0.39;6.90;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;1.63
CHEMBL3703623;;None;1123.67;None;None;BDBM156405;CC(C)(C)OP(=O)(O)OCO[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';4.0;nM;8.40;;363153;UO_0000065;7.47;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;4.0
CHEMBL3932954;;None;744.88;4;6.94;17;COC(=O)CCCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21;IC50;'=';483.0;nM;6.32;;;UO_0000065;8.48;0.16;-0.62;3.29;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.483
CHEMBL3917408;;None;856.49;2;6.87;BDBM232405;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4CCCN4CCOCC4)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';390.0;nM;6.41;;405205;UO_0000065;7.48;0.15;-0.46;4.61;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;390.0
CHEMBL2031026;;None;841.48;2;7.29;BDBM50384357;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCN(C)C)c(C)c1Cl;IC50;'=';10.0;nM;8.00;;405218;UO_0000065;9.51;0.19;0.71;5.96;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;10.0
CHEMBL2031012;;None;740.33;2;7.35;BDBM50384344;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';30.0;nM;7.52;;405176;UO_0000065;10.16;0.20;0.17;6.18;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;30.0
CHEMBL3901024;;None;774.77;2;8.00;BDBM232383;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';30.0;nM;7.52;;405178;UO_0000065;9.71;0.19;-0.48;6.18;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;30.0
CHEMBL3703608;;None;944.56;3;8.22;BDBM156388;CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';4.0;nM;8.40;;363137;UO_0000065;8.89;0.18;0.18;5.18;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;4.0
CHEMBL3968488;;None;841.48;2;7.68;BDBM232394;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';1460.0;nM;5.84;;405192;UO_0000065;6.93;0.14;-1.84;4.35;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;1460.0
CHEMBL3940231;;None;870.86;2;10.07;BDBM232419;CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2cccc(Cl)c2)c1;IC50;'=';50.0;nM;7.30;;405224;UO_0000065;8.38;0.16;-2.77;6.00;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;50.0
CHEMBL3918448;;None;716.83;4;6.16;16;COC(=O)CCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21;IC50;'=';825.0;nM;6.08;;;UO_0000065;8.49;0.16;-0.08;3.17;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.825
CHEMBL5182395;;None;516.40;2;6.01;39;C#CCCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';65.0;nM;7.19;;;UO_0000065;13.92;0.29;1.18;10.12;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.065
CHEMBL376408;ABT 737;1.0;813.45;2;7.88;ABT-737;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';3.6;nM;8.44;;;UO_0000065;10.38;0.21;0.56;6.59;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.0036
CHEMBL3948552;;None;639.19;2;5.38;BDBM179544;CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)OCC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';511.89;nM;6.29;;326147;UO_0000065;9.84;0.19;0.91;5.51;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;511.89
CHEMBL3899211;;None;651.81;2;5.80;BDBM179549;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';2092.72;nM;5.68;;326152;UO_0000065;8.71;0.16;-0.12;4.85;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2092.72
CHEMBL3962105;;None;815.46;2;7.56;BDBM179585;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(CNC(=O)c4ccc(Cl)cc4)s3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';2392.61;nM;5.62;;326244;UO_0000065;6.89;0.14;-1.94;3.93;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2392.61
CHEMBL3972844;;None;756.71;2;6.96;BDBM179593;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(F)c(Br)cc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';327.93;nM;6.48;;326252;UO_0000065;8.57;0.18;-0.48;5.70;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;327.93
CHEMBL4470807;;None;417.29;1;5.75;S1b;N#CC1=C(C#N)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O;IC50;'=';700.0;nM;6.16;;;UO_0000065;14.75;0.32;0.40;9.52;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;0.7
CHEMBL51483;GOSSYPOL;3.0;518.56;3;6.38;(-)-Gossypol;Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O;IC50;'=';600.0;nM;6.22;;;UO_0000065;12.00;0.22;-0.16;4.00;1;CHEMBL5232571;Displacement of biotinylated Bim peptide from Bcl-2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5230155;1;Scientific Literature;Eur J Med Chem;2021;None;;BINDING AGENT;;0.6
CHEMBL4228713;A-1211212;None;896.51;3;9.44;EUB0000263b;CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1;IC50;'=';1.4;nM;8.85;;;UO_0000065;9.88;0.19;-0.59;5.15;0;CHEMBL5210488;Affinity Biochemical interaction (TR-FRET assay) EUB0000263b BCL2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;Mode of action: Inhibitor | Negative control: A-1210227 | Protein family: Apoptosis regulator | Recommended concentration = 1.0 uM;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5210307;65;EUbOPEN Chemogenomic Library Literature Data;;2023;None;Affinity Biochemical Source Knowledge: https://doi.org/10.1126/scitranslmed.aaa4642, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1211212;;;1.4
CHEMBL3900742;;None;735.93;3;5.77;BDBM179594;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3scc(C(=O)OC)c3OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';565.68;nM;6.25;;326253;UO_0000065;8.49;0.17;0.48;4.18;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;565.685
CHEMBL3926618;;None;608.81;1;4.33;BDBM179578;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])N(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';2387.99;nM;5.62;;326192;UO_0000065;9.23;0.18;1.29;4.81;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.387.985
CHEMBL3950260;;None;655.87;2;6.06;BDBM179601;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';666.03;nM;6.18;;326215;UO_0000065;9.42;0.18;0.12;5.43;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;666.035
CHEMBL3936947;;None;918.34;2;8.86;BDBM232430;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4Cc4ccc(Cl)c(Cl)c4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';8.85;nM;8.05;;405235;UO_0000065;8.77;0.18;-0.81;5.48;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;8.85
CHEMBL3960038;;None;939.75;2;11.38;BDBM232439;CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2ccc(Cl)cc2)c1;IC50;'=';40.0;nM;7.40;;405244;UO_0000065;7.87;0.16;-3.98;6.08;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;40.0
CHEMBL2030864;;None;859.83;2;9.94;BDBM50384329;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1;IC50;'=';6.37;nM;8.20;;405254;UO_0000065;9.53;0.19;-1.74;6.26;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;6.37
CHEMBL3963540;;None;790.36;2;6.54;BDBM232411;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3S(=O)(=O)C2)c(C)c1Cl;IC50;'=';440.0;nM;6.36;;405214;UO_0000065;8.04;0.16;-0.18;4.08;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;440.0
CHEMBL3701323;;None;603.68;2;5.73;BDBM161508;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C;IC50;'=';7.2;nM;8.14;;304807;UO_0000065;13.49;0.25;2.41;7.98;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7.2
CHEMBL3701370;;None;705.26;2;6.77;BDBM161559;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';3.4;nM;8.47;;304857;UO_0000065;12.01;0.23;1.70;8.81;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.4
CHEMBL3701385;;None;729.28;2;7.12;BDBM161574;Cc1c(C(=O)N(c2ccc(O)cc2)c2cc3ccn(C)c3cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';14.7;nM;7.83;;304872;UO_0000065;10.74;0.20;0.71;8.15;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;14.7
CHEMBL3701363;;None;692.79;2;5.47;BDBM161552;COc1cc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)cc1F;IC50;'=';21.1;nM;7.68;;304850;UO_0000065;11.08;0.21;2.21;7.29;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;21.1
CHEMBL3701380;;None;659.76;2;6.12;BDBM161569;Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';9.7;nM;8.01;;304867;UO_0000065;12.15;0.22;1.89;8.79;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;9.7
CHEMBL4286311;;None;914.09;3;7.05;28b;C[C@H]1[C@@H](CCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24O3;IC50;'=';1.8;nM;8.74;;;UO_0000065;9.57;0.18;1.69;4.38;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;1.8
CHEMBL4279038;;None;952.02;3;7.47;28a;C[C@@H]1CC[C@H]2C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)=C(C(F)(F)F)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32O4;IC50;'=';2.8;nM;8.55;;;UO_0000065;8.98;0.17;1.08;4.28;0;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;2.8
CHEMBL3929521;;None;686.25;2;6.45;BDBM179546;CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)Nc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';421.44;nM;6.38;;326161;UO_0000065;9.29;0.18;-0.07;5.45;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;421.435
CHEMBL3926219;;None;604.75;1;4.72;BDBM179547;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';773.35;nM;6.11;;326162;UO_0000065;10.11;0.19;1.39;5.35;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;773.35
CHEMBL3897154;;None;666.85;2;5.79;BDBM179595;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(C#N)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';562.23;nM;6.25;;326254;UO_0000065;9.37;0.18;0.46;4.54;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;562.23
CHEMBL3927159;;None;683.88;2;6.12;BDBM179560;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(C)=O)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';412.24;nM;6.38;;326220;UO_0000065;9.34;0.18;0.26;4.88;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;412.24
CHEMBL3962530;;None;786.83;2;8.89;BDBM179568;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cc(Cl)cc(Cl)c4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';7278.41;nM;5.14;;326183;UO_0000065;6.53;0.13;-3.75;4.52;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;7278.41
CHEMBL2442251;;None;3049.34;None;None;BH3 puma;CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CCC(=O)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O;IC50;'=';3.3;nM;8.48;;;UO_0000065;2.78;None;None;None;0;CHEMBL4378480;Inhibition of human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells by surface plasmon resonance assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4376822;1;Scientific Literature;J Med Chem;2020;None;;;;3.3
CHEMBL3982550;;None;752.38;2;8.24;BDBM179564;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccc(Cl)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'>';16000.0;nM;;;326179;UO_0000065;;;;;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;16000.0
CHEMBL3959636;;None;748.79;2;7.24;BDBM179570;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)cc3CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';2174.8;nM;5.66;;326185;UO_0000065;7.56;0.16;-1.58;4.98;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;2.174.795
CHEMBL3899521;;None;689.84;2;5.30;BDBM179573;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(=O)OC)o3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';584.68;nM;6.23;;326188;UO_0000065;9.04;0.17;0.93;4.07;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;584.685
CHEMBL555017;GAMBOGIC ACID;None;628.76;2;7.24;28;CC(C)=CCC[C@]1(C)C=Cc2c(O)c3c(c(CC=C(C)C)c2O1)O[C@]12C(=C[C@@H]4C[C@H]1C(C)(C)O[C@@]2(C/C=C(/C)C(=O)O)C4=O)C3=O;IC50;'=';122.0;nM;6.91;;;UO_0000065;11.00;0.21;-0.33;5.79;0;CHEMBL5241841;Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5241079;1;Scientific Literature;Eur J Med Chem;2021;None;;INHIBITOR;;0.122
CHEMBL5268884;;None;1411.86;None;None;SF-8-089;COc1cc(C(=O)NCCNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F;IC50;'<';20.0;nM;;;;UO_0000065;;;;;0;CHEMBL5260438;Inhibition of BCL-2 (unknown origin) using FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 as substrate incubated for 4 hrs by fluorescence polarization competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5257141;1;Scientific Literature;ACS Med Chem Lett;2023;None;TIME = 4.0 hr;INHIBITOR;;20.0
CHEMBL5276934;;None;1286.82;None;None;SF-8-037;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCOCCOCCNC(=O)CCNC(=O)COc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'<';20.0;nM;;;;UO_0000065;;;;;0;CHEMBL5260438;Inhibition of BCL-2 (unknown origin) using FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 as substrate incubated for 4 hrs by fluorescence polarization competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5257141;1;Scientific Literature;ACS Med Chem Lett;2023;None;TIME = 4.0 hr;INHIBITOR;;20.0
CHEMBL5283597;;None;1499.96;None;None;SF-8-104;COc1cc(C(=O)NCCOCCOCCNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F;IC50;'<';20.0;nM;;;;UO_0000065;;;;;0;CHEMBL5260438;Inhibition of BCL-2 (unknown origin) using FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 as substrate incubated for 4 hrs by fluorescence polarization competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5257141;1;Scientific Literature;ACS Med Chem Lett;2023;None;TIME = 4.0 hr;INHIBITOR;;20.0
CHEMBL5202782;;None;478.35;1;5.62;33;COC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';2100.0;nM;5.68;;;UO_0000065;11.87;0.25;0.06;8.00;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;2.1
CHEMBL5203025;;None;527.44;2;6.24;19;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3nccs3)C2)cc1;IC50;'=';1610.0;nM;5.79;;;UO_0000065;10.98;0.24;-0.45;6.91;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;1.61
CHEMBL392723;;None;399.43;0;3.24;12;CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccco3)C(c3ccco3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5189940;;None;427.46;0;3.78;2;CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(F)cc3)C(c3ccco3)C2)cc1;IC50;'=';12660.0;nM;4.90;;;UO_0000065;11.46;0.22;1.12;5.32;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;12.66
CHEMBL5201193;;None;491.39;1;5.53;41;CN(C)C(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';2410.0;nM;5.62;;;UO_0000065;11.43;0.24;0.09;8.64;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;2.41
CHEMBL5176388;;None;517.43;2;6.07;42;O=C(Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1)N1CCCC1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL5170955;;None;521.42;2;6.18;46;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cn1;IC50;'=';309.0;nM;6.51;;;UO_0000065;12.49;0.26;0.33;7.76;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.309
CHEMBL5183315;;None;521.42;2;6.04;50;CC(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2C)cn1;IC50;'=';2.0;nM;8.70;;;UO_0000065;16.68;0.35;2.66;10.37;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.002
CHEMBL5197785;;None;491.39;1;6.01;54;CC(C)OC(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';110.0;nM;6.96;;;UO_0000065;14.16;0.30;0.95;11.80;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.11
CHEMBL5197785;;None;491.39;1;6.01;54;CC(C)OC(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';4360.0;nM;5.36;;;UO_0000065;;;;;0;CHEMBL5149882;Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;T;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;4.36
CHEMBL4460727;;None;909.86;2;6.22;C3;O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O;IC50;'=';540.0;nM;6.27;;;UO_0000065;6.89;0.14;0.05;3.28;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;0.54
CHEMBL4533471;;None;833.77;2;6.35;H3;N#CC1=C(NCCC(=O)NCCCCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O;IC50;'=';1940.0;nM;5.71;;;UO_0000065;6.85;0.14;-0.64;3.22;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;1.94
CHEMBL4579774;;None;899.47;3;8.30;7e;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCCCC(=O)NO)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'=';230.0;nM;6.64;;;UO_0000065;7.38;0.14;-1.66;3.13;0;CHEMBL4332203;Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4330103;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;0.23
CHEMBL4524407;;None;298.27;0;2.85;2;O=C(O)c1ccc(-c2ccc(F)cc2)c(S(=O)(=O)F)c1;IC50;;;;;;Not Determined;;;;;;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;
CHEMBL443684;NAVITOCLAX;3.0;974.63;3;8.83;ABT-263;CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1;IC50;'=';2.0;nM;8.70;;;UO_0000065;8.93;0.18;-0.13;6.78;0;CHEMBL4409525;Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4406861;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;0.002
CHEMBL3892056;;None;774.77;2;8.00;BDBM232385;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(Cl)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';90.0;nM;7.05;;405181;UO_0000065;9.09;0.18;-0.95;5.79;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;90.0
CHEMBL3703614;;None;966.57;3;9.24;BDBM156394;N#C[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';7.0;nM;8.15;;363144;UO_0000065;8.44;0.17;-1.09;5.48;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;7.0
CHEMBL3985961;;None;656.85;2;5.50;BDBM179597;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3N)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';270.38;nM;6.57;;326211;UO_0000065;10.00;0.19;1.07;4.70;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;270.38
CHEMBL51483;GOSSYPOL;3.0;518.56;3;6.38;(+)-1;Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O;IC50;'=';300.0;nM;6.52;;;UO_0000065;12.58;0.23;0.14;4.19;0;CHEMBL1106537;Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1157826;1;Scientific Literature;J Med Chem;2010;None;;;;0.3
CHEMBL413158;;None;1839.08;None;None;15 (Bid BH3);CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)C(C)C;IC50;'=';22340.0;nM;4.65;;;UO_0000065;2.53;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;22.34
CHEMBL438732;;None;2889.25;None;None;16 (Bid BH3-26);CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)[C@@H](C)CC)C(C)C;IC50;'=';14080.0;nM;4.85;;;UO_0000065;1.68;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;14.08
CHEMBL3942106;;None;724.75;2;7.37;BDBM179577;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';1653.19;nM;5.78;;326191;UO_0000065;7.98;0.16;-1.59;5.08;0;CHEMBL3887238;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;1.653.195
CHEMBL3916294;;None;708.88;2;6.57;BDBM179599;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cnco4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';522.1;nM;6.28;;326258;UO_0000065;8.86;0.17;-0.29;4.49;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;522.095
CHEMBL136987;;None;488.50;1;7.57;13;O=C1c2ccccc2-c2cc(O)c3c4c(O)cc5c6c(ccc(c7ccc1c2c73)c64)C(=O)c1ccccc1-5;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL875933;"In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive";B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;
CHEMBL3704779;;None;698.14;2;8.35;BDBM161613;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3CC2C(F)(F)F)n1C;IC50;'=';19.9;nM;7.70;;304911;UO_0000065;11.03;0.21;-0.65;9.21;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;19.9
CHEMBL3704786;;None;701.77;2;6.73;BDBM161620;Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)c(C#N)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';4.4;nM;8.36;;304918;UO_0000065;11.91;0.22;1.63;8.19;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;4.4
CHEMBL3704787;;None;677.21;2;6.03;BDBM161621;Cc1c(C(=O)N(c2ccc(O)cc2)c2cnccn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C;IC50;'=';11.3;nM;7.95;;304919;UO_0000065;11.73;0.22;1.92;7.64;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;11.3
CHEMBL3704798;;None;686.13;2;7.99;BDBM161635;Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4CC3C(F)(F)F)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C;IC50;'=';6.5;nM;8.19;;304932;UO_0000065;11.93;0.23;0.20;8.66;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;6.5
CHEMBL3701406;;None;740.86;2;5.87;BDBM161597;Cc1c(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCCO4)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C;IC50;'=';3.1;nM;8.51;;304895;UO_0000065;11.48;0.21;2.64;6.78;0;CHEMBL3705658;Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB® primary accession number: P10415), at a final concentration of 2.50×10−8 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10−8 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638572;37;BindingDB Patent Bioactivity Data;;2015;None;;;;3.1
CHEMBL2170836;;None;1065.70;None;None;29;Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(C)(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C;IC50;'=';18.6;nM;7.73;;;UO_0000065;7.25;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;18.6
CHEMBL51483;GOSSYPOL;3.0;518.56;3;6.38;(-)-gossypol, 1;Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O;IC50;'=';500.0;nM;6.30;;;UO_0000065;12.15;0.23;-0.08;4.05;0;CHEMBL909445;Binding affinity to human Bcl2 by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;None;;;;0.5
CHEMBL376408;ABT 737;1.0;813.45;2;7.88;ABT-737;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';72.0;nM;7.14;;;UO_0000065;;;;;0;CHEMBL5149882;Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;T;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.07200000000000001
CHEMBL3966210;;None;980.76;2;11.39;BDBM232443;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2cccc(Cl)c2)cc1;IC50;'=';20.0;nM;7.70;;405253;UO_0000065;7.85;0.16;-3.69;5.62;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;20.0
CHEMBL3957861;;None;740.33;2;7.03;BDBM232453;CCCCN(CCCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';60.0;nM;7.22;;405265;UO_0000065;9.75;0.19;0.19;5.44;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;60.0
CHEMBL3703611;;None;957.56;3;8.66;BDBM156391;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';253.0;nM;6.60;;363140;UO_0000065;6.89;0.14;-2.06;4.54;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;253.0
CHEMBL3703615;;None;966.57;3;9.24;BDBM156396;N#C[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';1195.0;nM;5.92;;363145;UO_0000065;6.13;0.12;-3.32;3.98;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;1195.0
CHEMBL4111781;;None;1014.65;None;None;BDBM204937;CCNC[C@@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';0.3;nM;9.52;;363147;UO_0000065;9.39;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.3
CHEMBL3703621;;None;987.58;3;8.03;BDBM156402;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOC[C@@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.4;nM;9.40;;363151;UO_0000065;9.52;0.19;1.37;5.68;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.4
CHEMBL3964186;;None;712.32;2;7.71;BDBM232426;CCCCN(CCCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';260.0;nM;6.58;;405231;UO_0000065;9.24;0.18;-1.12;6.29;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;260.0
CHEMBL2030850;;None;832.98;2;9.32;BDBM50384315;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2ccccc2)cc1;IC50;'=';100.0;nM;7.00;;405246;UO_0000065;8.40;0.16;-2.32;5.11;1;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;100.0
CHEMBL3939961;;None;714.96;None;None;BDBM232442;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)CC[Si](C)(C)C)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccccc1;IC50;'=';580.0;nM;6.24;;405248;UO_0000065;8.72;None;None;None;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;580.0
CHEMBL2030853;;None;825.39;2;9.29;BDBM50384318;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1;IC50;'=';7.83;nM;8.11;;405251;UO_0000065;9.82;0.19;-1.18;6.20;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;7.83
CHEMBL3890311;;None;762.93;2;5.81;BDBM232446;CCCCN(CCCC)C(=O)c1cn(CC(=O)NC)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';430.0;nM;6.37;;405258;UO_0000065;8.34;0.16;0.56;4.22;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;430.0
CHEMBL3965698;;None;702.88;2;7.26;BDBM232451;CCCCN(CCCC)C(=O)c1cccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1;IC50;'=';600.0;nM;6.22;;405263;UO_0000065;8.85;0.17;-1.04;5.33;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;600.0
CHEMBL2322024;;None;836.48;2;9.11;3;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2cccc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)cnc23)cc1[N+](=O)[O-];IC50;'=';68.0;nM;7.17;;;UO_0000065;8.57;0.17;-1.94;5.78;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;68.0
CHEMBL1417970;;None;392.33;0;2.64;CID-2980973;CCOC(=O)CS(=O)(=O)c1nc(-c2ccc(F)cc2)cc(C(F)(F)F)n1;IC50;'>';100000.0;nM;;;;UO_0000065;;;;;0;CHEMBL5337577;Inhibition of GST fused Bcl-2 (unknown origin) incubated for 5 min by TR-FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5335817;1;Scientific Literature;Bioorg Med Chem Lett;2024;None;TIME = 0.08333 hr;;;100.0
CHEMBL3137309;VENETOCLAX;4.0;868.46;3;8.66;"ABT-199; 1";CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'=';7.4;nM;8.13;;;UO_0000065;9.36;0.18;-0.53;4.73;1;CHEMBL4264659;Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4261603;1;Scientific Literature;Eur J Med Chem;2018;None;;;;7.4
CHEMBL51483;GOSSYPOL;3.0;518.56;3;6.38;SID106063;Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O;IC50;'=';2110.0;nM;5.68;;;UO_0000065;10.95;0.20;-0.70;3.65;0;CHEMBL2379960;Inhibition of Bcl-2 (unknown origin) after 15 hrs by FRET method;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2375247;1;Scientific Literature;Bioorg Med Chem Lett;2013;None;;;;2.11
CHEMBL5202594;;None;506.40;2;6.40;35;CC(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1;IC50;'=';4.4;nM;8.36;;;UO_0000065;16.50;0.35;1.96;11.77;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.0044
CHEMBL5193713;;None;596.53;2;8.18;49;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2c2ccccc2)cc1;IC50;'=';172.0;nM;6.76;;;UO_0000065;11.34;0.23;-1.42;9.53;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;INHIBITOR;;0.172
CHEMBL371861;;None;551.62;2;5.72;206;O=C(NS(=O)(=O)c1ccc(NCCSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1;IC50;'=';93.0;nM;7.03;;;UO_0000065;12.75;0.25;1.31;5.94;0;CHEMBL2208697;Binding affinity to Bcl2 by fluorescent polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2203023;1;Scientific Literature;J Med Chem;2011;None;;;;93.0
CHEMBL3917569;;None;705.88;2;6.69;BDBM232422;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)cc1C;IC50;'=';230.0;nM;6.64;;405227;UO_0000065;9.40;0.18;-0.05;5.46;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;230.0
CHEMBL3968982;;None;772.68;2;8.29;BDBM232429;CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(F)(F)F)c1Cl;IC50;'=';40.0;nM;7.40;;405234;UO_0000065;9.57;0.19;-0.89;7.07;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;40.0
CHEMBL3893121;;None;809.22;2;8.65;BDBM232397;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';7.25;nM;8.14;;405195;UO_0000065;10.06;0.21;-0.51;6.69;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;7.25
CHEMBL3962921;;None;915.15;2;8.69;BDBM232408;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(c3)c(Br)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';4.19;nM;8.38;;405208;UO_0000065;9.15;0.21;-0.31;6.62;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;4.19
CHEMBL2031024;;None;770.35;2;6.71;BDBM50384355;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';50.0;nM;7.30;;405209;UO_0000065;9.48;0.18;0.59;5.14;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;50.0
CHEMBL3893974;;None;784.34;2;6.80;BDBM232409;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@@H]2C(=O)O)c(C)c1Cl;IC50;'=';1650.0;nM;5.78;;405211;UO_0000065;7.37;0.14;-1.02;3.64;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;1650.0
CHEMBL3931548;;None;868.29;2;6.70;BDBM232433;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(c3)CCN4CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';9.15;nM;8.04;;405238;UO_0000065;9.26;0.20;1.34;5.54;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;9.15
CHEMBL2030851;;None;790.94;2;8.64;BDBM50384316;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccccc2)cc1;IC50;'=';130.0;nM;6.89;;405249;UO_0000065;8.71;0.16;-1.75;5.26;1;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;130.0
CHEMBL2031008;;None;745.73;2;6.87;BDBM50384339;CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1;IC50;'=';5.09;nM;8.29;;405268;UO_0000065;11.12;0.22;1.42;5.98;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;5.09
CHEMBL3938600;;None;676.28;2;6.57;BDBM179569;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';558.67;nM;6.25;;326229;UO_0000065;9.25;0.18;-0.32;5.50;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;558.67
CHEMBL3918229;;None;532.69;1;4.79;BDBM179555;CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';282.81;nM;6.55;;326170;UO_0000065;12.29;0.23;1.76;7.45;0;CHEMBL3887237;Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25° C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses.Â  Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U.Â  Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886230;37;BindingDB Patent Bioactivity Data;;2015;None;;;;282.815
CHEMBL3967288;;None;694.27;2;6.71;BDBM179572;CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(Cl)ccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1;IC50;'=';849.56;nM;6.07;;326232;UO_0000065;8.74;0.17;-0.64;5.34;0;CHEMBL3887239;Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886231;37;BindingDB Patent Bioactivity Data;;2015;None;;;;849.56
CHEMBL4848284;;None;331.40;0;3.39;S1;N#CC1=C(C#N)c2ccc(N3CCSCC3)c3cccc(c23)C1=O;IC50;'=';800.0;nM;6.10;;;UO_0000065;18.40;0.35;2.71;8.98;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;0.8
CHEMBL3928986;;None;774.77;2;8.00;BDBM232382;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)cccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';200.0;nM;6.70;;405177;UO_0000065;8.65;0.17;-1.30;5.51;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;200.0
CHEMBL3898017;;None;784.34;2;7.05;BDBM232410;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccc(C(=O)O)cc3C2)c(C)c1Cl;IC50;'=';4710.0;nM;5.33;;405213;UO_0000065;6.79;0.13;-1.72;3.35;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;4710.0
CHEMBL3927011;;None;1031.51;None;None;BDBM232431;CCCCN(CCC(=O)NCCN1CCN(C)CC1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';1010.0;nM;6.00;;405236;UO_0000065;5.81;None;None;None;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;1010.0
CHEMBL3912610;;None;866.28;2;7.29;BDBM232435;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(ccn4CC)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';3.59;nM;8.45;;405240;UO_0000065;9.75;0.21;1.15;5.75;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;3.59
CHEMBL3957469;;None;841.48;2;7.68;BDBM232392;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OC(C)CN(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';490.0;nM;6.31;;405190;UO_0000065;7.50;0.15;-1.37;4.70;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;490.0
CHEMBL4210809;;None;753.31;2;6.60;38;CN(C)c1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F;IC50;'=';65.1;nM;7.19;;;UO_0000065;9.54;0.20;0.59;6.71;0;CHEMBL4182824;Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4177735;1;Scientific Literature;Bioorg Med Chem;2018;None;;;;65.1
CHEMBL595134;;None;331.40;0;3.01;3;N#CC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13;IC50;'=';715.0;nM;6.15;;;UO_0000065;18.54;0.35;3.14;10.89;0;CHEMBL2318341;Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2311285;1;Scientific Literature;Bioorg Med Chem;2013;None;;;;715.0
CHEMBL3952199;;None;883.51;2;7.45;BDBM232390;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCOCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';290.0;nM;6.54;;405188;UO_0000065;7.40;0.14;-0.91;4.56;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;290.0
CHEMBL3975289;;None;814.41;2;6.72;BDBM232414;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCO)c(C)c1Cl;IC50;'=';50.0;nM;7.30;;405219;UO_0000065;8.96;0.17;0.58;4.83;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;50.0
CHEMBL3918448;;None;716.83;4;6.16;(+)-16;COC(=O)CCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21;IC50;'=';452.0;nM;6.34;;;UO_0000065;8.85;0.17;0.18;3.31;0;CHEMBL3865725;Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3864191;1;Scientific Literature;ACS Med Chem Lett;2016;None;;;;0.452
CHEMBL337153;;None;602.63;2;6.33;9;O=c1c2ccc(S(=O)(=O)c3ccc4c(=O)n5c6ccccc6nc5c5cccc3c45)c3cccc(c32)c2nc3ccccc3n12;IC50;'=';14000.0;nM;4.85;;;UO_0000065;8.05;0.15;-1.48;4.72;0;CHEMBL651292;In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;14.0
CHEMBL1272170;;None;490.51;0;4.85;BDBM142745;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(C)C)C2=O)C(=O)c2cc(O)c(O)c(C(C)C)c2C1=O;IC50;'=';370.0;nM;6.43;;278901;UO_0000065;13.11;0.24;1.58;4.31;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;370.0
CHEMBL217354;;None;573.71;2;6.90;5, TW-37;CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(S(=O)(=O)c3ccccc3C(C)(C)C)cc2)c(O)c(O)c1O;IC50;'=';200.0;nM;6.70;;;UO_0000065;;;;;0;CHEMBL909448;Inhibition of growth of human PC3 cell overexpressing Bcl2;F;BAO_0000219;cell-based format;Homo sapiens;None;None;PC-3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1137390;1;Scientific Literature;J Med Chem;2006;CHEMBL3307570;;;;0.2
CHEMBL538616;;None;700.79;3;7.58;"26; BI-97C1";Cc1cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c1O;IC50;'=';320.0;nM;6.50;;;UO_0000065;9.27;0.17;-1.09;3.62;1;CHEMBL5241833;Inhibition of Bcl-2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5241079;1;Scientific Literature;Eur J Med Chem;2021;None;;INHIBITOR;;0.32
CHEMBL3890787;;None;866.48;2;6.73;BDBM232398;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(C(=O)N5CCN(C)CC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';90.0;nM;7.05;;405196;UO_0000065;8.13;0.16;0.32;4.85;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;90.0
CHEMBL2031031;;None;742.30;2;7.14;BDBM50384361;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2COc3ccccc3C2)c(C)c1Cl;IC50;'=';120.0;nM;6.92;;405212;UO_0000065;9.32;0.18;-0.22;5.29;1;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;120.0
CHEMBL3889549;;None;881.50;2;5.30;BDBM232421;CCCCN(CCC(=O)NCCN1CCN(C)CC1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';70.0;nM;7.16;;405226;UO_0000065;8.12;0.16;1.85;4.55;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;70.0
CHEMBL3945459;;None;969.13;2;9.66;BDBM232423;CCCCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';20.0;nM;7.70;;405228;UO_0000065;7.94;0.18;-1.96;6.33;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;20.0
CHEMBL2030852;;None;825.39;2;9.29;BDBM50384317;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccc(Cl)cc2)cc1;IC50;'=';20.0;nM;7.70;;405250;UO_0000065;9.33;0.18;-1.59;5.88;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;20.0
CHEMBL3601398;CGM-097;1.0;659.27;2;6.58;1, NVP-CGM097;COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2;IC50;'>';50000.0;nM;;;;UO_0000065;;;;;0;CHEMBL3603526;Inhibition of Bcl2 (unknown origin) assessed as inhibition of Bcl2-Bak interaction by TR-FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3600357;1;Scientific Literature;J Med Chem;2015;None;;;;50000.0
CHEMBL4446378;TAPOTOCLAX;1.0;613.22;2;5.90;"2; AMG 176";CO[C@H]1/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3c(c2)N(C[C@@H]2CC[C@H]21)C[C@@]1(CCCc2cc(Cl)ccc21)CO3;IC50;'=';1930.0;nM;5.71;;;UO_0000065;9.32;0.19;-0.19;6.73;0;CHEMBL4356645;Inhibition of recombinant C-terminal His10x-tagged human Bcl-2 (2 to 211 residues) expressed in Escherichia coli cells interaction with biotinylated human Bim (51 to 76 residues) incubated for 60 mins by HTRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4354823;1;Scientific Literature;J Med Chem;2019;None;;;;1930.0
CHEMBL334590;;None;470.76;1;5.75;3;Cc1cc(Cl)cc(C(=O)Nc2cc(S(=O)(=O)c3ccc(Cl)cc3)ccc2Cl)c1O;IC50;'=';3300.0;nM;5.48;;;UO_0000065;11.64;0.26;-0.27;6.57;0;CHEMBL651293;Inhibitory activity against Bcl-2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1134645;1;Scientific Literature;J Med Chem;2001;None;;;;3.3
CHEMBL3137309;VENETOCLAX;4.0;868.46;3;8.66;ABT-199;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'=';230.0;nM;6.64;;;UO_0000065;7.64;0.15;-2.02;3.86;0;CHEMBL4332203;Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4330103;1;Scientific Literature;Bioorg Med Chem Lett;2019;None;;;;0.23
CHEMBL4568556;;None;881.81;2;5.44;C2;O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O;IC50;'=';10020.0;nM;5.00;;;UO_0000065;5.67;0.12;-0.44;2.62;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;10.02
CHEMBL4436367;;None;946.93;3;7.03;H4;N#CC1=C(NCCC(=O)NCCCCCC(=O)NCCCCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O;IC50;'=';11650.0;nM;4.93;;;UO_0000065;5.21;0.11;-2.10;2.39;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;11.65
CHEMBL5279723;;None;1215.74;None;None;SF-8-032;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCOCCOCCNC(=O)COc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'<';20.0;nM;;;;UO_0000065;;;;;0;CHEMBL5260438;Inhibition of BCL-2 (unknown origin) using FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 as substrate incubated for 4 hrs by fluorescence polarization competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5257141;1;Scientific Literature;ACS Med Chem Lett;2023;None;TIME = 4.0 hr;INHIBITOR;;20.0
CHEMBL1269107;;None;586.60;2;5.78;"8; (-)-BI-97D6";CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O;IC50;'=';31.0;nM;7.51;;;UO_0000065;12.80;0.23;1.73;5.03;0;CHEMBL4052842;Inhibition of FITC-labeled Bim BH3 binding to GST-tagged Bcl-2 (unknown origin) preincubated for 2 mins followed by FITC-Bim-BH3 addition measured after 10 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4052581;1;Scientific Literature;J Med Chem;2017;None;;;;31.0
CHEMBL3936837;;None;867.51;2;8.21;BDBM232395;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';3780.0;nM;5.42;;405193;UO_0000065;6.25;0.12;-2.79;4.04;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;3780.0
CHEMBL3982792;;None;788.92;2;5.58;BDBM232444;CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(OCC(O)CO)cc1;IC50;'=';8.13;nM;8.09;;405255;UO_0000065;10.25;0.19;2.51;4.72;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;8.13
CHEMBL1269107;;None;586.60;2;5.78;"27; BI-97D6";CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O;IC50;'=';1300.0;nM;5.89;;;UO_0000065;10.03;0.18;0.11;3.95;0;CHEMBL5241841;Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5241079;1;Scientific Literature;Eur J Med Chem;2021;None;;INHIBITOR;;1.3
CHEMBL3703603;;None;1032.64;None;None;BDBM156383;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(C[C@H](O)CF)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';1.0;nM;9.00;;363132;UO_0000065;8.72;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;1.0
CHEMBL3703613;;None;870.49;3;8.28;BDBM156393;O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1;IC50;'=';0.8;nM;9.10;;363142;UO_0000065;10.45;0.21;0.82;5.89;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;0.8
CHEMBL3703627;;None;1027.65;None;None;BDBM156411;CNCC(=O)N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1;IC50;'=';27.0;nM;7.57;;363157;UO_0000065;7.36;None;None;None;0;CHEMBL3887911;"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization ('FP') described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization ('FP')assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.";B;BAO_0000219;cell-based format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886500;37;BindingDB Patent Bioactivity Data;;2016;None;;;;27.0
CHEMBL379173;;None;577.53;1;4.33;8, MI-63;CC(C)(C)C[C@H]1N[C@@H](C(=O)NCCN2CCOCC2)[C@H](c2cccc(Cl)c2F)[C@@]12C(=O)Nc1cc(Cl)ccc12;IC50;'>';50000.0;nM;;;;UO_0000065;;;;;0;CHEMBL866343;Displacement of Flu-Bid from human recombinant Bcl2 receptor;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1148527;1;Scientific Literature;J Med Chem;2006;None;;;;50.0
CHEMBL409228;;None;2813.22;None;None;11(N-AEM-Bak BH3-C-AEM);CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC;IC50;'=';650.0;nM;6.19;;;UO_0000065;2.20;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;0.65
CHEMBL288542;;None;409.24;0;2.36;HA14-1;CCOC(=O)C1=C(N)Oc2ccc(Br)cc2C1C(C#N)C(=O)OCC;IC50;'=';9000.0;nM;5.05;;;UO_0000065;12.33;0.28;2.69;4.52;0;CHEMBL5234917;Inhibition of Flu-BakBH3 binding to recombinant GST-tagged Bcl-2 (unknown origin) incubated for 30 mins by competitive fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5233252;1;Scientific Literature;Eur J Med Chem;2020;None;TIME = 0.5 hr;INHIBITOR;;9.0
CHEMBL442325;;None;2927.35;None;None;17 (N-AEM-Bid BH3-C-AEM);CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C;IC50;'=';1560.0;nM;5.81;;;UO_0000065;1.98;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;1.56
CHEMBL4530348;;None;587.54;2;7.08;Nap-1;CC(C)(C)c1ccc(C(=O)NCCN2C(=O)c3cccc4c(Sc5ccc(Br)cc5)ccc(c34)C2=O)cc1;IC50;'=';3180.0;nM;5.50;;;UO_0000065;9.36;0.20;-1.58;8.27;0;CHEMBL4322321;Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4321796;1;Scientific Literature;J Med Chem;2019;None;;;;3.18
CHEMBL3137309;VENETOCLAX;4.0;868.46;3;8.66;ABT-199;CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'>';100.0;nM;;;;UO_0000065;;;;;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;;;0.1
CHEMBL4551344;A-1210227;None;904.37;3;8.88;EUB0000746a;O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1;IC50;'=';296.0;nM;6.53;;;UO_0000065;7.22;0.14;-2.35;3.80;0;CHEMBL5210503;Affinity Biochemical interaction (TR-FRET assay) EUB0000746a BCL2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;Mode of action: Negative control for A-1211212 | Protein family: Apoptosis regulator | Recommended concentration = 1.0 uM;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5210307;65;EUbOPEN Chemogenomic Library Literature Data;;2023;None;Affinity Biochemical Source Knowledge: https://doi.org/10.1126/scitranslmed.aaa4642, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1211212;;;296.0
CHEMBL5276080;;None;457.33;1;6.77;171a;Cc1ccc(Nc2nnc(-c3cc(-c4ccc(Br)cc4)nc4ccccc34)o2)cc1;IC50;'=';1930.0;nM;5.71;;;UO_0000065;12.50;0.26;-1.06;8.95;0;CHEMBL5232571;Displacement of biotinylated Bim peptide from Bcl-2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5230155;1;Scientific Literature;Eur J Med Chem;2021;None;;BINDING AGENT;;1.93
CHEMBL376408;ABT 737;1.0;813.45;2;7.88;1, ABT-737;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';20.0;nM;7.70;;;UO_0000065;9.46;0.19;-0.18;6.01;0;CHEMBL2328210;Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2321763;1;Scientific Literature;ACS Med Chem Lett;2013;None;;;;20.0
CHEMBL3914542;;None;846.45;2;8.93;BDBM232386;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCc5ccccc5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';10.0;nM;8.00;;405183;UO_0000065;9.45;0.18;-0.93;6.11;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;10.0
CHEMBL3981017;;None;896.55;2;7.36;BDBM232391;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCN(C)CC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';510.0;nM;6.29;;405189;UO_0000065;7.02;0.14;-1.07;4.58;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;510.0
CHEMBL3955216;;None;918.34;2;8.63;BDBM232401;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';200.0;nM;6.70;;405201;UO_0000065;7.29;0.15;-1.93;4.72;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;200.0
CHEMBL3954188;;None;791.80;2;7.82;BDBM232406;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)c(Cl)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl;IC50;'=';20.0;nM;7.70;;405206;UO_0000065;9.72;0.19;-0.12;6.08;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;20.0
CHEMBL2031025;;None;842.46;2;7.77;BDBM50384356;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCCOC)c(C)c1Cl;IC50;'=';20.0;nM;7.70;;405215;UO_0000065;9.14;0.18;-0.07;5.49;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;20.0
CHEMBL3938217;;None;920.36;2;8.42;BDBM232425;CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl;IC50;'=';10.0;nM;8.00;;405230;UO_0000065;8.69;0.18;-0.42;5.51;0;CHEMBL3888503;Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 μl prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK® Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3886736;37;BindingDB Patent Bioactivity Data;;2016;None;;;;10.0
CHEMBL51483;GOSSYPOL;3.0;518.56;3;6.38;Gossypol;Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O;IC50;'=';600.0;nM;6.22;;;UO_0000065;12.00;0.22;-0.16;4.00;0;CHEMBL4001923;Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4000233;1;Scientific Literature;Bioorg Med Chem Lett;2017;None;;;;0.6
CHEMBL4872862;;None;447.60;0;4.62;S1g-6;N#CC1=C(NCCN2CCOCC2)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O;IC50;'=';18700.0;nM;4.73;;;UO_0000065;10.56;0.20;0.11;7.23;0;CHEMBL4837884;Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4837197;1;Scientific Literature;Eur J Med Chem;2021;None;TIME = 0.5 hr;INHIBITOR;;18.7
CHEMBL2170837;;None;1065.70;None;None;30, BM-957;CCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1;IC50;'=';5.4;nM;8.27;;;UO_0000065;7.76;None;None;None;0;CHEMBL2173962;Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2169845;1;Scientific Literature;J Med Chem;2012;None;;;;5.4
CHEMBL265917;;None;2922.41;None;None;14 (N-AEM-Bax BH3-C-AEM);CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O;IC50;'=';1330.0;nM;5.88;;;UO_0000065;2.01;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;1.33
CHEMBL5199110;;None;442.52;1;5.42;30;CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccccn3)C(c3ccccc3)C2)cc1;IC50;;;;;;NA;;;;;;0;CHEMBL5149881;Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5143754;1;Scientific Literature;ACS Med Chem Lett;2022;None;TIME = 3.0 hr;;;
CHEMBL3342191;A-1107969;None;674.77;3;6.02;EUB0003078;O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(CCOc3ccc(-n4ncc5cncnc54)cc3)s1)CC2;IC50;'=';3780.0;nM;5.42;;Not Active;UO_0000065;8.04;0.15;-0.60;3.66;0;CHEMBL4883619;Time-resolved fluorescence energy transfer (TR-FRET) with BCL2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;Assay publication: PMID: 25313317 | Target protein length: full length | Target protein type: recombinant protein (GST-Bcl-2);;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4507311;54;SGC Frankfurt - Donated Chemical Probes;;2021;None;Num of experiments None 3.0 None;;;3.78
CHEMBL439314;;None;2029.23;None;None;2 (Bad BH3);CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)O;IC50;;;nM;;;Not Active;UO_0000065;;;;;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;
CHEMBL376408;ABT 737;1.0;813.45;2;7.88;1, ABT-737;CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-];IC50;'=';6.1;nM;8.21;;;UO_0000065;10.10;0.20;0.33;6.41;0;CHEMBL1693055;Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1687940;1;Scientific Literature;J Med Chem;2011;None;;;;6.1
CHEMBL3137309;VENETOCLAX;4.0;868.46;3;8.66;Venetoclax, ABT-199 (29);CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1;IC50;'=';23.0;nM;7.64;;;UO_0000065;8.80;0.17;-1.02;4.44;0;CHEMBL5096798;Inhibition of BCL-2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5096156;1;Scientific Literature;J Med Chem;2021;None;;INHIBITOR;;23.0
CHEMBL449132;;None;148.21;0;2.27;204;Oc1cccc2c1CCCC2;IC50;'=';4300000.0;nM;;Outside typical range;;UO_0000065;;;;;0;CHEMBL2208697;Binding affinity to Bcl2 by fluorescent polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2203023;1;Scientific Literature;J Med Chem;2011;None;;;;4300.0
CHEMBL2063897;;None;922.57;3;9.83;21;CCc1c(-c2ccc(Cl)cc2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(C(=O)O)n1C;IC50;'=';4.1;nM;8.39;;;UO_0000065;9.09;0.18;-1.44;5.47;0;CHEMBL2066619;Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BL21-DE3;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL2062483;1;Scientific Literature;J Med Chem;2012;None;;;;4.1
CHEMBL4297482;AZD-5991;1.0;672.28;2;8.18;AZD5991;Cc1c2c(nn1C)CSCc1cc(n(C)n1)CSc1cc(c3ccccc3c1)OCCCc1c(C(=O)O)n(C)c3c-2c(Cl)ccc13;IC50;'=';20000.0;nM;4.70;;;UO_0000065;6.99;0.14;-3.48;5.39;0;CHEMBL5035037;Inhibition of Fluor 647-labeled Bim peptide C binding to human C-Terminal 6His-tagged Bcl-2 expressed in Escherichia coli incubated for 120 to 180 mins by lanthascreen TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5034015;1;Scientific Literature;J Med Chem;2021;None;Time_Lower = 120.0 min | Time_Upper = 180.0 min;INHIBITOR;;20.0
CHEMBL1269110;;None;655.49;2;7.09;6l;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccc(Cl)cc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccc(Cl)cc3)c2C1=O;IC50;'=';340.0;nM;6.47;;;UO_0000065;9.87;0.19;-0.62;4.34;0;CHEMBL1273517;Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1269007;1;Scientific Literature;J Med Chem;2010;None;;;;0.34
CHEMBL441321;;None;1724.94;None;None;9 (Bak BH3);CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)[C@@H](C)CC)[C@@H](C)CC;IC50;'=';8360.0;nM;5.08;;;UO_0000065;2.94;None;None;None;0;CHEMBL880570;Inhibition of BCL2 by fluorescence polarization based competitive binding assay;B;BAO_0000357;single protein format;None;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL1142844;1;Scientific Literature;Bioorg Med Chem Lett;2005;None;;;;8.36
CHEMBL4297482;AZD-5991;1.0;672.28;2;8.18;AZD5991;Cc1c2c(nn1C)CSCc1cc(n(C)n1)CSc1cc(c3ccccc3c1)OCCCc1c(C(=O)O)n(C)c3c-2c(Cl)ccc13;IC50;'=';20.0;nM;;Potential transcription error;;UO_0000065;;;;;1;CHEMBL5096358;Inhibition of C-terminal His6-tagged Bcl-2 (1 to 212 residues) (unknown origin) expressed in Escherichia coli using biotin-labeled Bim peptide GGMRPEIWIANELRRIGDEFNA as substrate incubated for 120 to 180 mins by TR-FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5096144;1;Scientific Literature;Bioorg Med Chem Lett;2021;None;Time_Lower = 120.0 min | Time_Upper = 180.0 min;INHIBITOR;;20.0
CHEMBL4228713;A-1211212;None;896.51;3;9.44;EUB0000263;CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1;IC50;'=';1.4;nM;8.85;;Active;UO_0000065;9.88;0.19;-0.59;5.15;0;CHEMBL4883619;Time-resolved fluorescence energy transfer (TR-FRET) with BCL2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;Assay publication: PMID: 25313317 | Target protein length: full length | Target protein type: recombinant protein (GST-Bcl-2);;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4507310;54;SGC Frankfurt - Donated Chemical Probes;;2021;None;Num of experiments None 3.0 None;;;1.4
CHEMBL1269107;;None;586.60;2;5.78;"27; BI-97D6";CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O;IC50;'=';31.0;nM;7.51;;;UO_0000065;12.80;0.23;1.73;5.03;1;CHEMBL5241833;Inhibition of Bcl-2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5241079;1;Scientific Literature;Eur J Med Chem;2021;None;;INHIBITOR;;31.0
CHEMBL1269107;;None;586.60;2;5.78;BDBM142756;CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O;IC50;'=';290.0;nM;6.54;;278904;UO_0000065;11.14;0.20;0.76;4.38;1;CHEMBL3707868;Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL3638406;37;BindingDB Patent Bioactivity Data;;2015;None;;;;290.0
CHEMBL5196783;;None;344.42;0;4.14;20;CCCn1cc(/C=N/N=C2\C(=O)Nc3ccc(C)cc32)c2ccccc21;IC50;'=';460.0;nM;6.34;;;UO_0000065;18.40;0.33;2.20;10.79;1;CHEMBL5150894;Inhibition of BCL2 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;;;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL5149978;1;Scientific Literature;Eur J Med Chem;2021;None;;INHIBITOR;;0.46
CHEMBL4551344;A-1210227;None;904.37;3;8.88;EUB0000746;O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1;IC50;'=';296.0;nM;6.53;;Not Active;UO_0000065;7.22;0.14;-2.35;3.80;0;CHEMBL4883619;Time-resolved fluorescence energy transfer (TR-FRET) with BCL2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;Assay publication: PMID: 25313317 | Target protein length: full length | Target protein type: recombinant protein (GST-Bcl-2);;;CHEMBL4860;Apoptosis regulator Bcl-2;Homo sapiens;SINGLE PROTEIN;CHEMBL4507310;54;SGC Frankfurt - Donated Chemical Probes;;2021;None;Num of experiments None 3.0 None;;;296.0
